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ABSTRACT
The suitability o f  in vitro  immunisation, for monoclonal antibody (Mab) 
production, was investigated. A panel o f  nine Mabs were produced, and analysed for 
polyreactivity. Three different assays for polyreactivity were utilised, including 
measurement of the affinity o f each Mab for a small panel o f antigens. Using these 
three assays, eight o f the nine Mabs were demonstrably polyreactive. It was 
concluded, that in vitro immunisation may not be suitable for Mab production.
A second area o f interest was the generation o f intrabody libraries, for 
functional genomic analyses. A PCR-based strategy was developed to convert any 
ScFv gene, from the Nissim library, to an intrabody gene. As a model, an anti-NIP 
ScFv gene was converted to an intrabody gene. Cytochemical studies indicated 
correct cytoplasmic localisation o f this intrabody, but poor expression levels.
The strategy was applied to  generate a large intrabody library. A novel PCR- 
cloning methodology was used. This utilised T4 DNA polymerase, and required the 
creation o f a novel vector, referred to as pM K . The cloning strategy proved very 
successful and a 'one-shot' intrabody library o f 1.3xl07 independent clones was 
generated.
These studies demonstrate the feasibility o f the strategy, but suggest that 
further studies are required to improve intrabody stability.
xix
CHAPTER 1 
INTRODUCTION
1
In 1890, von Behring and Kitasanto demonstrated, that immunisation 
with diptheria and tetanus toxins, resulted in the production, in the serum, o f  a 
soluble substance, capable o f neutralising the toxins. They coined the term 
antibody for this substance and ever since, its function has been inextricably 
linked to vertebrate immunity, specifically, acquired immunity.
The pre-eminent theoretical framework, used to explain the role o f 
antibody in acquired immunity, is the clonal selection theory, articulated in the 
1950's by, among others, Burnet, Talmage and Lederberg (Talmage, 1995). 
This theory was based on the numerous physicochemical observations on 
antibodies, since their discovery, and also on a number o f ad  hoc postulates. 
Briefly, antibody was not one chemically defined substance. Rather, it was a 
class o f heterogeneous, and yet, structurally and functionally related proteins. 
These proteins were largely identical but individual species varied, primarily, at 
one structure referred to as a receptor or binding site. Individual binding sites 
w ere chemically defined and allowed th a t species of antibody to bind with 
great specificity to  com plem entary m olecular structures. I t  was this 
specificity, which, for the purposes of im m unity, required  the body to 
produce a heterogeneous population of binding sites. Antibodies were 
expressed on or secreted from B cells, and individual B cells w ere restricted to 
the production of only one species of binding site (referred to as a 
monoclonal binding site). Finally, a primary repertoire o f antibodies was 
constitutively expressed  on the surface o f B cells. Within this framework, it was 
postulated that foreign pathogens, which manage to invade the body, are bound, 
by that fraction o f B cells constitutively expressing com plem entary antibody on 
its surface. The selected B cells then respond, by clonally expanding and 
secreting antibody possessing the same binding site as on its surface. The 
secreted antibody binds the pathogen and, subsequently, neutralises it. During 
the course o f this immune response, the antibody displayed by the selected B 
cells mutates; only those B cells expressing antibodies with improved binding 
characteristics for the antigen survive and secrete the improved antibody. It is 
primarily this induced (acquired) antibody that appears in the serum of 
vertebrates during immune responses.
Antibody fragmentation studies and amino acid sequencing o f
monoclonal antibodies soon demonstrated, that antibodies vary, primarily, at one
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structure, as predicted (Nisonoff, 1995). This structure was then identified by 
crystallographic studies as the putative binding site (Lesk and Tramontano, 
1992). The postulate th a t binding sites possess great specificity was 
justified, by reference to the  m any immunochemical studies, since before 
the tu rn  of the century, on antisera fro m  anim als undergoing im m une 
responses (Silverstein, 1989). Formal proof was obtained in 1976, that B cells 
express one species o f  binding site only (Nossal, 1995), although the theory had 
found almost complete acceptance well before this date. Finally, genetic 
analyses, carried out in the late 1970's and early 1980's (Tonegawa, 1995), 
demonstrated that humans can produce, constitutively, up to lx l  O10 different 
binding sites.
T hat the phrase 'specific antibody' is almost considered a  tautology 
in most textbooks, is due in p a rt to the dom inance of this clonal selection 
theory and the immunochemical observations underlying it. This perception 
has lead to the widespread use o f monoclonal antibody binding sites (antibodies 
or related molecules) in many scientific disciplines unrelated to immunology. 
The specificity o f antibodies is invaluable in many analytical tools such as 
enzyme-linked immunosorbent assays (ELISAs), allowing the quantification o f 
ligands such as pesticides, in complex biological matrices, such as foodstuffs. 
The clinician can also take advantage o f monoclonal antibody specificity. In 
total, 30% of all recombinant proteins currently undergoing clinical trials, are 
antibodies or related molecules. One concept, frequently described, is the 
destruction o f a tumour, by using a specific antibody to target a toxin to the 
tumour.
However, immunochemical studies carried out over the past 15 years call
into question the established dogma o f antibody specificity. These m ore recent
studies do not dispute earlier studies on the specificity of antibodies induced
during in vivo im m une responses. W hat they do suggest, is th a t constitutively
expressed antibodies can show a poly specific binding pattern. It is the
primary aim o f this chapter, to review these observations (Section 1.2). These
observations are o f interest, not only to theoretical immunologists, but also to
anyone using or producing monoclonal antibodies, due to the fact, that they
suggest that the mode of production o f monoclonal antibodies could affect their
specificity. It is with this in mind, that section 1.3 reviews the production of
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thèse important reagents. In section 1.4, anovel use o f  monoclonal antibodies is 
introduced. This is their ectopic expression for phenotypic knockout. This 
chapter starts, however, with a general introduction to  the production and 
structure o f antibodies and derivatives thereof, particularly as it relates to  their 
ability to  bind antigen.
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1.1 THE PRODUCTION, STRUCTURE AND INTERECTION, OF 
ANTIBODIES AND DERIVATIVES, WITH ANTIGENS
1.1.1 Prototypic antibody structure: A diagram o f a typical antibody, an 
immunoglobulin G (IgG) molecule, is shown in Fig. 1.1. It is composed o f four 
polypeptide chains, with two identical heavy chains and two identical light 
chains. The heavy and light chains o f this molecule are held together by 
interchain disulphide bonds and also by non-covalent interactions. The heavy 
chain consists o f four domains named from the N-terminus as Vh, ChI, Ch2 and 
Ch3. V stands for variable domain and C for constant domain. The domains are 
referred to as variable or constant depending on the amino acid sequence 
variation among individual antibody molecules. The light chain consists in the 
main o f two domains named, from the N-terminus, as V l and Cl. Between the 
ChI and Ch2 domains lies the hinge region, which allows the two arms o f the Y 
shaped molecule a certain degree o f flexible independent motion.
All o f the above domains show considerable structural similarity. They 
consist o f two stacked layers o f P sheets surrounding an internal space filled 
with hydrophobic amino acid side chains (Bradbury, 1997) (see Fig. 1.2). A 
very important feature o f the domains is the intrachain disulphide bond which 
links one P sheet to the second P sheet and stabilizes the entire domain structure.
The antibody binding site is formed by the juxtaposition o f one Vh 
domain with one V l domain. Thus, each IgG contains two antibody binding 
sites. The antibody binding site allows the antibody molecule to bind different 
m olecular structures (referred to as antigens) selectively and potentially with 
great specificity. I t  is the sequence variation in the variable domains with 
consequent variation o f  binding site structure tha t underlies the ability o f  
different antibody m olecules to bind to d ifferent antigens. The binding site 
structure is discussed more fully in section 1.1 .1.3 and its interaction with 
antigens is the subject o f section 1.1.4.
The constant domains (the sum o f which is referred to as the constant 
region), play no part in the binding activity o f  the antibody although they have a 
variety o f biological activities, which will not be discussed. The interested 
reader is referred to Elgert (1996).
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Fig. 1.1 : A schematic o f a typical IgG  molecule. CHO indicates glycosylation. 
The intrachain disulphide bonds, which stabilise each immunoglobulin fold, are 
clearly visible. A lso depicted are the interchain disulphide bonds, which 
covalently link the heavy and light chains. The greek symbols /a, %  a, §, and s  
refer to the 5 different variants o f the heavy chain constant region and the 
symbols k  and k  refer to different form s o f the light chain constant region (see 
section 1.1.1.1). Diagram reproduced from  the internet (http://www.mcms- 
dal.ca/) with the artists permission.
Bio 1 ORical 
activity
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1.1.1.1 Antibody heterogeneity: The antibody molecule is the most variable protein 
expressed in vertebrates. As discussed by Elgert (1996), there are three types o f 
variation that occur in the antibody molecule.
Isotypic variation: Isotypic variation is a reflection o f the expression, by 
vertebrates, o f a limited number of different constant regions. For example 
humans express five variants of the heavy chain referred to as \x, a, y, 8 and e. 
Antibodies containing these heavy chains are referred to as IgM, IgA, IgG, IgD 
and IgE, respectively. Four different subclasses of the y chain exist referred to as 
y l, y2, y3 and y4 (IgGi^). Two different subclasses o f the a  chain exist, a l  and 
a2  (IgAi and IgA2). The light chain occurs in two major isotypic variants 
named k  and X but there are four A, isotypic variants, A*, Xi, X3 and A,6- Each 
different constant region is encoded for in the germline o f all members o f  the 
species by separate gene segments (see section 1.1.2).
Allotypic variation: This is a reflection o f limited polymorphism in the constant 
region gene segments.
Idiotypic variation: This is the primary type of variation in antibodies. It has 
already been alluded to, and is due to the huge variety o f variable domains that 
can be expressed. In other words idiotypic variability is a consequence o f 
binding site diversity. Humans, for example, can constitutively produce 
approximately lx lO 10 different binding sites (see section 1.1.2).
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Fig. 1.2 : Ribbon diagram of a typical IgG. The structural similarity between all 
domains, along with the ¡5 sheets, are clearly visible. This diagram is available on the 
internet at http://www.path.cam.ac.uk/ and is reproduced here with the permission of 
the artist.
1.1.1.2 D im eric and polym eric antibody m olecules: The secreted IgM molecule exists 
in pentameric form. The five monomeric units are arranged radially with the 
variable domains pointing outwards and the constant region inwards (Elgert, 
1996). They are connected to each other by disulfide bonds mediated by a 
cysteine residue at the C-terminus o f the p, chain. This pentameric IgM 
molecule also has a protein, referred to as the J chain, associated with it. This 
chain appears to restrict polymerisation to pentamers, as opposed to higher 
polymers (Bradbury, 1997).
Similarly, IgA exists primarily in dimeric form with an associated J chain 
and another protein referred to as the secretory component which serves to
8
protect the dimer from proteolytic cleavage. The precise alignment o f these 
proteins in the polymer is unknown (Elgert, 1996).
1.1.1.3 Antibody binding sites: The huge variety o f antibody binding sites that the body 
can produce might suggest that antibody binding sites are generated in a chaotic 
and random fashion. This is not so. On the contrary, at the protein level, 
crystallographic analyses have indicated that there is a substantial degree of 
rigor to the way the binding site is composed. This is mirrored by the orderly 
fashion in which the vast diversity o f antibody binding sites is encoded in the 
genome (see section 1.1.2)
Large-scale amino acid sequencing o f monoclonal antibodies gave 
some of the first clues to the structure o f the antibody binding site. Wu and 
Kabat (1970) on comparing these sequences noted that variability was most 
pronounced in three regions o f the variable sequence o f the heavy and light 
chains, these regions being separated by the so-called framework sequences. 
These regions were referred to as hypervariable regions or complementarity 
determining regions (CDRs). They were named from the N-terminus (H for 
heavy, L for light) as H I, H2, H3, and L I, L2 and L3. Wu and Kabat (1970) 
predicted that upon analysis o f the quaternary structure o f the antibody molecule 
these regions would be found juxtaposed and would form the antibody binding 
site. This prediction was borne out upon analysis o f the three-dimensional 
structure o f a number o f antibodies and complexes thereof (Lesk and 
Tramontano, 1992).
Like all other antibody domains, variable domains all contain a double P- 
sheet motif. This structure is formed by the framework sequences. Each double 
P-sheet has associated with it three loops which connect its strands. The loops 
correspond to the CDRs. This correspondence is not absolute and there are 
differences between the definitions o f the CDRs based on primary sequence and 
based on the three dimensional structure (MacCallum et al., 1996). Four of 
these loops (CDRsl-2) are hairpin loops; i.e. they connect successive strands of 
the anti-parallel P-sheet. The remaining two connect the two P-sheets o f their 
respective domains (Lesk and Tramontano, 1992). All loops are exposed on top 
o f the variable domains and come together to form the antibody binding site
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(Fig. 1.3). Thus, it has been said that the framework regions provide a scaffold 
upon which the antibody binding site is constructed (Lesk and Tramontano,
1992).
Chothia and Lesk have analysed the loop structures on all antibodies, 
whose three-dimensional structures have been solved, and have noted a further
Fv Antibody Fragments: CDR Regions
Amino Acid Backbone
antigen 
binding
linker 
c > tags
Spacefill Model
Graphics byS  Ditbel, Heidelbeig
Fig. 1.3 : Colour coded diagram showing the 6 CDRs o f a  F v (see section!. 1.3) 
molecule. Note also the dotted line indicating where the linker segment would 
be in an ScFv (see section 1.1.3) molecule. The space fillin g  diagram clearly 
shows how the juxtaposition o f  the CDRs form s a ridged binding site (in this 
case). This diagram was obtained from  the internet (http://www.mgen.uni- 
heidelberg.de/) and is reproduced here with the artists permission.
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level o f order to binding site construction (Lesk and Tramontano, 1992). They 
have observed that five of the six loops (the exception being H3) can each take 
on only a limited number o f main chain conformations or “canonical structures” 
(Chothia et a l , 1989). Thus L I loops have four basic canonical structures, L2 
one, L3 three, H I two and H2 four (Lesk and Tramontano, 1992). Whether one 
canonical structure is chosen over another is determined primarily by the length 
o f the loop, and the presence o f particular residues at certain sites in the loop. 
These sites are relatively conserved in the hypervariable regions (Lesk and 
Tramontano, 1992). For example the presence in position 90 o f a polar side- 
chain and a proline at position 95 determines one particular canonical structure 
for L3. The remaining residues in the hypervariable loops are free to vary and 
do not greatly affect the main-chain conformation. However, their different 
side-chains determine the surface topography o f the binding site along with the 
charge distribution and other physiochemical characteristics. (Lesk and 
Tramontano, 1992). It is also worth noting that the determinants o f canonical 
structure do not reside exclusively in the loops themselves. Rather the 
framework regions do not solely act as a scaffold for the loops but residues 
within it can affect loop conformation. For example, the size o f  the residue at 
position 71, a site in the double p-sheet motif o f V h , affects the conformation 
and position o f H2 (Lesk and Tramontano, 1992).
Even an analysis o f the overall topography o f antibody binding sites o f 
known three-dimensional structure has indicated some degree o f “restriction” or 
order. Using an objective fractal measure, MacCallum et al. (1996) showed that 
binding site topographies all segregate in one o f four classes: concave, 
moderately concave, ridged and planar. These classes also correlate quite well 
with antigen type. Thus concave and moderately concave are associated with 
binding of haptens, ridged with peptides, DNA and carbohydrates and planar is 
associated with protein antigens (MacCallum et al., 1996).
Finally most o f the observations noted above have been based on 
crystallographic analyses and assume that antibodies are stable entities. 
Nonetheless, observations of antibodies in solution indicate th a t antibodies 
may exist in a t least two structu ra l forms in dynamic equilibrium  (Milstein 
and N euberger, 1996).
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1.1.2 Genetics of binding site diversity: The generation o f binding site diversity 
varies between species (Milstein and Neuberger, 1996) and this discussion 
focuses on humans and mice who appear to utilise similar mechanisms. Somatic 
events are the primary generators o f diversity. The primary (naive) repertoire, o f 
antibody binding sites, is generated at the pre-B cell stage o f lymphopoiesis, by 
a process known as recombination (Milstein and Neuberger, 1996). This 
reperto ire, in the terminology of some authors (see fo r example Coutinho,
1989), is referred  to as preim m une, to indicate th a t it is constitutively 
expressed on B cells in the absence of any in vivo  im m une response.
In the germline o f each individual, families o f gene fragments exist in 
multiple non-identical copies. For example the human immunoglobulin heavy 
chain gene locus is located at band q32, o f the long arm o f chromosome 14 
(Kipps, 1997). It contains 50 functional heavy chain variable region gene 
segments ( V h ), at least 24 diversity (D) gene segments and 6 functional Jh gene 
segments (See Fig. 1.4). The light chain gene loci (kappa on chromosome 2 and 
lambda on chromosome 22) are similarly arranged, containing multiple V l  and 
J l gene segments. Recombination o f one element from each o f the Vh, D and Jh 
families creates an exon encoding the Vh domain and, similarly, recombination 
between V l and J l  fragments creates an exon encoding the V l domain (Milstein, 
1990; Milstein and Neuberger, 1996). The V fragments encode the CDRs 1-2 
and the junctional regions (V(D)J or VJ) encode CDRs 3.
O f note, this process primarily generates diversity in CDR3 (in particular 
H3) and there is only limited diversity in CDRsl-2 (Table 1.1) (Milstein and 
Neuberger, 1996). The greater diversity in CDR3 is not solely due to the greater 
number o f elements that recombine to encode it. It is also dependent to a major 
extent on the imprecision in the joining mechanism (Milstein and Neuberger,
1996). In the case o f H3 it is also dependent to a large extent on the addition of 
extra bases (N) at the VD and DJ boundary during joining (Milstein and 
Neuberger, 1996).
Overall, a picture has emerged o f a potential preimmune repertoire o f  at 
least lx lO 10 different antibody binding sites encoded in the germline. It should 
be noted that the generation o f the preimmune repertoire is a quasi-random (not 
completely random) process for a number o f reasons.
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Fig. 1.4 : The structure o f  the immunoglobulin heavy chain locus, is shown 
above. Green boxes represent functional Vjj gene segments. Yellow boxes 
represent ORFs. R ed  boxes represent pseudogenes. Navy boxes represent D  
segments. The J  segments are represented by bright yellow  boxes. The constant 
region gene segments are shown in blue. This diagram is reproduced here with 
the permission of: "IMGT, the international ImM unoGeneTics database 
http://imgt.cnusc.fr8104 (Coordinator: M arie-Paule Lefranc, Montpellier, 
France lefranc@ ligm.igh.cnrs.fr)  For reference: Nucleic Acids Research, 25, 
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Firstly, the fragments carried in the germline are conserved and reflect 
the evolutionary gene history o f  the species and Darwinian selection (Milstein,
1990). Secondly, the recombination process itself is not a random one and some 
combinations are found with much greater frequency than others (Milstein and 
Neuberger, 1996).
Thus, upon initial challenge by a pathogen, the individual relies on the 
chance recognition o f the pathogen, by antibodies o f  the preimmune repertoire 
on the surface o f B cells. Antibodies are selected from this repertoire based on 
their frequency and affinity for antigen (Milstein and Neuberger, 1996). This 
initial response is referred to as a primary response. However, following this 
initial chance encounter the individual “learns” or “adapts” to recognise the 
antigen. This “learning” process takes place in the microenvironment o f the 
germinal center. In this microenvironment Darwinian selection for antibodies 
with improved binding characteristics takes place (Milstein, 1990; Milstein and 
Neuberger, 1996). In general, the result o f this selection is the generation o f 
antibodies with increased affinity for the antigen. Hence, this process is referred 
to as affinity maturation. This selection is wholly dependent upon and must be 
preceded by mutation o f antibody genes to provide a population o f binding sites 
from which to select the best. A specific mutation mechanism has evolved to 
accomplish this. It is referred to as somatic hypermutation and is the second 
generator of diversity.
A limited number o f B cells selected by the antigen from the preimmune 
repertoire enter the germinal center and undergo rapid pauci-clonal proliferation. 
During this stage o f B cell development the rearranged V(D)J and VJ loci are 
subject to a high rate o f mutation (lxlO '3 mutations per base per division) 
(Milstein and Neuberger, 1996). The mechanism o f somatic hypermutation is 
uncertain but may rely on Topoisomerase II to create single-strand nicks 
followed by the recruitment o f error-prone DNA-repair mechanisms (Milstein 
and Neuberger, 1996). Regardless o f the mechanism, the net result is the 
generation o f a population o f daughter cells derived from antigen-selected 
preimmune B cells but expressing antibody o f widely diverging affinity for the 
selecting antigen on their surface. Within the germinal center it is considered 
that antigen is trapped in limiting amounts on the surface o f specialised cells
referred to as follicular dendritic cells (Milstein and Neuberger, 1996).
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f Param eter D iversity o f C D R l and C D R 2  I
v germline genes 100 ( V K and V x) x 50 V n
com binatorial
junctional diversity
total SxlO3
Diversity o fC D R 3  (heavy chain) D iversity o f C D R 3  flight chain) 1
50 V H  x 4 JH  x 20 D (50  V K x  4 JK)  +  (50  V xx4 h)
x 6 (V D ), x 6 (D J), x 50 (N x 3
segments)
lxlO7 lxlO3
Table 1.1: A simple mathematical model allowing a calculation o f  the total 
antibody diversity generated by somatic recombination is presented. The total 
diversity due to HI, H2, LI and L2 is calculated based on the assumption that 
any o f the 100 VK or Vx gene segments can be paired with any Vh gene segment. 
The diversity due to H3 and L3 are considered separately from HI, H2, LI and 
L2, as they are generated in a different fashion (recombination and junctional 
diversity). For both H3 and L3, this mathematical treatment assumes that all V, 
D  (if applicable) and J  segments are equally permitted to recombine with each 
other. To take into account, junctional diversities, multiplication factors are 
provided (taken from Milstein and Neuberger, 1996). When these are used, to 
multiply the diversity due to recombination, the total diversity due to L3 
becomes lx l0 3. The total diversity due to H3 is 1x107. To calculate the total 
diversity due to somatic recombination, it is assumed that each L3 is equally 
likely to pair with a given H3. This gives a  total antibody diversity o f lx l  O10. 
Ihe diversity due to HI, H2, LI andL2 is not taken into this calculation. This is 
because, diversity in these loops, being dependent on V gene usage, is not 
generated independently o f  the diversity in L3 and H3.
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Under these limiting conditions cells expressing antibody o f highest affinity are 
at a selective advantage with regard to binding o f trapped antigen. Failure to 
bind antigen results in apoptosis, whereas those B cells that bind antigen are 
programmed for survival, emerge from the germinal center and become memory 
cells and plasma cells (Milstein and Neuberger, 1996). This stage of the 
immune response is referred to as secondary and the antibodies are 
referred to as secondary antibodies. They can also be referred to as 
immune antibodies to indicate that their appearance is wholly dependent 
upon an in vivo immune response. The combination o f somatic recombination 
and hypermutation results in almost unimaginable antibody diversity with 
figures such as lxlO 30 different antibody binding sites being mentioned in the 
literature (Milstein and Neuberger, 1996).
In many important respects hypermutation and recombination are two 
complementary mechanisms. Thus, somatic recombination results in a diverse 
population o f antibody binding sites, selected in a Darwinian fashion over many 
hundreds o f thousands o f years, and reflects the evolutionary history o f the 
species. Somatic hypermutation results in the generation o f a diverse population 
o f binding sites, selected in a Darwinian fashion but over the course o f a couple 
o f days, and reflects the history o f the individual. Also, somatic hypermutation 
is a quasi-random process; even in the absence o f the bias induced by antigen 
selection certain residues in the variable region appear to be “hot-spots” for 
mutation (Neuberger and Milstein, 1995). At the level o f CDRs, CDR1 appears 
to be mutated with the greatest frequency, followed by CDR2 and CDR3 
(Milstein and Neuberger, 1996). This is the exact opposite o f the pattern o f 
variability created by recombination. Indeed, there is as much variability in the 
framework residues in the human germline as there is in CDR1 (Huston et al.,
1996). Therefore, hypermutation complements recombination in that it spreads 
diversity to apical regions o f the binding site (Huston et al., 1996). The net 
effect appears to be fine-tuning of the binding site topography, or indeed apical 
residues in the binding site making contact with the antigen (Milstein and 
Neuberger, 1996).
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1.1.3 Antibody derivatives: The antibody domain structure has greatly facilitated the 
production, by chemical and genetic means, o f a variety o f antibody derivatives 
with binding activity similar to the parental antibody molecule.
1.1.3.1 Chem ical methods. Fab fragments are generated by digesting whole IgG with 
papain. Papain digests in the hinge region just above the double interchain 
disulfide bonds (see Fig. 1.1). Fab fragments contain the Vh and ChI domains 
from the heavy chain and the entire light chain. The chains are linked by a 
disulfide bond and the resulting monovalent fragment maintains binding activity 
(Nisonoff, 1995).
F(ab ')2 fragments result from the digestion o f whole IgG with pepsin. 
Pepsin digests at a similar position to papain but results in a bivalent fragment 
(Nisonoff, 1995). This is because it digests in the hinge region, but just below 
the two disulfide bonds.
These two antibody derivatives may be useful in certain circumstances. 
This might be the case for the clinical use o f antibodies. I f  an anti-tumour 
antibody was to be used clinically, a smaller molecule would presumably be 
advantageous in so far as it would have better tumour penetration characteristics. 
Also the Fc portion of IgG can lead to non-specific binding o f whole IgG.
1.1.3.2 Genetic m ethods. It is possible to generate genes encoding antibody heavy and 
light chains. Insertion of these genes into a suitable vector allows functional 
expression, o f the antibody or a variety o f antibody-like molecules, in a number 
o f hosts. Much o f this technology has been made possible by the elucidation o f 
the structure o f the genetic loci encoding antibody heavy and light chains in the 
late 70's and early 80's (see section 1.1.2). Furthermore, this technology has 
been greatly facilitated by PCR.
Although functional antibody and fragments can be expressed in 
myeloma cells (Morrison, 1985) and yeast (Cabilly et al., 1984), by far the most 
common host for production is E. coli. This is due primarily to the ease with 
which it can undergo genetic manipulation and fermentation.
Initial work expressing whole heavy and light chains in E. coli was not
promising. Heavy and light chains formed intracellular inclusion bodies with no
activity (Wood et a l, 1985). Activity could be restored by denaturation o f the
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inclusion bodies followed by refolding in vitro. Lack o f expression o f functional 
antibody was not too surprising. Antibody folding and assembly in the 
endoplasmic reticulum (ER) o f lymphoid cells is a complex process involving 
disulfide bond formation and requiring many chaperone proteins. The ectopic 
environment o f E.coli may not provide a suitable environment for correct 
antibody folding and assembly (Wood e ta l., 1985).
Two papers, demonstrating the feasibility o f  functional expression of 
antibody fragments in E. coli, appeared in 1988. Skerra and Pluckthun (1988) 
approached the problem by attempting to express synthetic genes encoding the 
V h  and V l  domains from the myeloma protein McPC603 in E. coli, while 
translocating the resulting nascent polypeptides into the periplasm. 
Heterodimerisation o f correctly folded domains was expected to produce a 
monovalent antibody fragment, referred to as a Fv, with binding activity.
The rationale for this approach was twofold. Firstly, a Fv fragment 
should have reduced problems with incorrect folding and assembly and, 
secondly, translocation into the periplasm o f the chains might more closely 
resemble transport of polypeptides across the ER membrane. Synthetic genes 
encoding the V h  and V l  domains were precisely fused to the ompA and phoA  
signal sequences, respectively, in a dicistronic operon and expressed from a 
suitable vector. Fully functional soluble Fv accumulated in the periplasm and 
showed the same affinity as the parental myeloma protein (Skerra and 
Pluckthun, 1988).
Using a similar approach Better et al. (1988) fused the leader sequence 
from pelB  to a gene encoding the Vh and ChI domains o f an antibody and also 
to a separate gene encoding the corresponding light chain o f  the antibody. The 
resulting genes were cloned into a vector as a dicistronic operon and functional 
Fab was excreted into the culture supernatant.
Fv fragments unfortunately are of limited stability at low protein
concentrations and under physiological conditions. A number o f strategies have
been published to increase their stability (Glockshuber et al., 1990). The most
popular strategy has been to create an artificial antibody derivative referred to as
a single-chain Fv (ScFv). Huston et al. (1988) constructed a synthetic gene
containing the coding sequence for the Vh domain o f an antibody and also the
coding sequence for its Vl partner. Connecting the 3' end o f the Vh domain to
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the 5' end of the V l domain was a linker sequence encoding (gly-gly-gly-gly- 
ser)3. Thus the Vh and V l domains are both on the one polypeptide chain. The 
15 amino acid linker was chosen because it is just long enough to bridge the gap 
between the C-terminus o f the Vh domain and the N-terminus o f the V l domain 
and also because it should not form any secondary structure. The resulting ScFv 
had an association constant for digoxin about six times smaller than a Fab 
fragment o f the parental antibody.
All the above mentioned reports cloned genes or gene fragments using 
techniques such as classical cDNA cloning from libraries using constant region 
gene probes followed by site-directed mutagenesis, amino acid sequencing of 
heavy and light antibody chains followed by solid phase synthesis o f  the 
complementary genes, to name but two. These techniques are almost invariably 
successful but take a long time. The application o f PCR has resulted in a much 
shorter time frame for cloning antibody genes and gene fragments. However, 
there are potentially a number o f problems inherent to cloning antibody genes 
from hybridomas by PCR and these are well discussed by Bradbury (1997).
Orlandi et al. (1989) were the first to clone antibody genes using PCR. 
Although V h , V l , Jh  and J l  gene segments are variable they do contain some 
relatively conserved regions particularly at the 5' ends o f V h  and V l gene 
segments and the 3' ends o f Jh and J l gene segments. Thus Orlandi et al. (1989) 
constructed "universal" primers to clone genes encoding Vh and V l domains 
from hybridomas by reverse transcriptase PCR. The resulting genes were cloned 
into special vectors allowing them to be expressed as part o f a full antibody 
heavy chain and a full antibody light chain, respectively. NSO double 
transfectants secreted full antibodies with binding activity.
Variable regions cloned in this fashion are now normally assembled in 
the form of a ScFv or a Fab and expressed in E. coli. Genes encoding Fabs are 
generated using 3' primers recognising the 3' sequence o f the ChI or C l 
domains, (Bradbury, 1997).
Two other antibody fragments have been found to possess binding 
activity. Ward et al. (1989) found that Vh domains expressed on their own had 
binding activity. Unfortunately these fragments have low solubilities, which has 
hindered their usage. Even individual CDRs have been explored as potential
binding molecules (Levi e ta l., 1993).
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1.1.4 Antibody-antigen interactions: Antibodies and antigens interact solely at the 
antibody binding site. Interactions are characterised by a high degree of 
complementarity (surface topography, charge etc..) between the surfaces at the 
interface (Wilson and Stanfield, 1993). It is this requirement for 
complementarity that underlies the ability of monoclonal antibodies to 
selectively bind certain antigens only. It does not imply great specificity, 
however, as will be discussed in section 1.2. Furthermore, although 
antibody-antigen interactions have often been explained in terms of a lock 
and key mechanism (as befits the concept of specificity), an induced-fit 
mechanism may be more appropriate as indicated by analyses of antibodies 
in both free and complexed forms (Wilson and Stanfield, 1993). In fact 
rather large conformational changes can take place in the antibody binding 
site including changes in gross topography (MacCallum et al., 1996).
Analyses o f the contribution of individual CDRs to binding indicates that 
at least four CDRs are involved in each case analysed so far, although it is also 
true that all six are never involved (Wilson and Stanfield, 1993). L3 and H3 
tend to predominate in binding interactions (MacCallum et al., 1996) and 
conversely L2 only rarely engages in antibody-antigen interactions (Wilson and 
Stanfield, 1993; MacCallum et al., 1996).
Examination o f the contribution o f individual residues to binding have 
also been carried out (MacCallum et al., 1996). On average only 28% of 
residues in the CDRs form contacts with antigen in all of the complexes 
whose structures have been determined so far (MacCallum et al., 1996). 
Results indicate that the propensity o f a residue in a CDR to form a contact with 
the antigen correlates with its position in the binding site. Those residues closest 
to the center have the greatest chance o f interacting with an antigen. The 
“binding epicenter” (MacCallum et al., 1996) is slightly displaced towards H3. 
Residues apical to the binding site interact less frequently and then only with 
larger antigens. The results o f MacCallum et al., (1996) also suggest that 
residues outside the conventionally defined CDRs (i.e. in the framework 
regions) can be important to antibody-antigen interactions when they are solvent 
accessible. Indeed, they have proposed a new classification for CDRs based on 
their contact analysis.
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1.2 ANTIBODY POLYSPECIFICITY
1.2.1 Historical and theoretical background: The absolute specificity o f the 
antibody-antigen interaction was an integral part o f Erhlich's influential side- 
chain theory o f antibody formation (Silverstein, 1989). This concept o f absolute 
specificity was partly based on Fischer's work on the specificity o f enzyme- 
substrate reactions and also immunochemical studies o f antisera. It was also 
based on the philosophical viewpoint that nature was discontinuous and that 
biological interactions were qualitatively absolute (Silverstein, 1989). This 
theory also suggested a structural basis for this absolute specificity. It was 
said to be a consequence of the interaction of chemically defined 
complementary molecular structures (Silverstein, 1989).
Landsteiner took a diametrically opposite philosophical viewpoint. 
Antibodies should show a quantitative and continuous gradation o f affinity with 
various antigens (Silverstein, 1989). He studied the immune response to haptens 
in order to better understand immune cross-reactivity. He demonstrated that 
appropriate antisera could distinguish between, while at the same time show 
reactivity against ortho-, meta- and para-substituted azobenzoates (Silverstein, 
1989). Landsteiner took this as evidence o f cross-reactivity but many others 
took it as proof o f the great specificity o f  the immune response.
Proof, originating in the 1940s, that an antiserum was composed o f a 
mixture o f different antibodies against the antigenic structure, again affected the 
concept o f immunological specificity. As pointed out by Talmage (Silverstein, 
1989a), the fact that a mixture of antibodies showed specificity did not 
imply that the individual antibody molecules were just as specific. In fact, as 
long as each individual antibody showed reactivity with the antigen used to raise 
the antiserum, they could each have distinct reactivity patterns and the antiserum 
would still show statistical specificity for that antigen. This theory not only 
allowed cross-reactivity among similar antigens but among dissimilar antigens.
However, it was primarily the advent o f  clonal selection theories and, in 
particular, clonal deletion theories, that affected the concept o f  antibody 
specificity. It was Erhlich who coined the phrase 'horror autotoxicus' to indicate 
that, since antibodies mediate the destruction o f the substance they bind to, there
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must be some mechanism by which antibodies are prevented from reacting 
against self-constituents o f the vertebrate. The clonal deletion theory stated that 
the protective mechanism was the deletion o f all B cell clones, with specificity 
towards self, during fetal and neonatal life. As discussed by Cohn (1992) a 
highly specific antibody molecule is a prerequisite if  deletion of autoreactive 
clones is a physiological process and is the explanation for the self/ nonself 
discrimination. This high specificity, in turn, required a very large primary 
repertoire in order to provide the vertebrate with an adequate degree of 
protection against the wide variety of pathogens in the environment. 
Indeed, there is an immense primary repertoire o f  antibody binding sites (see 
Table 1.1).
To summarise, the arguments in favour o f a highly specific antibody 
molecule are three-fold. Immune antisera are highly specific. The structure o f 
antibodies (they are chemically defined) ensures that they cannot be but specific. 
Finally, their function (they provide acquired immunity against foreign 
substances without reacting against the self) implies that they must be specific. 
However, those very characteristics o f  antibodies (structural and functional) 
used as the basis o f  arguments for a specific molecule can equally be used to 
argue in favour of a polyreactive molecule. For example, the notion that a 
binding site is chemically defined, and as a result binds with great specificity 
may be incorrect. Ghosh and Campbell (1986) have pointed out, that if  you 
raise an antibody to an antigen there are a number o f possible degrees o f 
interaction. The antigen, conceivably, could avail o f all possible contact points 
in the antibody binding site, and the interaction should be o f high affinity. Even 
if  this was so, a similar antigen, which can only make contact with a subset of 
the available contact points, should still result in an interaction o f  moderate 
affinity. If  the original antigen only avails o f a subset o f the available contact 
points, then a completely dissimilar antigen may bind to the binding site with a 
moderate affinity using the excess binding sites. It has already been discussed in 
section 1.1.4 that antibodies, on average, only utilise 28% o f their available 
contact sites when binding to antigens. Other aspects, o f binding site structure, 
which may mitigate against a highly specific molecule, includes the flexibility o f 
the binding site already alluded to (see section 1.1.4) and the fact that antibodies
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may exist in a number o f different forms, in dynamic equilibrium (section 
1.1.1.3).
Biological arguments can also be made in favour o f a polyreactive 
antibody molecule. Current knowledge o f the generation o f antibody diversity 
(see section 1.1.2) suggests that the preimmune repertoire is not sufficiently 
large for host protection if a highly specific antibody molecule is the rule. It 
has been argued, on theoretical grounds, that antibody multispecificity is 
essential to defend the body against the universe o f potential pathogens. 
Calculations indicate that as much as 1016 different antigenic structures may 
exist in nature (Silverstein, 1989a). As a result, neither man (1013), mouse (109) 
or even smaller vertebrates possess enough lymphocytes for protection if 
absolute specificity is inherent to antibodies (Silverstein, 1989a). In fact, 
significant multispecificity would appear to be a pre-requisite for survival. The 
case for absolute specificity is diminished even further when the degeneracy o f 
the immune response is analysed. There may be 5000 different clonotypes in 
mice capable o f reacting with a hapten such as dinitrophenol (DNP). Each 
clonotype may be present at 10 precursors per mouse (Silverstein, 1989a). 
Given the number o f B cells the mouse possesses there could only be 6000 
different antigenic structures against which it can react if  absolute specificity is 
invoked (Silverstein, 1989a).
Similar notions were put forward by Milstein and Neuberger (1996). 
They noted that clonal selection per se does not impose a requirement on the 
preimmune antibody repertoire, to be either highly specific or o f  high affinity. 
Diversity in the preimmune antibody repertoire, in their view, is required to 
increase the average affinity of the initial immune response, not as a 
consequence of the monospecificity of this repertoire. They argue that 
specificity and affinity are opposite sides o f the same coin, and, with affinity 
maturation, the immune response becomes increasingly specific for antigen.
How does one counter the argument that clonal deletion imposes a 
biological pressure for a highly specific antibody molecule? This may be 
achieved by arguing that clonal deletion is not the sole mechanism by which 
self-tolerance is maintained. Two-signal models, as exemplified by 
Matzingers 'danger hypothesis' (Matzinger, 1994), suggest that the body
actually does not have to make a self/non-self discrimination. In recent
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times, Coutinho and colleagues have put forward an immune network 
theory postulating that the immune system actively recognises self, the so- 
called 'self-assertion'. All self-reactive antibodies are internally activated and 
recruited into a highly connected network of self components (including variable 
regions). This is the so-called 'central immune system (CIS)'. It is inhibited from 
undergoing large clonal exponential expansions (which characterise 
conventional immune responses to exogenous antigens and would in this case 
lead to pathologic autoimmunity) by network dynamics. The remaining resting 
lymphocytes (constituting the 'peripheral immune system (PIS)') are, however, 
free to undergo conventional large clonal expansions in response to foreign 
pathogens along with affinity maturation, as described in section 1.1.2. It is the 
PIS that gives rise to protective immune responses. This second generation 
immune network theory is more fully discussed in the following references: 
(Holmberg and Coutinho, 1986; Coutinho, 1989; Cohen and Young, 1991; 
Varelo and Coutinho, 1991; Coutinho and Avrameas, 1992; Coutinho, 1995). 
This theory is not only robust to the existence o f polyreactive antibodies, but, 
establishing and maintaining an immune network is absolutely dependent on 
polyreactive antibodies (section 1.2.6).
The final argument for a specific antibody molecule is that immune 
antisera are highly specific. This fact cannot be contested. Nonetheless, much 
evidence is now available that preimmune antibodies may be polyreactive in 
contrast to immune antibodies.
.2 Evidence for multispecificity: Formal proof that monoclonal antibodies can be 
multispecific was first provided by Richards et al. (1975). They showed that a 
myeloma protein could bind with moderate affinity to two "shelf-selected" 
chemicals namely DNP-lysine and methyl naphthoquinone. Much 
experimental evidence, both direct and indirect, has since accumulated 
indicating that, in both mice and men, preimmune antibodies can be 
polyreactive.
The serum (and indeed bodily secretions such as saliva and colostrum -  
see Quan et al. (1997)) o f unimmunised (and antigen-free) mice and humans is 
reactive with a plethora o f antigens both self-antigens (blood-group antigens, 
organ extracts, polypeptides.) and foreign antigens (bacteria, virus'). These
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reactivities are due to antibody referred to as natural antibody as initially it was 
not considered to be specifically induced by antigen (Avrameas and Temynck, 
1995; Coutinho et al., 1995). More recent evidence suggests that this repertoire 
o f antibodies is the result o f a normal T cell dependent primary immune 
response to self-antigens (Coutinho et al., 1995). From the point o f  view of 
idiotype network theory it is a consequence o f and evidence for the internal 
activity o f the CIS (Coutinho, 1989). This autoreactivity is referred to as a 
physiologic autoreactivity to distinguish it from pathologic autoreactivity. 
Reactivity appears to be unequal over the somatic self and is primarily directed 
against evolutionarily conserved autoantigens (Coutinho et al., 1995; Dighiero,
1997). From the point o f view o f this discussion what is important is that much 
o f the analyses o f polyreactivity have been carried out on natural antibodies. 
This work has provided impressive evidence in favour o f the concept o f 
polyreactive antibodies.
On passing normal serum through a TNP-lysine immunoadsorbent 
column, Berneman et al. (1992) found that 20% o f the total antibody could be 
eluted from the column. Such a large percentage is indicative o f polyreactivity. 
Many similar findings have been reported in the literature (Avrameas and 
Temynck, 1995 and ref. therein; Dighiero, 1997 and ref. therein). The eluted 
antibody was then used in an immunoblot. Crude protein extracts from a variety 
o f Balb/C organs were separated through a SDS-PAGE gel and 
electrotransferred to nitro-cellulose. When the eluted antibody was used as a 
primary probe o f this protein template, many protein bands were stained. This 
again is indicative o f polyreactivity. Such observations as these have been 
extended and strengthened by analyses at the clonal level.
Unimmunised splenocytes have been immortalised by somatic cell fusion 
and the resulting hybridomas (presumed generated from naturally activated 
splenocytes) are characteristically polyreactive as indicated by measuring their 
affinity for a small panel (in general < 10) o f randomly chosen antigens 
(Temynck and Avrameas, 1986). Indeed, even for proponents o f the concept o f 
polyreactivity, the polyreactivity can often be puzzlingly large. Some Mabs 
show significant affinities for all antigens that they are tested against.
An assay referred to as a chamber ELIspot assay has been developed
which allows analysis o f  B cells at the single cell level for reactivity against a
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pair o f antigens simultaneously (Klinman e t al., 1991; Klinman, 1992). This 
assay has been used to assay for B cells secreting polyreactive antibody among 
the naturally activated splenic B cells in mice. For example in Balb/C mice 5- 
23% of B cells secreting IgM reactive with TNP-KLH could also react with 
actin or ovalbumin (Klinman, 1994). Similar levels o f cross-reactivity were 
determined using this assay in the naturally expressed repertoire o f  IgM- 
secreting B cells in the peripheral blood o f humans (Klinman et al., 1994).
Other B cell repertoires have been analysed for polyreactivity. For 
example, evidence that B cells have the potential to produce polyreactive 
antibody has been provided by studies o f leukaemic cells from sufferers o f  
chronic lymphocytic leukaemia. Analysis by ELISA of antibody produced by 
cultured leukaemic cells have indicated that they tend to secrete antibody 
reactive against a broad panel of antigens (Kipps, 1993).
Casali's group has used EBV to polyclonally activate and transform 
human B cells. The transformed B cells can subsequently be grown, under 
limiting dilution conditions, to produce large numbers o f B cell clones. The 
resulting population o f clones appears to be an unbiased sample o f the original 
infected B cell population (Casali and Notkins, 1989). Using this strategy 
indirect evidence was obtained that at least some of the B cells in human 
peripheral blood are polyreactive. Culture supernatants from over 100 
monoclonal IgM-secreting B cells were analysed by ELISA for reactivity against 
a panel o f  self and foreign antigens. In the case o f each antigen tested 
approximately 3-13% of the clones tested positive (Nakamura et al., 1988; 
Casali and Notkins, 1989). It was suggested that this could only be explained by 
the presence o f  B cells secreting polyreactive antibody in this B cell repertoire. 
This was formally proved by producing hybridomas from a panel o f transformed 
B cells secreting antibody with rheumatoid factor activity and measuring the 
affinity o f  the resulting monoclonal antibodies against a panel o f self and foreign 
antigens. O f 10 IgM secretors tested all showed affinity for more than one o f the 
antigens on the panel (Nakamura et al., 1988).
All the repertoires referred to above are preimmune repertoires.
With regard to immune antibodies (antibodies associated with an ongoing
in vivo immune response), it appears to be a generally held view that they
are monospecific (e.g. Bouvet and Dighiero, 1998). Avrameas and Temynck
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(1995) urged caution in that this is an assumption that needs to  be 
experimentally verified. Some evidence can be found in the literature to support 
the concept o f the monospecific immune antibody. Upon intentional 
immunisation and boosting o f a mouse with TNP-KLH it was found that the 
resulting repertoire o f IgG-secreting cells reactive with this antigen was highly 
specific, showing only 0.1-0.4% cross-reactivity with a variety o f  antigens in a 
chamber ELIspot assay (Klinman, 1994).
In summary, it is evident that using a variety o f methodologies, 
antibodies have been observed to  be polyreactive (observed to react with more 
than one antigen). The perception that an antibody is polyreactive, nonetheless, 
is very much dependent upon the method employed for its analysis. It depends 
on the sensitivity o f the assay and also the number o f antigens employed. It also 
depends on how the antibody was treated (such as exposure to low pH during 
purification). As a result, there is no clear consensus as to the meaning, 
relevance or usefulness o f these observations.
With regard to their relevance, one extreme view is, that all observations 
o f polyreactivity are artifactual, and due to the means o f analysis employed 
(Cohn, 1992). These observations are then assumed to have no bearing on the 
physiology of antibodies. Other authors, taking the observations at face value, 
have speculated as to their implications for the physiological role(s) o f 
antibodies (see section 1.2.6).
The usefulness, in general, o f  a classification system, whereby Mabs are 
polyreactive if  shown to react with more than one antigen but otherwise are said 
to be monoreactive, can be questioned. It has not lead to any agreement as to the 
relative sizes o f these two repertoires. Casali's group has provided evidence that 
B la  and B ib  cells produce polyreactive antibody (see section 1.2.4). As these 
are minor B cell subsets, it may be concluded that, the majority o f B cells 
produce monoreactive antibody. At the other extreme, Avrameas and Temynck 
(1995) have stated that all preimmune B cells are polyreactive to some extent. 
As a second example, comparison o f the structures o f antibodies classified as 
polyreactive, with those classified as monoreactive, have not resulted, so far, in 
any consensus as to the structural differences between these two groupings 
(section 1.2.5).
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The usefulness o f such a classification system might be improved by 
taking probability theory into account. To illustrate this, imagine a hypothetical 
panel o f 10 Mabs, of equal polyreactivity, tested against a limited and randomly 
chosen panel o f 10 antigens. On the law of averages one would expect to get a 
distribution o f reactivities (see Fig. 1.5). The crude classification system 
mentioned above would, as a result, incorrectly classify 3 o f  this panel o f Mabs 
as monoreactive. Therefore, any useful classification o f Mabs as monoreactive 
or polyreactive must involve a statistical analysis. Such statistical analyses are 
rarely if  ever carried out. Also, for a sensitive statistical test, capable o f 
efficiently discriminating between polyreactive and monoreactive antibodies, 
one would need to use a very large panel o f antigens. The immunoblots of organ 
extracts already referred to may fulfil this criterion.
4.5
E 3.5 oS 3
>. 2.5 .£
0 2 
fe 1.5-QE 1
1 0.5
n -------
il
1 U  I  —
M l
In u m b er o f hybridom as
0 1 2 3 4 5 6 7 8 9  10 
num ber o f reactivities
Fig. 1.5: A hypothetical situation is presented. A  panel o f 10 M abs o f equal 
polyreactivity (the probability o f  any M ab reacting with any antigen (p) = 0.1. 
The probability o f any M ab not reacting with any antigen (q) is 0.9) are each 
tested fo r  reactivity with a panel o f 10 antigens. The number o f M abs expected 
to react with 0, 1, 2, 3 .... 10 o f the 10 antigens are depicted in the above graph. 
These values were calculated using the follow ing binomial model: P n = 10Cn x  p n 
x q10n. P  is the probability o f a M ab reacting with n o f the antigens.
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The classification of Mabs as either polyreactive or monoreactive also gives the 
impression that polyreactivity is qualitatively absolute and disregards the 
possibility that B cells differ quantitatively in their degree o f polyreactivity. 
Evidence can be found that the degree o f polyreactivity varies widely among 
preimmune B cells. Grandien et al. (1994) analysed a randomly chosen panel 
of 128 hybridomas generated from B cells from bone marrow. These were 
analysed by ELISA for reactivity against a panel of eight antigens. From a 
potential total o f 1024 positives 142 positives were obtained. A statistical 
analysis of these results is presented in Fig. 1.6
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Fig. 1.6 : The null hypothesis to be tested is that the 128 Mabs analysed by 
Grandien et al. (1994) are equally polyreactive. Under this hypothesis the 
probability o f  a Mob reacting with an antigen (p) is 0.138 (142/1028). The 
probability o f  a  Mab not reacting with an antigen (q) is thus 0.862. The 
expected distribution o f Mabs, plotted above, is then calculated based on the 
binomial distribution Pn = 8C„ x p n x q8n. The null hypothesis is then tested, by 
comparing the observed and expected distributions, using a 'tf goodness-of-fit 
test' (Ostle and Malone, 1988). When this test is carried out the null hypothesis 
is rejected at the 95% confidence level. It is accepted that the Mabs differ in 
their degree o f  polyreactivity. The observed distribution does not indicate two 
discrete populations. This suggests that rather than two discrete populations o f  
Mabs (one polyreactive and one monoreactive), one is observing a continuous 
gradation o f polyreactivity.
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1.2.3 Characteristics of polyreactive antibodies: There is broad agreement with 
regard to a number o f characteristics o f  antibodies classified as polyreactive. 
They tend to be produced by preimmune B cells. In general, they tend to react 
with antigen, with only modest affinities o f between lxlO"6 -  1x10'8M. They 
tend to utilise gene segments in germline configuration (Dighiero, 1997). Most 
importantly, perhaps, polyreactive antibodies are not simply "sticky" but at the 
monoclonal level show very fine discrete sets o f  specificities. This has been 
demonstrated, most elegantly, using a newly developed immunoblot assay in 
which monoclonal polyreactive antibodies are assayed for reactivity against 
many 100's o f antigens at once (Nobrega et al., 1993; Haury et al., 1994). There 
is some disagreement, however, with regard to the prevalent isotype among 
polyreactive antibodies. Casali and Schettino (1996) have indicated that the IgM 
isotype dominates at least among the natural antibody repertoire. While this 
may simply reflect the dominance o f the IgM isotype, in general, the results of 
Klinman (1994) tend to refute this explanation. He found using a chamber 
ELIspot assay that the IgG repertoire o f naturally activated splenic B cells (in 
mice) is much less cross-reactive than the IgM repertoire. In contrast to the view 
o f Casali and Schettino (1996), Avrameas and Temynck (1995) have indicated 
that, for the natural antibody repertoire o f mice and men, IgG and not IgM, is the 
predominant isotype o f polyreactive antibody. Nevertheless they have indicated 
that, at least in mice, this IgG activity can be masked in normal serum and is 
only manifest upon purification o f the IgG from the serum.
1.2.4 Cell surface markers for polyreactivity: Evidence is available that 
polyreactive B cells segregate with the CD5+ B cell subset (Nakamura et al., 
1988a; Casali and Notkins, 1989; Bhat et al., 1997). Nevertheless, this is a 
controversial issue and more recent evidence appears to indicate that this cell 
surface marker may not be indicative o f polyreactivity. For example, Chen et al. 
(1995) found that both CD5+ and CD5- B cells from the peripheral blood of 
healthy humans could produce polyreactive antibody although the CD5+ subset 
did contain a greater frequency o f cells secreting polyreactive antibody.
A possible explanation for such contradictory results may lie in recent 
advances in our understanding o f B cell subsets. B cells have been divided into 
two broad subsets based on the expression or lack o f expression of the CD5
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antigen (reviewed by: Herzenberg et al., 1986; Hiyakawa and Hardy, 1988; 
Kipps, 1989; Kantor, 1991; Lydyard e t al., 1993). These cells are not only 
phenotypically distinct but they respond differently to cytokines and have 
different bodily distributions. As previously suggested, they may express 
different repertoires o f antibodies and hence may fulfil different physiological 
roles (Lydyard et al., 1993). There also is evidence that these subsets have 
completely different cell lineages although some workers have suggested that 
the CD5 antigen is simply an activation marker on B cells (Lydyard et al.,
1993). More recently it was found (mice and humans) that a third B cell subset 
exists, which appears to be identical to the CD5+ subset in every way except for 
its lack o f expression o f the CD5 antigen (Kasaian and Casali, 1993). In modem 
parlance this subset is referred to as the B ib  subset, the CD5+ B cell subset is 
the B la  subset with the remaining B cells being referred to as the B2 subset. As 
a result it is possible that, while polyreactive B cells do not segregate with the 
CD5+ B cell subset, they do segregate with cells o f  the B1 lineages (Kasaian and 
Casali, 1993). This viewpoint is, however, made less tenable by the finding 
(Grandien et al., 1994), that emergent B cells in the bone marrow are very 
polyreactive. All available evidence points to the bone marrow being a source 
of B2 cells only (Kantor, 1991).
A better phenotypic marker for polyreactive B cells may be their ability 
to bind antigen. Chen et al. (1995) separated enriched B cells based on their 
ability to bind |3-galactosidase, a randomly chosen antigen. 30% of B cells were 
positively selected and the frequency o f B cells producing polyreactive antibody 
was 10 times greater in this population than the remaining B cells.
1.2.5 Structural correlates for polyreactivity: Efforts have been made to compare 
antibodies classified as polyreactive or monoreactive in order to determine if any 
discrete structural features predispose to one characteristic over the other. One 
suggestion is that the IgM isotype is an important structural correlate for 
polyreactivity (Ghosh and Campbell, 1986). However, although polyreactive 
antibodies may frequently be o f the IgM isotype the relationship is unlikely to be 
a causal one. The elegent gene shuffling experiments o f Ichiyoshi and Casali 
(1994) demonstrated that the variable regions o f a polyreactive IgM antibody
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could be successfully grafted on to an IgG  constant region with retention o f 
polyreactivity. The relationship between polyreactivity and IgM isotype (if any) 
is more likely a reflection o f the fact that the IgM isotype is associated with the 
preimmune repertoire and IgG with the immune repertoire.
There are, presumably, some features o f an antibody binding site that 
predispose to polyreactivity. Polyreactive Mabs tend to utilise minimally 
mutated (germline) Vh gene segments. This cannot be sufficient for 
polyreactivity as monospecific B cells also utilise germline genes and IgG and 
IgA polyreactive antibodies contain somatic mutations (Harindranath et al., 
1993; Ichiyoshi and Casali, 1994). It was postulated that the gene segments 
coding for polyreactive antibodies are distinct from those encoding specific 
antibodies, but there is no conclusive evidence to suggest that Vh gene segments 
preferentially segregate with polyreactive or monospecific B cells (Ichiyoshi and 
Casali, 1994; Bhat e ta l, 1997).
There is some evidence to suggest that the CDR3 o f the heavy chain may
be an important structural correlate for polyreactivity. Kipps et al. (1993) have
shown that CLL cells express a very skewed repertoire o f DH and Jh gene
segments relative to a normal B cell repertoire. Using a recombinant approach
they demonstrated that replacing the CDR3 of a polyreactive CLL antibody with
a variety o f randomly chosen CDR3s resulted in the loss o f polyreactivity. They
have also shown that the CDR3 of CLL antibodies tend to be significantly
longer than those in a general B cell repertoire and have suggested that this is a
structural correlate for polyreactivity (Kipps et al., 1993). The chain shuffling
experiments o f Ichiyoshi and Casali (1994) also suggest that the CDR3 can play
an important role in polyreactivity. They demonstrated that replacing the CDR3
of a monospecific antibody with the CDR3 of a polyreactive antibody was
sufficient to generate a chimaeric antibody that had lost its monospecificity.
Although the CDR3 of this particular polyreactive antibody was very long they
cautioned that in general the CDR3s of polyreactive antibodies appear to be
diverse in terms o f length and amino acid composition. Hence, they suggested
that length may not be the sole characteristic o f  the CDR3 responsible for
polyreactivity or that different structures outside o f the CDR3 can be responsible
for polyreactivity in different antibodies (Ichiyoshi and Casali, 1994). The
value o f  these observations on the importance o f CDR3 for polyreactivity may
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be questioned given that it appears to be important for antibody binding in 
general (see section 1.1.1.3).
As suggested in section 1.2.1, general characteristics o f the antibody 
binding site such as its flexibility ('plasticity') may be responsible for 
polyreactivity. Padlan (1994) has suggested that the antibody binding site may 
simply be very plastic in polyreactive antibodies. It has also been suggested that 
very large binding sites may be a characteristic o f  polyreactive binding sites. In 
this regard analysis o f  the overall three-dimensional structure o f polyreactive 
antibodies may be useful. Ramsland et al. (1997) have made a start in this 
direction by homology modelling the three-dimensional structures o f three 
polyreactive binding sites. No common structural feature was found that might 
distinguish them from monospecific antibodies. Labrousse et al. (1997) have 
approached the problem by analysing the effect o f physicochemical parameters, 
such as temperature and pH, on the binding of monoreactive and polyreactive 
antibodies. They found that polyreactive binding was much more sensitive to 
variations in these parameters and concluded that polyreactive binding sites are 
more plastic than monoreactive.
It was suggested that polyreactivity might be dependent upon post- 
translational modification o f the antibody molecule (Fernandez et al., 1997 and 
1997a). These authors have shown that polyreactive binding is dependent on 
glycosylation o f the antibody molecule at least in some instances.
Finally, it has also been suggested that it is not the structure o f their 
binding sites, but rather the nature o f the epitopes that they recognise that 
distinguishes polyreactive antibodies from their monospecific counterparts. 
Polyreactive antibodies may recognise 'public epitopes' carried on many 
antigens. In this regard, Tchemychev et al. (1997) have provided evidence that 
the epitopes for natural polyreactive antibodies are rich in proline. They have 
suggested that structures containing proline can serve as conformation 
dependent 'public epitopes' for polyreactive antibodies.
.6 Physiological roles of polyreactive antibodies: The concept o f polyreactivity 
has been incorporated into conventional thinking (clonal selection) on the role o f 
antibodies in acquired immunity. For example, it has been argued that a 
preimmune polyreactive repertoire would provide better coverage o f the
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potential universe o f antigens and would provide a template upon which somatic 
hypermutation would act to increase specificity and affinity. Several authors 
have discussed this concept (Harindranath et a l ,  1993; Dighiero, 1997 and 
1997a).
As previously discussed, antibody monospecificity is a basic tenet o f 
clonal deletion theories. Therefore, it is curious that some authors have 
considered the notion that polyreactive B cells may play a role in deletion. Chen 
et al. (1995 and 1996) have suggested that polyreactive B cells with many anti­
self reactivities could act as antigen presenting cells for T cells with deletion o f 
the T cell or induction o f anergy.
Other researchers have postulated that polyreactive antibodies may fulfil 
defensive roles distinct from those o f monoreactive antibodies. Since, the 
natural antibody of the serum (and bodily secretions) is reactive against many 
foreign pathogens (presumably due to its polyreactive antibody component), the 
suggestion is that this antibody forms an antibody-mediated innate defensive 
mechanism against bacteria and other pathogens (Harindranath et a l, 1993; 
Casali and Schettino, 1996; Quan e ta l., 1997). These authors hypothesize that 
B2 cells are the B cells committed to conventional immune responses, while B la  
and B ib  cells function in the antibody-mediated innate defensive mechanism. In 
support o f this concept the theory advanced is that the B la  cell is a rather 
primitive B cell lineage as it is the first to appear in phylogeny and that it may 
represent a stepping stone between innate immunity and acquired immunity 
(Lydyard et a l ,  1993). Bouvet and Dighiero (1998) have also suggested the 
concept o f a layered humoral immune system. They posit an initial, primordial, 
polyreactive, autoreactive, antibody molecule, which may have been o f use in 
the clearance o f degraded auto-antigen. Gene duplication and mutation followed 
by auto-antigen driven natural selection resulted in a simple preliminary immune 
system which functioned in cell debris clearance. Due to its polyreactivity it 
developed a secondary protective role by binding to pathogens. Later in 
evolution modem monospecific antibodies evolved to fight off pathogens which 
had mutated to avoid binding the natural antibodies. Modem vertebrates have 
maintained the primordial immune system as the modern immune response to 
pathogen has to be induced and to prevent pathologic autoimmunity (by binding 
to and masking autoantigen).
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A number o f authors have gone so far as to speculate that polyreactive 
antibodies may fulfil roles o f a non-defensive nature. It was noted in section
1.2.1 that polyreactive antibodies are essential to the setting up and functioning 
of the CIS. For example, the Vh genes expressed first during ontogeny are 
highly polyreactive in so far as they show very high idiotypic connectivity with 
each other (Kearney and Vakil, 1986; Varelo and Coutinho, 1991). This 
developmentally regulated expression o f  antibody gene segments may facilitate 
the early organisation o f an idiotype network (Varelo and Coutinho, 1991). This 
network is then maintained (in part) by recruiting from the emergent B cell 
population, those B cells showing polyreactivity (Varelo and Coutinho, 1991). 
(This recruitment into the CIS, o f polyreactive antibodies, may actually be the 
reason that the PIS and hence immune antibodies, tend to show monoreactivity). 
From the point o f view of host defense the CIS may serve no other role than the 
prevention o f pathologic autoimmunity (Coutinho and Avrameas, 1992). 
However, the suggestion was also made that rather than playing a role in host 
defense the CIS may in fact play a role in the homeostasis o f all other biological 
systems (Coutinho and Avrameas, 1992). Stewart (1992) has proposed that 
immunoglobulins arose in evolution for this purpose and that their defensive role 
was a relatively late evolutionary development.
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1.3 Monoclonal antibody production
As mentioned at the start o f this chapter, antibody binding sites are considered 
the paradigm for specific biomolecular interactions. The biotechnological 
importance of antibodies and antibody derivatives is predicated upon this 
perception. In basic, applied and clinical research, they are important 
components o f many analytical tools. Their use in ELISAs allows the detection 
and quantification o f ligands in complex biological matrices. HIV diagnosis is 
frequently dependent upon detection o f the p24 antigen by ELISA. The 
detection of pesticides in foodstuff extracts, currently assayed in the laboratory 
by relatively cumbersome tools such as high pressure liquid chromatography 
(HPLC), will soon be assayed, in the field, using ELISA-based 'dipsticks'. The 
use o f monoclonal antibodies allows the visualization o f ligands in biological 
matrices (e.g. immunocytochemistry). This is the case, frequently, in post­
mortem analysis o f tissue samples, for viral infections.
Antibodies are also expected to find many therapeutic uses in the future. 
30% o f all biological molecules currently undergoing clinical trials are 
recombinant antibodies (Hudson, 1998). They may find a role in cancer therapy, 
targeting toxins to tumours (immunotoxins and genetic immunotoxins) (Chen 
and Marasco, 1997). Other, more speculative proposals, include their use to 
target gene vectors to specific tissues or cell types (Roth and Cristiano, 1997), 
which is a prerequisite for many forms o f gene therapy.
However, in light o f  the observations o f polyreactive antibodies reported 
in section 1.2, the perception that antibodies are invariably specific is no longer 
tenable. While one may argue about the relevance of such observations to the 
physiological roles o f antibodies (e.g. Cohn, 1992), from a biotechnological 
point o f view it is the observation in and o f itself that is important. For example, 
if  one observes that an antibody binds in solution to more than one ligand, 
one clearly could not use the antibody in a competitive ELISA to detect and 
quantitate a specific ligand. It is with this point o f view that, in this section, 
monoclonal antibody production by immortalisation o f B cells or repertoire 
cloning is reviewed. It is suggested that the means o f production o f Mabs 
greatly influences the probability o f generating a specific Mab.
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1.3.1 B cell immortalisation: The conventional approach for the production of 
monoclonal antibodies relies on the immortalisation and subsequent cloning o f B 
cells, prior to screening secreted antibody, for the reactivity desired. A number 
o f approaches for immortalisation are possible. Murine B cells are normally 
immortalised by fusing B cells with myeloma (a cancerous cell line o f  lymphoid 
origin) cells. This results in a population o f cells referred to as hybridomas with 
the twin attributes o f  immortality (from the myeloma) and antibody secretion 
(from the B cell partner). The population o f hybridomas can be cloned, by 
culturing under limiting dilution conditions, and then screened
Human B cells, normally, are immortalised by fusion with either a 
myeloma or preferably a heteromyeloma (Kozbor et a l, 1986; Zanella et a l, 
1992). They may also be immortalised using Epstein Barr Virus (EBV) (Steinitz 
et al., 1977).
1.3.1.1 Fusion: Two methods are now predominantly used to induce membrane fusion. 
These are electrofusion and the chemical fusogen polyethylene glycol (PEG).
Kohler and Milstein (1976) were the first to use PEG for cell fusion. 
PEG causes two obvious effects on cells: i) dehydration and shrinkage of cells 
and ii) cellular aggregation (Lucy, 1978; Klebe and Bentley, 1987; Hui and 
Stenger, 1992). Dehydration o f cells is due to hydration o f the hydrophilic PEG 
molecules. Fusion may occur, during PEG dilution (cell rehydration), due to 
weakening o f cytoskeletal and membrane protein restraints and subsequent 
increase in membrane fluidity (Lucy, 1978). The driving force for coalescence 
o f the adjacent bi-layers is not obvious but PEG may introduce structural 
deformities into the bi-layer (Hui and Stenger, 1992).
Electrofusion was first applied to lymphocytes by Bishoff et al. (1982)
and the first monoclonal antibodies produced by Karsten et al. (1985). Two
processes are involved in the electrofusion o f freely suspended cells: i)
formation o f cell chains (pearl chains) to induce membrane contact and ii)
application o f an electrical field pulse o f sufficient strength to cause reversible
membrane breakdown (Zimmerman, 1982). A number o f methods have been
used to induce cell alignment, dielectrophoresis being the preferred method
(Zimmermann, 1987). The following provide excellent indept reviews of the
theory o f dielectrophoresis and electrical membrane breakdown: (Zimmermann,
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1982; Zimmermenn, 1987; Zimmermann et al., 1990; Perkins et al., 1989; Neil 
and Zimmermann, 1993).
Both these techniques are quite inefficient with PEG immortalising only 
one out o f every 100,000 B cells and electrofusion one out o f every 10,000. It 
should also be noted that in both cases, the resulting population o f  hybridomas is 
not a random sample, o f the B cell population, as the fusibility o f cells varies 
with their state o f differentiation. The optimum state o f differentiation is 
unknown but it is clear that activated cells are preferentially fused over resting 
cells (Shay, 1985).
1 .3 .1 .2E B V  transform ation. EBV is a human lymphotrophic herpes virus that can 
activate and transform human B cells (Crawford, 1985). Although all resting B 
cells appear to have the receptor for EBV infection, there are conflicting views 
on its expression during the cell cycle. Nonetheless, transformed B cells appear 
to be a random sample o f  the resting B cell population (Casali and Notkins, 
1989).
Transformation o f B cells with EBV is a well-documented procedure and 
details can be found in Crawford (1985). Transformation efficiencies o f up to 
40% o f all input B cells have been reported (Chan et a l, 1986) although 1% 
appears to be a reasonable average.
1.3.2 B cell populations for immortalisation: In the case o f murine B cells, 
generating the required B cell population prior to fusion does not present any 
problems, in general. One simply hyperimmunises a mouse with the ligand o f 
interest, sacrifice it three days after the final boost, and fuse its splenocytes with 
a myeloma cell line. Having undergone an immune response, the splenocyte 
population will be enriched in B cells secreting antibody o f the desired 
reactivity, which, being activated, will be fused preferentially over the resting 
preimmune B cells. The activated immune B cells can reasonably be 
expected to be of high affinity and specificity. Although this is the preferred 
means o f generating a B cell population prior to fusion, in certain circumstances 
a technique referred to as in vitro immunisation (IVI) is said to be preferable. 
IVI is discussed in section 1.3.2.2.
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Unfortunately, generating a suitable source o f human B cells prior to 
fusion is not as trivial a task as in the case o f  the mouse. The major problem is 
an ethical one; one simply cannot inject most ligands into a human volunteer to 
generate an immune response as in the case described above for the mouse. 
Thus, in general, one must resort to immortalising preimmune B cells obtained 
from peripheral blood or immunise peripheral blood lymphocytes in vitro.
1.3.2.1 Preim m une B  cells: Preimmune B cells are not immortalised well by fusion (see 
section 1.3.1.1), so EBV is generally used. Steinitz et al. (1977) advised 
antigenic pre-selection o f lymphocytes, o f the desired reactivity, from the 
preimmune population, to remove problems o f clonal competition from 
irrelevant cell lines. This appears to be the preferred strategy with antigenic 
post-selection also being used (Bron et al., 1984).
Other strategies using preimmune B cells include use o f the EL-4 culture 
system (see Zubler et al., 1985; Zubler et al., 1987; Wen et al., 1987) to activate 
pre-selected B cells prior to immortalisation by electrofusion (Steenbakkers et 
al., 1994). The CD40 culture system (see Banchereau eta l., 1991) has also been 
used in combination with EBV transformation to produce monoclonal antibodies 
(Peyron et al., 1994). The main reason for activating B cells in these culture 
systems appears to be that they facilitate class switch o f preimmune IgM 
antibodies to IgG or IgA,
One potential problem, with strategies involving the use of 
preimmune B cells, is that they may suffer from polyreactivity. The results 
of Chen et al (1995) also suggest that antigen-selection of B cells will enrich 
for polyreactive B cells.
1.3 .2 .2In  vitro im m unisation: Moller and Borrebaeck (1988) have defined this type of 
culture system as a primary immunisation system i.e. one that allows an antigen- 
induced, antigen-specific response. The area has been extensively reviewed in 
the past (see Reading, 1982; Borrebaeck, 1986; James and Bell, 1987; 
Borrebaeck 1988 and 1988a; Borrebaeck, 1993) and will only be briefly 
introduced here. Instead the main thrust o f this section will be to point out areas 
o f concern with regard to the suitability o f this technique for monoclonal 
antibody production.
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Mishell and Dutton (1966) first achieved antigen-specific activation o f B 
cells. Since that time, a broad range o f protocols leading to the antigen-specific 
activation o f B cells have been published. Although differing in the fine-detail, 
most published protocols consist o f three main components. Firstly, a source o f 
immunocytes is required. For murine systems unfractionated splenocytes are 
almost invariably used. For human systems peripheral blood lymphocytes are 
generally used and for an optimal response need to be pretreated with 1-leucyl- 
leucine methyl ester. This removes the lysosomal-rich cell fraction (Borrebaeck 
et al., 1988). Secondly, a source o f lymphokines is required to facilitate the 
immune response. In general conditioned media is used for this purpose. 
Conditioned media which have been applied in murine systems include 
thymocyte-conditioned media (Luben and Moller, 1980), mixed lymphocyte- 
conditioned media (Borrebaeck, 1983), supernatant o f an EL4 thymoma cell line 
(Ma et al., 1984) and splenocyte-conditioned media (Reason et al., 1987). In 
human systems a number o f different polyclonal activators (poke weed mitogen 
(PWM), phytohaemagglutinin (PHA), concanavalin A (con A), 
lipopolysaccharide (LPS)) have been used to stimulate lymphoid cells and the 
resulting conditioned media is collected and utilised. The third component 
required, is the antigen against which an immune response is desired.
In  vitro immunisation was first used to provide activated B lymphocytes 
prior to fusion, by Hengartner et a l (1978) and Luben and Moller (1980). 
Borrebaecks group, in particular, have advocated its application for the antigen- 
specific activation o f human B cells prior to fusion. This is because ethical 
considerations preclude in vivo immunisation. Other characteristics o f in vitro 
immunisation, which supposedly make it an attractive proposition for 
immunising human or indeed murine B cells, include the following. Firstly, the 
culture period prior to fusion, generally, does not exceed five days. Secondly, 
only very small amounts of antigen are required. Concentrations used have 
varied from lng/ml to 100(a.g/ml (Borrebaeck, 1986). Thirdly, immune 
responses to self-antigens can be obtained and immunogenic epitopes, which 
dominate in vivo, are moderated. Finally, toxic antigens can be used in vitro  but 
not in vivo. Regardless of the above, the suitability of this technique for 
monoclonal antibody production can be questioned.
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Firstly, it is by no means certain that in vitro immunisation is indeed an 
accurate mimic o f the in vivo immune response. While, it cannot be denied that 
in vitro immunisation protocols give rise to an increase in frequency of antigen- 
reactive B cells, many of its other characteristics are foreign to in vivo responses, 
i) in vitro immunisations occurring in suspension obviously cannot recreate the 
organised structure o f an immune organ, this organisation being assumed to  play 
a role in the in vivo immune response (Zubler et al., 1987). ii) 2- 
mercaptoethanol, which is toxic in vivo, is an essential nutrient in all published 
in vitro immunisation protocols, iii) In certain in vitro immunisation protocols 
(e.g. Borrebaeck and Moller, 1986) T cells, which are essential in vivo, have 
been demonstrated to be superfluous. A related observation is that hapten- 
induced, hapten specific immune responses appear to occur in vitro (Stahl et al., 
1995). iv) Antigen-induced, antigen-reactive immune responses, at least in 
certain protocols, are superimposed on a very large polyclonal B cell response 
(Borrebaeck and Moller, 1986). v) Most crucially, however, it should be pointed 
out, that clonal expansions of self-reactive B cells, one o f the cited advantages o f 
in vitro immunisation, is totally at odds with one o f the most distinctive 
characteristics o f  the immune system in vivo. In healthy mammals clonal 
expansions o f self-reactive B cells does not occur! This characteristic may 
indicate that naturally activated B cells including/and/or B -l cells may be 
preferentially activated in vitro.
Secondly, the robustness and reproducibility o f the technique has been
queried. A number o f authors such as Uthoff and Boldicke (1993) and Brams et
al. (1993a) have failed to generate antigen-reactive immune responses using
published in vitro immunisation protocols. As noted by Grandien et al. (1994)
referring to B cell culture systems “Widely discrepant results have been
observed and reported after in vitro exposure o f B cells to Ig ligands: death of
the cells, complete activation to increassed DNA synthesis (which some
interpret as repair), activation of responsiveness to various lymphokines, etc., let
alone all the biochemical phenomenology on "signalling pathways" and early
activation events. Differences in normal cell populations or transformed cell
lines, in the ligands (antibodies) used, in the culture conditions, in the assays
employed, all can be invoked to explain such discerpancies, but do not entirely
remove the widespread conviction that any result can be obtained, with the
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consequent reservations as to the value o f the observations for B cell physiology 
in vivo.”
Thirdly, the common assertion that the five-day culture period in vitro is 
a tremendous advantage over the 30-day culture period required for an immune 
response in vivo is blatant misrepresentation. In  vitro  immune responses are 
primary responses, in general, and the 30-day period referred to, allows a 
secondary immune response to occur in vivo. In fact, a primary immune 
response will occur in vivo in three to five days.
Fourthly, and perhaps of greatest practical consequence, since in 
vitro immunisation protocols generally mimic primary immune responses 
only, the resulting antibodies might be expected to be of low affinity and 
perhaps also of broad specificity. At worst, if  for example B -l cells are 
preferentially activated, the resulting monoclonal antibodies can clearly be 
expected to be polyreactive. Unfortunately there is a lack o f information with 
regard to these characteristics in the published literature although Moller et al. 
(1990) have reported generating an IgM antibody o f high affinity (3xl09 M '1) 
using an in vitro immunisation protocol. It should also be noted that there have 
been two reports in the literature o f secondary immune responses being 
generated in vitro from preimmune human B cells as defined by class switch and 
possibly affinity maturation (Brams et al., 1993 and 1993a; Zafiropoulos, et al.,
1997). Nonetheless, until the monoclonal antibodies produced by in vitro 
immunisation are more fully characterised, with regard to specificity and 
affinity, doubts about its general utility for monoclonal antibody production may 
be justified.
.3 Immunological repertoire cloning: As pointed out in section 1.1.2, the advent
o f PCR has facilitated the cloning o f gene segments, encoding V h  and V l
domains from hybridomas. This technology has been brought to its logical
conclusion by utilising it to clone repertoires o f rearranged gene segments
encoding Vh and Vl domains from B cell populations (Fig. 1.7). These
amplified gene segments are, in general, randomly recombined in ScFv format
by e.g. slice-overlap-extension (Krebber et al., 1997) to form combinatorial
libraries of genes, encoding hopefully a diverse repertoire o f binding site
reactivities. The resulting repertoire can be cloned into a vector and maintained
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Fig. 1.7: Steps in the generation o f a combinatorial antibody library 
from 4 B cells. Note that the complexity o f the library varies to a first 
approximation with the square o f the number o f B cells used to create 
the library.
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indefinitely in E. coli. This overall process is referred to as “immunological 
repertoire cloning” (Persson et a l, 1991). These repertoires can be probed, by 
screening or selection, to isolate genes encoding a desired reactivity. Isolated 
genes, subsequently, can be expressed in E. coli for monoclonal antibody 
production. Proof-of-principle' experiments have clearly demonstrated the 
feasibility o f the approach. Ward et al. (1989) isolated Vh domains, reacting 
with lysozyme or keyhole limpet haemocyanin, with affinities o f around 2x1 O'8 
M  from secondary immune repertoires (see section 1.3.3.1). Huse et al. (1989) 
isolated Fabs reacting with p-nitrophenyl phosphonamidate, from a secondary
*  ’ 7  Q  *  *combinatorial library, with apparent affinities o f 10' to 10' M. Nissim et al. 
(1994) have isolated ScFvs reacting with various foreign and self-antigens from 
a naïve human immune repertoire (see section 1.3.3.1). The technology has been 
extensively reviewed recently (Hoogenboom, 1997; Aujame et a l, 1997; 
Griffith and Duncan, 1998; Hudson, 1998) and the reader is referred to these for 
a more in-dept treatment o f the technology, which is only briefly outlined below. 
Subsequent sections address the following questions. What B cell populations 
should we use for cloning? How can we best probe the resulting repertoires for 
the desired reactivity? What are the advantages o f this system over B cell 
immortalisation?
1.3.3.1B  cell populations. The first choice to be made is between a B cell population
from an individual immunised with the antigen of interest or from an
unimmunised (naïve) individual. A B cell population from an immunised
individual will be enriched in somatically mutated Vh -Vl combinations selected
for high affinity with the desired antigen. The resulting secondary repertoire can
reasonably be expected to be enriched in high-affinity binders, relative to a
repertoire cloned from a naïve individual (naïve repertoire), even with the
random recombination inherent in repertoire cloning, which scrambles up the in
vivo pairing o f heavy and light chains (see Gherardi and Milstein, 1992). The
disadvantage o f this process o f course is that separate secondary libraries must
be generated for each antigen o f interest. A naïve library can be used again and
again for many different antigens but can be expected to contain reactivities of
only moderate to weak affinity, the mean affinity increasing with size o f the
naïve repertoire. On a positive note, it is possible to treat genes isolated from a
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naïve library (or indeed any other kind), which are o f insufficient affinity, as a 
“lead” gene. Strategies to randomly mutate such “leads”, generate libraries from 
which genes encoding higher affinity reactivities can be isolated. Such 
strategies include, random mutations using mutator strains o f E. coli, targeted 
mutations, chain shuffling, error-prone PCR and sexual PCR (Bradbury, 1997).
The second choice to be made is from which organ to obtain B cells. The 
generation of secondary libraries, from immunised mice, requires that the B cells 
are isolated from a secondary organ and the spleen is invariably used. For 
generating naïve repertoires it appears to be accepted that bone marrow B cells 
are the theoretically best source o f B cells. This appears to be based on the 
belief, that bone marrow B cells are generated, and proliferate, in an antigen- 
independent fashion, and hence represent an unbiased, highly diverse, source o f 
rearranged immunoglobulin genes. In actual fact no stage o f lymphopoiesis 
appears to be antigen-independent (Grandien et al., 1994a). Furthermore, 
studies o f characteristics, such as diversity, although in their infancy, have 
indicated that the splenic B cell repertoire, o f mice, is as diverse as the bone 
marrow repertoire with the potential advantage that it appears to be less 
polyreactive (Grandien et a l, 1994a). For humans the only ethical choice is to 
obtain B cells from peripheral blood.
It should be mentioned that completely synthetic libraries, generated 
independently o f any B cell population, are considered by many authors to be 
the best strategy for repertoire cloning, as one has better control over the content 
o f the library (Hudson, 1998).
1.3.3.2 Probing cloned repertoires. Initially libraries were screened for reactivities o f 
interest. Ward et al. (1989) generated V h  secondary libraries to lysozyme and 
keyhole limpet haemocyanin and cloned the library into an E. coli expression 
vector. Screening was carried out, by assaying the supernatants, from individual 
transformants, by ELISA. A similar strategy was used by Huse et al. (1989).
As pointed out by McCafferty et al. (1990) selection is a much more 
powerful means o f  probing libraries than screening. They demonstrated that by 
phage display o f ScFvs, one ScFv, with a desired reactivity, could be selected 
from a million irrelevant ScFv, by affinity chromatography.
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Phage display is based on the observation by Smith (1985) that peptides 
(and as subsequently shown proteins) could be fused to the coat protein o f 
filamentous phage without completely abrogating their infectivity for E. coli. 
The strategy as applied to probing immune repertoires is depicted in Fig. 1.8 
with specific reference to the Nissim library (Nissim et al., 1994). p ill refers to a 
M l3 (filamentous phage) coat protein. PelB is a bacterial leader sequence 
allowing export to the periplasm. C-myc refers to a short peptide tag derived 
from the C-terminus o f the c-myc protein. This tag is recognised by the mouse 
monoclonal antibody 9E10. pHenl-VA.3 is a phagemid vector, i.e. it contains 
the IG (intragenic) region from M l3 thus allowing it to be packaged into a phage 
particle if  the M l 3 structural proteins are provided in trans. An amber stop 
codon exists between c-myc and g ill.
The Nissim library was composed from 50 germline Vh gene segments, 
amplified in such a fashion as to introduce a random synthetic CDR3. The 
resulting product was cloned into the pHenl-VA-3 vector generating a library 
encoding diverse PelB-ScFv-c-myc-pIII fusion proteins. The resulting library is 
propagated in E. coli TGI and upon induction a specific ScFv-c-myc-pIII fusion 
protein is expressed in the periplasm o f individual cells. I f  induction is 
accompanied by infection with a helper phage (a filamentous phage whose 
genome contains the genetic information for all its structural proteins but lacks 
an IG  region so its genome cannot be packaged) a library o f phage particles are 
excreted. Individual phage particles will contain both native p ill and a specific 
ScFv-c-myc-pin on their surface and, as a genome, will contain the specific 
phagemid vector encoding the ScFv fused on their surface. Thus, affinity- 
purification o f phage particles with a relevant antigen, (panning), enriches for 
phagemid vectors encoding ScFvs with antigen-binding activity. Affinity- 
purified phage can infect E. coli TGI again to  allow the propagation in E. coli o f 
this enriched sublibrary. In general, this selection procedure is repeated twice. 
The final phage population is used to infect E. coli HB2151, which recognises 
the amber stop codon, and hence produces an ScFv-c-myc fusion protein, and 
the resulting E. coli clones are screened for the desired reactivity, by e.g. ELISA 
making use o f the c-myc tag.
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start codon amber stop codon stop codon
Extrusion of phage
pHen l-VA, +  insert (encoding the S cFv displayed on its
surface).
structural proteins, provided in trans by 
helper plasm id
S c F v -g lll fusion protein
F ig . 1.8a: One clone from cm immune repertoire library has just been infected with 
helper phage and cultured in the presence of isopropyl ft-D-thiogalactopyranoside 
(IPTG). This results in extrusion of specific phage particles, expressing on their 
surface, and encoding only one species of ScFv. Infection and induction of the entire 
library results in a mixture of phage particles, each expressing on its surface, and 
encoding, a different species of ScFv (phage library). Antigen can then be used to 
affinity-purify, from the phage library, those phage expressing and encoding ScFv 
with anti-antigen binding activity (see Fig. 1.8b).
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F ig . 1.8b: Affinity-purification, of phage expressing and encoding ScFv with anti­
protein X binding activity, from a phage library. The phage library is harvested from a 
culture of E. coli TGI, and are incubated on a plastic surface, coated with protein X. 
Phage expressing and encoding ScFv, reactive with protein X, are isolated by washing 
off irrelevant phage and then eluting bound phage. This population of phage 
('sublibraryj can be expanded, in E. coli TGI, prior to repeating the affinity- 
purification. Alternatively E. coli HB2151 can be infected to produce soluble ScFv-c- 
myc proteins. See text for additional details.
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1.3.3.3 Advantages o f  immunological repertoire cloning: A  num ber o f  advantages are 
attendant upon  this technology. F ro m  an ethical p o in t o f  v ie w  anim al suffering  
is reduced as naive libraries have to be created just once and no im m unisation  is 
required. E q u a lly , there are m any pragm atic reasons fo r em ploying  this 
technology, i) B  ce ll im m ortalisation is a very  in effic ien t process and hence  
does not provide com prehensive or easy access to the in vivo antibody  
repertoire. In vitro repertoires in  E. coli are, how ever, easily and e ffic ien tly  
accessed b y  selection and screening, ii) A s  already indicated  the generation o f  
hum an m onoclonal antibodies using  fu sio n  tech n o logy  has had lim ited  success 
and few  c lin ica lly  or com m ercia lly  successful applications. R epertoire clon in g  
is set to overcom e this problem , iii) T h e  tim e period  fo r  generation o f  a 
m onoclonal antibody should  be m uch reduced com pared to in vivo 
im m unisation, iv) It has allow ed the generation o f  m on oclona l antibodies  
against antigens to w h ich  m on oclonal antibodies cannot be produced in vivo 
such as the protein B iP  (N issim , 1994) and it has been cla im ed  that antibodies 
w ith greater specific ity  and affin ity  can be generated in vitro than in vivo 
(H udson, 1998). v) M o st im portantly, screening strategies at the end o f  the 
selection stage can be chosen, so that on ly  those S c F v s  capable o f  fo ld in g  
correctly and being secreted into the perip lasm  o r culture broth are isolated. 
T h is  is  a notable advantage over the engineering o f  S c F v s  fro m  hybridom as, 
w here one cannot kn ow  a priori w hether it w ill fo ld  correctly  o r fo rm  an 
in c lu s io n  body.
A  w ord  o f  caution m ay be warranted. C lo n ed  repertoires are com pletely  
artificia l and the extent to w h ich  they m ay suffer from  p o lyreactiv ity  is  uncertain  
(A u jam e et ah, 1997).
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1.4 Intracellular expression of antibody binding sites (intrabodies) 
for phenotypic knockout
Studies have demonstrated that in  eukaryotic cells, linear contiguous stretches o f  
am ino acids referred to as signal sequences are used to direct proteins to their 
final intracellu lar location. In the past ten years it has been em pirica lly  
determined, that b y  transfecting genes encoding  signal sequence -  antibody  
b in d ing  site fusion  proteins into cells, fu lly  functional b in d ing  activ ities can be 
expressed in  a variety o f  sub-cellu lar sites. T h e  b in d ing  m olecu le , then, is 
referred to as an intrabody (C h en  et al, 1994) and can interfere w ith  the activity  
o f  its corresponding antigen (review ed b y  B io c c a  and Cattaneo, 1995; Cattaneo  
and B io cc a , 1997; M a ra sco , 1997).
T h e  concept o f  the product o f  one gene (say an intrabody) being used to  
a rtific ia lly  dow n-regulate in trans the activ ity o f  a second gene (say that 
encoding the corresponding antigen) is referred to as “ phenotypic knockout”  or 
“ intracellu lar im m unisation”  (Baltim ore, 1988; Cattaneo and B io cc a , 1997) (see 
F ig . 1.9). T h is  concept is o f  particular im portance as applied  to eukaryotic 
cells. C lass ica l m eans o f  genetica lly  m anipulating  ce lls  such as random  
m utagenesis o f  the genom e are not applicable to  eukaryotic ce lls  due to 
p o ly p lo id y  and the recessive nature o f  m ost mutants. A lth o u g h  genotyp ic  
knockout b y  hom ologous recom bination is feasib le  it is not generica lly  
applicable and is not am enable to the generation o f  conditional mutants.
Phenotypic kn ockou t is one approach fo r investigating the in vivo 
function o f  an isolated eukaryotic gene or protein (proposed b y  H erskow itz, 
1987). Phenotypic kn ockou t can also be used to genetica lly  engineer plants w ith  
desirous properties such as increased disease resistance (Tav lad orak i et al,
1993), delayed ripen ing (H am ilto n  et al., 1995), m od ified  co lo u r (deLange et al., 
1995) and lo w  fat content (K n a u f and Facciotti, 1995). S im ilar approaches 
cou ld  be used to engineer im proved  lifestock  (M u lle r and B re m , 1996; Staeheli, 
1991). H ow ever, the greatest enthusiasm  has been generated b y  the idea that 
phenotyp ic kn ockou t approaches co u ld  be applies as gene therapies against v ira l 
diseases such as A I D S  (Anderson, 1994) o r genetic diseases such as cancer 
(Gottesm an, 1994).
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F ig . 1.9 : The flow of genetic information (central dogma of molecular 
biology) is depicted above. The crosses indicate the stages at which this 
flow can be subverted by trans-regulating gene products. Intrabodies 
subvert this flow by binding to the protein. This may block the proteins 
active site or, perhaps, retain the protein in the wrong sub-cellular 
compartment. The net result is the same. The protein cannot express its 
functionality. See section 1.4.2 for a description of the modes of action oj 
antisense RNA, ribozymes and dominant negative mutants (DNMs).
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In the fo llo w in g  sections the 'proof-of-principal' experim ents indicating  
ectopic expression o f  functional antibody b in d in g  sites are review ed. 
Intrabodies are com pared and contrasted w ith  the other com m on gene products  
used fo r phenotypic knockout. Som e exam ples o f  intrabodies being used fo r this 
purpose are review ed. Finally, it is proposed that intracellular expression of 
diverse intrabody libraries may be of use in analysing the genotype or 
proteins involved in the expression of a specific phenotype.
1.4.1 Intrabody 'proof-of-principal' experiments: A n tib o d y  synthesis in  lym p h o id  
cells o f  the B  cell lineage is a tightly regulated process. It in vo lves fo ld in g  o f  
heavy and light chains, assem bly o f  these chains and p ossib ly  o ligom erisation  
(review ed b y  Cattaneo and B io cc a , 1997a). These events are catalysed b y  a 
fa m ily  o f  chaperone m olecu les in  the endoplasm ic reticu lum  (E R ). Thus, it w as 
by no means certain that antibodies, o r derivatives thereof, cou ld  assem ble  
correctly  in  any sub-cellu lar com partm ent other then the E R  or in  any ce lls  other 
then the B  cell.
Cattaneo and N eu berger (1987) first demonstrated that antibody  
m olecu les cou ld  assem ble in  ce lls  o f  non -lym ph oid  orig in . T h e y  show ed that 
non -lym ph oid  cells, such as g liom as, w hen transfected w ith  antibody |i and light 
chains cou ld  e ffic ien tly  assem ble and secrete po lym eric  IgM .
Intracellular expression (other then in  the E R )  w as first demonstrated in  
yeast. N ascent antibody heavy and light chains enter the exocytic pathw ay b y  
virtue o f  their n-term inal h ydrophob ic signal sequence, w h ich  is subsequently  
cleaved. C arlson  (1988) genetica lly  engineered the light and heavy chain genes 
o f  an anti-alcohol dehydrogenase 1 antibody so that the signal sequences w ere  
deleted. B y  default, proteins w ithout any signal sequence are expected to rem ain  
in  the cytoplasm  (the sub-cellu lar location o f  a lcoh ol dehydrogenase 1). 
Transfectants expressing both chains d id  show  lim ited  neutralisation o f  a lcoh ol 
dehydrogenase 1 activity. T h is  proved  that fu lly  functional antibody cou ld  
assem ble in  the cytosol.
C y to so lic  expression o f  antibodies in  m am m alian cells was first achieved  
by B io cc a  et al. (1990). Site-directed m utagenesis w as used to  generate a 
h ydrop h ilic  leader sequence from  the w ild  type, on  both a heavy and ligh t chain.
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T h e  mutated heavy and light chains w ere transfected into a variety o f  ce ll lines. 
C y to so lic  expression o f  functional antibody w as demonstrated by  
im m unofluorescence using  an anti-id io typ ic M a b . T h e  same paper described the 
nuclear loca lisation  o f  assem bled antibody, w h ich  w as achieved b y  rep lacing  the 
m utated leader sequence o f  the light chain w ith  a nuclear loca lisation  sequence 
(N L S ) . S im ila rly  W erge et al. (1990) used a N L S  to redirect an antibody heavy  
and ligh t chain aw ay from  the E R . W h e n  the heavy and light chain constructs 
w ere co-transfected into C O S  cells, im m unofluorescent analysis revealed  
staining patterns from  predom inantly nuclear to predom inantly cytoplasm ic. 
These studies, how ever, did not demonstrate functional inactivation o f  a 
cytoso lic protein due to the presence o f  the intrabody. P ro o f  that this w as 
possib le  w as not available until 1993 w hen B io c c a  et al. (1993) injected m R N A  
encoding a leaderless S c F v  into Xenopus oocytes. T h e  S c F v  w as derived from  
an anti-p21ras antibody. Insulin-dependent m eio tic  m aturation o f  the oocyte, a 
p21ras-dependent process w as inhib ited  in  the injected oocytes. T h is  w as also  
the first dem onstration that S c F v s  cou ld  fo ld  p roperly  in  m am m alian  cytosol. 
B io c c a  et al. (1994) then dem onstrated b y  im m unofluorescence that the S c F v  
co-localised  w ith  p21ras at the cytop lasm ic face o f  the p lasm a m em brane. U s in g  
the same S c F v  construct, it w as show n that T -c e ll receptor-m ediated activation  
o f  the Jurkat ce ll lin e  (dependent u p on  p21ras) w as inhib ited b y  the cytoso lic  
S c F v  (W erge et al., 1994).
Retention o f  a S c F v  in  the lu m en  o f  the E R  w as achieved b y  M a ra sco  et 
al. (1993). T h e y  found that a S c F v  contain ing  a w ild-type leader sequence w as 
retained in  the E R  by im m u n og lobu lin -b in d in g  protein (B iP). Su rpris in g ly  
addition to the C-term inus o f  the E R  retention sequence S E K D E L  adversely  
affected the expression leve l o f  the ScFv. T h is  cannot be a general characteristic 
o f  S cFvs as B io c c a  et al. (1995) demonstrated that this sequence w as v e ry  useful 
fo r active retention o f  a S c F v  in  the E R  lum en. In the same paper it w as 
reported that replacing the leader sequence o f  a S c F v  w ith  the n-term inal 
presequence o f  the m itochondria l protein, cytochrom e C  oxidase, w as suffic ient 
to target the S c F v  to the m itochondria. F in a lly , Chesnut et al. (1996) have  
demonstrated that a S c F v  w ith  a w ild -type  leader sequence and a mutated ja.-
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chain transm em brane dom ain can be targeted to the extracellu lar face o f  the 
plasm a m embrane.
A n tib o d ies  have also been expressed in  p lant cells. H ia tt et al. (1989) 
generated tobacco  plants, expressing fu ll-len gth  heavy and ligh t chains, and 
show ed that fu lly  functional antibody cou ld  assem ble in  the tobacco leaf. T h e  
location o f  the antibody w as not determ ined how ever. T h e y  d id  fin d  that the 
leader sequence w as required fo r good  expression leve ls to  be obtained. S im ila r  
results w ere obtained b y  B envenu to  et al. (1991) using a V h  dom ain. 
Surprisingly, w hen the m am m alian leader sequence w as replaced w ith  a p lant 
leader sequence the antibody m olecu le  w as targeted to the ch loroplast (D u rin g  et 
al., 1992). O w e n  et al. (1992) determ ined that no leader sequence w as required  
fo r expression o f  a S c F v  in  plants. A g a in  the location  o f  the S c F v  w as not 
determined. N onetheless, it cou ld  b in d  to the p lant regulatory photoreceptor 
protein phytochrom e. Seeds from  transgenic progeny d isp layed  aberrant 
phytochrom e-dependent germ ination. T av lad o rak i et al. (1993) designed a 
leaderless S c F v  against artichoke m ottled crink le  v iru s  w h ich  they assum ed w as 
expressed in  the cytoplasm . Regardless o f  the truth o f  this statement, transgenic 
tobacco plants show ed a reduction in  in fectious incidents com pared to  w ild  type  
tobacco.
These studies demonstrate the feasib ility  o f  the technology although it is
equally obvious that targeting is still not an exact science and appears to  be
dependent to som e extent on  the sp ecific  variab le  region. It is equa lly  obvious
that the expression levels achieved have varied  w ith  the precise antibody, its
design and its sub-cellu lar location. T h e  sub-cellu lar location is crucial. Th e
w orst location  appears to  be the cytoplasm . T h is  is  at least partially due to the
redox state o f  the cytoplasm . B io c c a  et al., (1995) demonstrated that S cFvs
targeted to the cytoplasm  accum ulate in  a reduced fo rm  w h ile  those targeted to
the E R  lum en o r the m itochondria  w ere oxidised. V a ria b le  dom ains o f
antibodies are kn ow n  to be re latively  unstable and in  general the d isu lfide  bond
is required to  stabilise the tertiary structure. T h e  antibody fragm ent utilised is
equally im portant. W h o le  m olecules, Fab s (e.g. C h e n  et al., 1994), S cFvs and
V h  dom ains have all been used. S c F v s  appear to be the form at o f  choice
because o f  its sim p ler assem bly requirem ents. Certa in ly  w h o le  antibodies
cannot accum ulate in  the cytoplasm  o f  plant ce lls although it appears that ScFvs
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can. Furtherm ore, there is  som e evidence that in  m am m alian  cells, w hole  
antibodies are proteo lytica lly  cleaved to  F v s  (B io c c a  et al, 1990). Increased 
know ledge o f  tra ffick in g  signals (review ed b y  B io c c a  and Cattaneo, 1997b, 
Fra n co n i et al, 1997) should lead to S cF vs  being targeted to other sub-cellu lar 
compartments.
1.4.2 Other strategies for phenotypic knockout:
1.4.2.1 Antisense RNA: T h is  top ic has been extensively review ed (see e.g. W eintraub et 
al, 1985; W alder, 1988; van  der K r o l et al, 1988; H e len e  and T ou lm e, 1990). 
B rie f ly , genetic regulation b y  antisense R N A  is a naturally occurring  
phenom enon utilised  by m ob ile  genetic elements, b y  v iru s ’ and b y  prokaryotes 
(S im ons and K lechner, 1988). P lasm id  cop y  num ber, conjugative transm ission, 
bacteriophage rep lication  and expression o f  a num ber o f  bacterial proteins are 
dependent upon antisense regulation. Antisense transcripts are also found in  
eukaryotic cells (van der K r o l et al, 1988; H e lene  and Tou lm e, 1990).
A ntisense R N A  inhib its the flo w  o f  genetic in form ation  b y  b ind ing  to 
R N A  transcribed from  the gene to be regulated. Q u ite  h o w  b in d ing  inhib its gene  
expression is not certain. It cou ld  con ceivab ly  be due to  prem ature transcript 
term ination, translation arrest, and induced degradation o f  m R N A  b y  nucleases 
acting upon  double-stranded R N A  or irreversib le m od ifica tion  o f  m R N A  
(H elene and T ou lm e, 1990).
T h e  design o f  an artific ia l antisense gene to regulate a specific  gene o f  
interest is a sim ple task once the gene sequence o f  interest is know n, as the m ost 
obvious structural feature o f  an anti sense m olecu le  is  its com plem entarity to the 
m R N A  o f  interest. A lth ou g h  the design o f  an antisense m olecu le  is a facile  task, 
the a priori design o f  the m ost efficaciou s m olecu le  is  not possib le  at present. 
Instead, the random  generation o f  antisense m olecu les based o n  the gene 
sequence o f  interest, fo llow ed  b y  expression selection fo r m ost efficient trans- 
regulation m ay be a far superior approach (see G u d k o v  et al, 1993 and section  
1.4.4.1).
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1.4.2.2 Ribozymes: T h e  b io log y, chem istry and potential app lications o f  ribozym es have  
been review ed extensively in the recent past (see e.g. Su llivan, 1994; 
Christoffersen and M a rr, 1995; K ashani-Sabet and Scanlon, 1995; K ie h n to p f et 
al., 1995). R ib ozym es are catalytic R N A  m olecu les w ith  endoribonuclease  
activity. T h e y  occu r naturally in  a  variety  o f  b io lo g ica l systems, v ira l, 
prokaryotic and eukaryotic (single and m u ltice llu lar organism s) w here they  
cleave (in cis or trcms) specific  single- o r double-stranded R N A  m olecules.
R ib o zy m e s b asica lly  consist o f  a  b in d in g  arm(s) and a catalytic dom ain. 
U tilis in g  the antisense p rin cipa l the b in d ing  arm  binds sp ecifica lly  to  the target 
R N A  substrate and a ligns the catalytic dom ain w ith  a suitable cleavage site.
T w o  naturally occurring  ribozym es, the ham m erhead and the hairp in  are 
quite sm all and have a re latively sim ple secondary structure. T h is  has facilitated  
the design o f  artific ia l ribozym es targeted to cleave any target R N A  o f  cho ice  
and hence to  frarm'-regulate any gene o f  interest. T h is  is achieved b y  sim p ly  
m utating the b in d ing  arm  so that it is com plem entary to the target R N A .
W h ile  antisense m olecules and rib ozym es are targeted in  a s im ilar 
fashion their m ode o f  actions d iffer com pletely . T h is  has one im portant 
consequence. B ecause  ribozym es are catalytic, u n lik e  antisense m olecules they  
do not have to be expressed in  sto ich iom etric am ounts to the target in  order to 
efficiently  dow n-regulate the gene.
1.4.2.3 Dominant negative mutants. A s  im p lied  in  section 1.4, m ost negative (loss-of- 
function) mutants are recessive in  p o ly p lo id  cells. H ow ever, a num ber o f  
naturally occurring  negative mutants are dom inant over the w ild  type (review ed  
b y  W ilk ie , 1994; Fe in berg  and T ro n o , 1992). F o r  example, certain hum an  
diseases such as ep iderm olysis bu llosa s im p lex  (K appe l et al., 1994) are due to 
dom inant negative mutants. Th e  popu lation  dynam ics and course o f  in fection  o f  
certain v ira l species a lso appears to  be determ ined b y  dom inant negative  
genom es (Feinberg and T ro n o , 1992).
There are a num ber o f  w ays in  w h ich  dom inance can be exerted. O ne
requires that the w ild  type activ ity  o f  a protein is  dependent upon tw o or m ore
discrete functional dom ains that can be repressed independently o f  one another.
M utants bearing o n ly  a subset o f  the functional dom ains cou ld  exert dom inance
b y  com peting w ith  the w ild  type fo r v ital ce llu lar factors o r substrate. Thus,
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H erskow itz (1987) has proposed that gene fragm ents generated from  a gene o f  
interest m ay encode dom inant negative mutants. H e  further proposed that 
dom inant negative mutants generated in this fash ion m ight be used as a general 
m ethod to dow n-regulate any gene o f  interest. A s  m entioned w ith  regard to 
antisense m olecules, w h ile  the a priori design o f  optim al genes is feasib le in  
certain instances (Christian  et al., 1991), random  approaches to the generation  
m ay be preferable (G u d k o v  et al., 1993).
1.4.2.4 Comparison of strategies for phenotypic knockout.
A ntisense R N A
Inhibition at level of: R N A
Generated based on gene sequence? Y e s
Generation requires purified protein? N o
Turnover 1
R ib ozym e D om inant negative mutant Intrabody
R N A Protein Protein
Y e s Y e s N o
N o N o Y e s
m ultip le 1-m ultip le 1
Table 1.2: A comparison o f  the four general classes o f  trans-regulating gene 
products is presented. Turnover refers to the number o f molecules o f  
RN.A/protein inhibited per molecule o f inhibitor.
Th e  four m ajor classes o f  /raws-regulating gene products are com pared in  
the above table. S im p ly  based on frequency o f  appearance o f  terms in the 
science citation index, antisense strategies are the preferred strategy. R ib ozym es  
are a m ore recent developm ent but the higher turnover o f  ribozym es m ay  
eventually m ake this approach m ore attractive than the antisense approach. In 
relative terms, dom inant negative mutants and intrabodies are relatively
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unknow n quantities. Som e successfu l applications o f  intrabodies are review ed  
in  the next section.
1.4.3 Practical applications of intrabodies:
1.4.3.1 Gene therapy for AIDS: U n til recently conventional chem otherapeutic 
interventions have proved disappointing, as have vaccinations, fo r  
curing/preventing A I D S . F o r  this am ong other reasons, this v ira l in fection  has 
been an attractive target fo r gene therapeutic intervention. H I V -1 , the etio log ic  
agent o f  A I D S , is a retrovirus w ith  a com plex  life cy c le  (review ed b y  T ro n o ,
1994). It w as suggested, that dow n-regulation o f  certain k e y  v ira l regulatory or  
structural proteins m ay be an e fficient approach, to  provide target cells w ith  
long-term  protection. Initial p re-clin ica l studies have in clu ded  the intrabody  
approach w ith  a sign ificant degree o f  success.
A  series o f  studies have been carried out b y  M arasco 's  group utilis in g  
intrabodies generated from  an a n ti-g p l2 0  antibody referred to as F I 05. g p l2 0  is 
an H IV -1  structural protein located on the v ir io n  surface. It is in itia lly  
synthesised as a g p l6 0  precursor, translocated into  the E R ,  cleaved in the g o lg i 
com plex  to the m ature g p l2 0  and then transported to the cell surface fo r  
assem bly into a v ira l particle. g p l2 0  facilitates entry o f  the v ira l particle  into  
C D 4 +  cells by b in d in g  to th is cell surface m olecule. W h e n  expressed on the cell 
surface, g p l2 0  can induce ce ll fusion, and hence death, b y  b in d ing  C D 4  on  
adjacent cells (syncythia  form ation). M a ra sco  et al. (1993) targeted a single­
chain F v  intrabody (ScF105) to the endoplasm ic reticu lum  in  an attempt to 
prevent g p l2 0  being transported to the ce ll surface. A s  expected in  stably 
transfected cell lines there w as a decrease in  syncythia  form ation and a lso in  the 
in fectiv ity  o f  H T V - 1 particles released b y  infected cells. T h e y  then m od ified  this 
approach in  order to gain  the benefit o f  both  intra- and extracellu lar 
im m unisation (C h en  et al, 1994). W h ile  ScF105  w as retained in  the E R  the 
corresponding Fab  construct w as effic ien tly  secreted from  stable transfectants. 
T h is  a llow ed neutralisation o f  g p l6 0  in tracellu larly  and g p l2 0  extracellu larly. 
B ased  on these results a pre-clin ica l trial w as approved in  the U .S .A .  in  1995 
utilis in g  ScF105 (M arasco , 1997).
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A  num ber o f  regulatory proteins in c lu d in g  tat, rev and reverse  
transcriptase (R T )  have also been targeted b y  intrabodies. R e v  is a sm all protein  
that interacts in  the nucleus w ith  ce llu lar cofactors to a llow  cytop lasm ic  
accum ulation o f  v ira l m R N A  ultim ately lead ing  to v ira l replication. D u a n  et al 
(1994) targeted a S c F v  intrabody w ith  anti-rev activ ity  to  the cytoplasm . Th e  
rational fo r this approach, w as to obstruct nuclear transport o f  rev  and hence  
in h ib it v ira l replication. T h e y  found that in  stable transfectants v ira l rep lication  
was reduced b y  >99% and syncythia form ation w as reduced drastically. S im ila r  
results w ere obtained b y  M h a sh ilk a r et al (1995) using  intrabodies targeting the 
tat protein. Ta t is a potent transcriptional activator o f  the H I V  long  term inal 
repeat. Productive in fection  b y  H I V -1 , o f  ce lls  stably expressing a  S c F v -C K 
(kappa ligh t chain constant dom ain) fu sio n  protein w as dram atica lly  reduced.
In all the exam ples m entioned above, post-integration steps in  the H I V -1  
life  cyc le  w ere targeted. W o rk in g  on  the reasonable assum ption that targeting a 
pre-integration step w ou ld  be m ore beneficia l, M a cie je w sk i et al. (1995) 
targeted the R T  protein. In M O L T - 3  cells expressing cytop lasm ic a n ti-R T  Fab, 
propagation o f  H I V - 1 w as com pletely  inhib ited fo r  the m onitored period o f  five  
weeks.
1.4.3.2 Gene therapy for cancer. Cancer, a m ultifactoria l genetic d isorder, in  m any  
instances is  refractory to conventional chem o- and radiotherapy (K ip p s, 1993) 
and hence has becom e a target fo r gene therapies. A m o n g  the m any approaches 
being pursued is the dow n-regulation o f  genes kn ow n to be critica l fo r 
m aintenance o f  the transform ed phenotype.
O ver-expression o f  the tyrosine kinase receptor, erbB-2  is im portant in  
the pathogenesis o f  a variety o f  neoplasm s in clu d in g  those o f  the breast, lung  
and stomach. D eS hane et al. (1996) attempted to inhib it transport o f  erbB-2  to 
the cell surface. T o  do so they generated gene constructs encoding an anti-erbB- 
2 S c F v  targeted to either the cytoso l o f  the E R . T h e  E R  targeted S c F v  w as not 
surprisingly the m ore successful. In fact it w as cytotoxic fo r  a variety  o f  erbB -2  
over-expressing ce ll lines due to in duction  o f  apoptosis. O f  note it w as m ore  
successful then an antisense m olecu le  w h ich  w as on ly  cytostatic. S im ilar but 
not identical results w ere reported b y  B e e rli et al. (1994).
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T h e  h ig h  affin ity  interleukin-2 receptor (IL -2 R a )  is constitutively up- 
regulated in  certain T -  and B -ce ll m alignancies. R ich ard so n  et al. (1995) have 
postulated that its dow n-regulation m ay be o f  c lin ica l benefit. T o  th is end they  
engineered an a n ti-IL -2 R a  S c F v  w ith  the S E K D E L  E R  retention signal 
( s F v T a c K D E L ) . T h e  ability  o f  s F v T a c K D E L  to  dow n-regulate I L - 2 R a  w as 
assessed in  Jurkat cells w h ich  do not express I L -2 R a  under norm al 
circum stances but can be induced to do so b y  treatment w ith  phorbol 12- 
m yristate 13-acetate. 16 out o f  16 independent clones stably transform ed w ith  
the intrabody show ed com plete in h ib ition  o f  I L - 2 R a  induction. It w as 
demonstrated that I L -2 R a  w as retained in  the E R .
N o t  all strategies aim ed at dow n-regulation have p roved  successful. 
B e e rli et al. (1994) attempted to retain the epiderm al grow th factor receptor 
( E G F R )  in  the E R  b y  targeting an a n t i-E G F R  S c F v  to the lum en o f  the E R  but 
o n ly  a 9% reduction in  expression o f  E G F R  w as achieved.
1.4.4 Speculations on the intracellular expression of intrabody libraries
In all the exam ples quoted so far, intrabodies have been genetica lly  engineered  
from  hybridom a ce ll lines. It is  o n ly  recently  that S c F v s  selected from  phage  
disp lay libraries have been used as intrabodies (G argano  and Cattaneo, 1997). 
Th e  successful results reported m ay pro v ide  the im petus to directly clone  
im m une repertoires fo r in tracellu lar expression (intrabody libraries). 
C onceptua lly  and techn olog ica lly , th is task is no  m ore challenging  then the 
generating phage d isp lay libraries. In th is section tw o applications o f  intrabody  
libraries are presented.
1.4.4.1 ‘Binding selection’ from intrabody libraries: A s  noted in  section 1.4.1, the 
effectiveness o f  an in d iv idu a l intrabody depends in  an unpredictable fash ion on  
its prim ary sequence. H ence, a S c F v  selected from  a phage d isp lay  library, 
based o n  its b in d in g  activ ity  in vitro, m ay not fu nction  at all w e ll in vivo. It 
w ou ld  therefore be advantageous to in clu de a selection step in vivo w hen  
isolating a S c F v  fo r use as an intrabody. Thu s, G argano et al. (1997) have 
proposed that in itia lly , one cou ld  carry  out panning o f  a phage d isp lay  lib rary  to  
generate a re latively  sm all lib rary  o f  S c F v s  enriched fo r the desired reactivity.
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O n e cou ld  then utilise the yeast-tw o-hybrid system  to select S cFvs , w h ich  b ind  
the antigen in vivo. Th e  tw o-hybrid  system  provides an experim ental system  in  
yeast cells, to  m onitor intracellu lar protein-protein interactions. It w ill not be  
discussed here but is thoroughly review ed b y  F ie ld s  and Stem glantz (1994) and 
F in la y  and B ren t (1995). Su ffice  it to  say that the enriched p o lyc lo n a l S c F v  
population cou ld  be engineered as ‘b a it’ and the antigen engineered as ‘p rey ’ . A  
subsequent screen w ou ld  a llow  iso lation  o f  a S c F v  w ith  good  intracellu lar 
bin d ing  properties.
T o  a certain extent, the techn ology fo r  iso lation  o f  genetic suppressor 
elem ents (G S E s )  fo r a specific  gene can be seen as a forerunner o f  the above  
technique. G S E  is the nam e g iven  by R on inson 's group to “ short b io lo g ica lly  
active gene fragm ents that encode dom inantly acting peptides o r in h ib itory  
antisense R N A s ”  (R oninson et al, 1995). Just as one cannot guarantee the 
effectiveness o f  an intrabody, an antisense m olecu le  o r dom inant negative  
mutant generated from  a sp ecific  gene cannot be guaranteed to be effective in 
vivo. In order to isolate G S E s  fo r a specific  gene, it w as proposed that one 
create a lib rary  o f  random  gene fragm ents from  the gene o f  interest. G S E s  are 
then selected b y  clon ing  the resulting lib rary  into a relevant ce ll host fo llow ed  
by b io lo g ica l selection o f  clones conferring  the phenotype associated w ith  
suppression o f  the target. U s in g  this strategy G u d k o v  et al. (1993) have isolated  
G S E s  fo r topoisom erase II.
1.4.4.2 'Phenotypic selection ’ from intrabody libraries. The idea of selecting 
intrabodies in vivo from relatively small biased intrabody libraries could be 
brought to its logical conclusion by selecting intrabodies in vivo from large 
unbiased intrabody libraries, a strategy referred to as ‘phenotypic selection’ 
by Gargano et al (1997). W h y  this strategy is w orth  pursuing is best illustrated  
w ith a concrete example. C o n sider the A I D S  virus. Intrabodies are considered  
to have considerable therapeutic potential against th is cytotox ic v irus. Attem pts 
to generate therapeutically relevant intrabodies have so far revo lved  upon  the a 
priori isolation o f  specific  antibodies considered to have therapeutic potential, 
fo llo w ed  b y  their engineering as intrabodies and subsequent evaluation (see 
section 1.4.3.1). T h is  rational strategy requires the fo llow ing:
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i) that the b iochem istry  o f  the v irus is understood in  su ffic ient detail that a
critica l protein can be chosen, in  order to isolate a specific  S c F v  from  a 
phage d isp lay library
ii) that the protein chosen is availab le in  su ffic ient quantity and purity
iii) that the engineered intrabody is o f  su ffic ient stability
iv) that b in d ing  o f  the intrabody to the target protein actually  does interfere  
w ith the function o f  the protein.
N o  such problem s pertain to the random  strategy o f  p henotyp ic selection. T h is
strategy in vo lves c lon in g  an entire intrabody lib rary  into a relevant ce ll host.
Subsequently, the transfected population o f  ce lls  can be challenged w ith  the
A I D S  virus. N atural selection should then result in  the iso lation  o f  intrabodies
conferring resistance (for w hatever reason) to the v irus, should the in itia l lib rary
contain such intrabodies.
L o o k e d  at from  a d ifferent perspective, the usefulness o f  this concept is
even m ore apparent. While the rational approach results in the in vivo
screening of only a tiny fraction of the phage display library, the random
approach allows screening of the entire library for anti-viral activity.
A g a in  this concept w as foreseen and w as applied fo r  the isolation o f
G S E s  conferring a desired selectable phenotype (R on in son  et al., 1995).
A lth ou g h  introduced b y  w a y  o f  a specific  exam ple, this strategy should be  o f  use
w herever a selectable o r screenable phenotype is invo lved. In particular,
phenotypic selection m ay be a very  use iu l too l fo r  functional genom ic analyses.
It has already been m entioned (section 1.4), that dow n regulation o f  a specific
gene m ay be one approach to analysing its in vivo function. O n e w ou ld  sim ply
generate a cell line  in  w h ich  the gene o f  interest is dow n-regulated. Com parison
o f  the phenotypes expressed b y  the engineered ce ll line w ith  the w ild-type
should p rovide  in form ation  o n  the functionality  o f  the gene. In effect this
strategy links phenotypes to  a specific gene.
T w o  potential problem s m ay ham per application o f  this paradigm .
F irstly , assum ing a phenotypic change occurs upon dow n-regulation o f  the gene,
i f  one has no idea at all in  advance as to the potential ro le  o f  the gene, detection
o f  the change m ay be very  d ifficu lt. Secondly, and perhaps m ore im portantly,
dow n-regulation o f  m any genes m ay not result in  any phenotypic changes
whatsoever due to the degeneracy in  protein function. I f  the protein encoded by
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the gene does not occu r at a crucia l regulatory step in  its b io ch em ica l pathw ay  
the ce ll m ay be able to com pensate fo r its absence and express the same 
phenotypes as the w ild-type.
O n e suggestion is that, these problem s cou ld  be circum vented, by  
inverting the paradigm  and lin k in g  proteins (genes) to a sp ecific  phenotype. 
P henotyp ic selection is adm irab ly  suited to this task. F o r  exam ple, i f  one 
wanted to isolate proteins in vo lv e d  in  program m ed cell death, one cou ld  clone  
an intrabody lib rary  into a relevant cell host, ch em ica lly  induce apoptosis, and 
let natural selection enrich fo r intrabodies preventing apoptosis. T h e  ce llu lar  
proteins bound b y  enriched intrabodies are then presum ed to  be part o f  the 
b iochem ica l pathw ays in vo lved  in  apoptosis. Furtherm ore, they presum ably  
occu p y  critica l positions in  the pathw ays. A s  another exam ple one cou ld  utilise  
F A C S  as a h igh  thoughput screen to isolate intrabodies targeting proteins 
in vo lved  in  ce ll p ro liferation  (see F ig . 1.10). In general, as long  as a b io lo g ica l 
selection o r a high throughput screen is availab le, intrabodies can be isolated  
conferring  any phenotype yo u  desire.
Such phenotyp ic selection strategies w ill be dependent upon:
i) generating very  large intrabody libraries (to increase the average a ffin ity  
o f  the library fo r any ran dom ly  chosen protein)
ii) increased understanding o f  the causes o f  intrabody instab ility  so that 
generic protein engineering solutions can  be found  to increase the 
intracellu lar concentration o f  functional intrabody
iii) c lon in g  the library  into as sm all a population o f  ce lls as possible.
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F ig . 1.10: A flow diagram suggesting a means of isolating apoptosis-inducing 
intrabodies. 1'he intrabody library is transfected into a relevant cell 
population. After a suitable time period has elapsed (say 24hrs) the cells are 
screened using a FACS and an antibody specific for annexin V. This is a 
component of the plasma membrane, normally residing at the cytoplasmic 
face. It is translocated to the external face, however, in apoptotic cells. The 
above schematic of a computer screen, shows cell numbers along the y-axis 
andfluorescent intensity along the x-axis. Only those cells fluorescing above a 
certain intensity are harvested. The plasmids they harvest are re-isolated by 
PCR, or transfection into E. coli. This sub-library can subsequently be 
rescreened.
O ne area o f  interest w as the nature o f  antibody b in d in g  sites and, in  
particular, the concept that they m ay be polyreactive. S p e c ifica lly , it w as 
suggested that IV I  (section 1.3.2.2) w ou ld  produce polyreactive  M a b s . In order 
to test this hypothesis it w as decided to  produce a panel o f  M a b s, b y  IV I , and to  
use a num ber o f  assays to  determ ine w hether they show ed a po lyreactive  b in d ing  
profile. These studies are reported in chapter three.
A  second area o f  interest w as the use o f  intrabodies fo r phenotypic  
knockout. In particular, interest focused  on  the generation o f  in trabody libraries  
because o f  their potential fo r use as functional genom ic tools o r as sources o f  
therapeutic proteins. These studies are reported in  chapters fo u r and five.
1.5 Aims
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CHAPTER 2 
M ATERIALS AND METHODS
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2.1 Equipment
Class Model Source
Biacore™ B ia c o re ™  1000 Pharm acia  B io se n so r
Centrifuges H eraeus C h rist Lab o fu g e  6000  
B io fiig e  A  M icro cen trifu g e  
Sorvall refridgerated centrofiige
H eraeus Instruments Inc. 
H eraeus Instruments Inc. 
D u  Pont Instruments
CO2 Tissue culture 
incubator
J o u a n E G  115 IR Jouan
Cytospin H eraeus Lab o fu g e  A e Heraeus Instruments Inc.
Electroporator G en e P u iser E lectroporator B io -R a d  Labs.
Microscope L e itz  L a b o r lu x  K  fluorescence  
m icroscope  
N ik o n  D iap h o t inverted  
m icroscope
Laboratory  Instruments 
and Supplies  
M ic ro n  O ptica l C o . L td .
Miniblotter M in ib lo tte r M N 1 00-25 Im m unetics
Orbital Incubator G allenkam p IN R -201-010P A G B
Protein Electrophoresis 
Apparatus
A tto  dual m inislab  system  A E -  
6450
A tto  Corp .
Protein Electrotransfer 
Cell
B io -R a d  Transblot cell B io -R a d  Labs.
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Rocker Platform Stuart Platform Shaker STR6 Lennox
Spectrophotometers U .V .- 1 6 0 A  Spectrophotom eter Sh im adzu Corp .
T itertek  M u ltisca n  Plate R eader F lo w  Lab . L td .
Thermocycler L E P  P R E M ™ M e d ic a l S u pp ly  C o .
Ultrafiltration Cell Stirred C e ll 8400 A m ic o n  Inc.
AGB: D u b lin  Industrial Estate, D u b lin  11, Ireland.
Amicon Inc.: B everly , M assachusetts 01915, U .S .A .
Atto Corp.: 2-3 H o n g o  7-Chrom e, B u n k y o -K u i, T o k y o  113, Japan.
Bio-Rad Labs.: 3300 Regatta B ou levard , R ich m o n d  C a lifo rn ia  94980, U .S .A .
Du Pont Instruments: Instrument Products D iv is io n , N ew tow n , Connetticut 06470,
U .S .A .
Flow Labs. Ltd.: W o o d co ck  H ill ,  H a re fie ld  R d ., R ichm answ orth , H ertfordsh ire W D 3  
1PQ, Eng land .
Heraeus Instruments Inc.: 111-a Corporate  B ou levard , South P la in fie ld  N e w  Jersey
07080, U .S .A .
Immunetics: 380 G reen St., C am bridge, M assachusetts 02139, U .S .A .
Jouan: Z on e  In du stria ls  de B ra is , Saint N azaire , France.
Laboratory Instruments and Supplies: A shbourne, C o . M eath , Ireland.
Lennox: P .O  B o x  2 1 2 A , John F . K e n n e d y  D r ., N aas R d ., D u b lin  12, Ireland.
Medical Supply Company: D am estow n, M ulhuddart, D u b lin  15, Ireland.
Micron Optical Co. Ltd.: B ray , C o . W ick lo w , Ireland.
Pharmacia Biosensor: St. A lb a n s, H ertfordsh ire  A L I  3 A W , En g land .
Shimadzu Corp.: 1 N ish in o kyo -K u w ab arach o , N akagyo-ku , K y o to  604, Japan.
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2.2 Consumable items
Class Item Source
Bacteria E. coli D H 5 a  containing p C H l  10 D r. B arbara F in g leton
Electrocom petent E. coli X L  1-B lu e D r. T o n y  K illia rd
Electrocom petent E. coli X L  1-B lu e  M R F Stratagene Ltd .
N is s im  L ib ra ry M e d ic a l R esearch C o u n c il
Hardware C M 5  C h ip s Pharm acia  B io sen so r
E lectroporation  cuvettes B io -R a d  Labs.
N itroce llu lose S igm a C h em ica ls
N u n c  M a x iso rp  plates N u n c
T issue C u lture  plastic-w are C o m in g  C ostar
U ltra filtra tion  m em branes A m ic o n  Inc.
Amicon Inc.: B everley , M assachusetts 01915, U .S .A .
Bio-Rad Labs.: 3300 Regatta B ou levard , R ich m o n d , C a lifo rn ia  94980, U .S .A .
Corning Costar: H ig h  W y co m b e , B uck in gh am shire  H P  13 6 E Q , England.
Drs. Barbara Fingleton and Tony Killiard: D u b lin  C ity  U n ive rs ity , D u b lin  9, Ireland. 
Medical Research Council: Centre  fo r Protein  En g ineering , M e d ica l R esearch  C o u n c il
Centre, H ills  R d ., C am bridge C B 2  2 Q H , England.
Nunc: P .O . B o x  280-Kam strup  D K ,  R o sk ild e , Denm ark.
Pharmacia Biosensor: St. A lb a n s, H ertfordsh ire  A L I  3 A W , England.
Sigma Chemicals: Fa n cy  R d ., Poo le , D o rset B H 1 2  4 Q H , England.
Stratagene Ltd.: 140 Cam bridge Science P ark , M ilto n  R d .,C am b rid g e  C B 4  4 G F , Eng land .
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2.3 Reagents and Chemicals
A l l  chem icals w ere reagent grade and w ere purchased through Sigma Chemicals 
except as noted below .
Class Chemical Supplier
B io ch em istry A lk a lin e  phosphatase-labeled antibodies Southern B io te ch n o log y
a n ti-C D 5 , clone E5 1 .8 7 Seikagaku C orp .
anti-lipopolysaccharide, c lo n e l 1E10 Southern B io te ch n o log y
norm al m ouse TgM Southern B io te ch n o log y
M ic ro b io lo g y A g a r O x o id
T e rr if ic  m edium O x o id
Tryptone O x o id
Y east extract O x o id
M o le cu la r  B io lo g y EcoKl B oehringer M a n n h e im
EcoRV B oehringer M a n n h e im
E q u ilib ra ted  phenol O n co r-A p p lig en e
E u k a ry o tic  T A -c lo n in g  kit contain ing  
p C R ™ 3  -U n i
Invitrogen
Hindm B oehringer M a n n h e im
N ucleotides Prom ega Corp .
p c D N A 3 .1 + Invitrogen
P C R  'C lean-up' k it B oehringer M a n n h e im
P C R  Prim ers G en osys
Pwo polym erase B oeh rin g er M a n n h e im
Q iagen  gel extraction kit Q iagen
Q iagen  m axiprep kit Q iagen
R N a s e l B oehringer M a n n h e im
Synthetic duplex D N A G enosys
Taq polym erase Prom ega Corp .
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T 4  D N A  polym erase  
T 4  polynucleotide kinase
B oeh rin g er M a n n h e im  
B oehringer M a n n h e im
Tissue culture B ric lo n e
D u lbecco 's  m od ification  o f  E ag les m edium  
Feta l c a lf  serum  
H E P E S  
H y b rid o m a  S F M ™
Iscoves m od ification  o f  E a g le s  m edium  
L-glutam ine  
N on-essential am ino acids  
O le ic  acid  
P a lm itic  acid  
Phosphate-buffered saline tablets 
R ab b it serum  
Sodium  pyruvate  
Tfx™
V ectash ie ld  m ounting m edium
B io R e se a rch  Ireland  
G ib c o  B R L  
G ib c o  B R L  
G ib c o  B R L  
G ib c o  B R L  
G ib c o  B R L  
G ib c o  B R L  
G ib c o  B R L  
A ld r ic h  C h e m ica l C o . 
A ld r ic h  C h e m ica l C o .
O x o id  
G ib c o  B R L  
G ib c o  B R L  
Prom ega  
V e c to r  Labs.
Aldrich Chemical Co.: O ld  B ric k y a rd , N e w  R d ., G illin g h a m , D orset SP8 4 JL , England. 
BioResearch Ireland: G lasnev in , D u b lin  9, Ireland.
Boehringer Mannheim: B e ll L an e , L ew es, E a st Sussex B N 7  1 L G , Eng land .
Genosys: 1 6 2 A  C am bridge  Science P ark , M ilto n  R d ., Cam bridge C B 4  4 G H , Eng land . 
Gibco BRL: Trident H o u se , R en frew  R d ., Pa is ley  P A 4  9 R F , Scotland.
Invitrogen: D e  Schelp 12, 9351 W ,  L e e k , Netherlands.
Oncor-Appligene: Chester-le-Street, D u rham  D H 3  2 T D , England.
Oxoid: Basingstoke, H am pshire, Eng land .
Promega Corp.: 280 W o o d s H o llo w  R d ., M ad iso n , W isco n s in  53711-5399, U .S .A .  
Qiagen: B oundary  C ourt, G a tw ick  R d ., C raw ley , W est Sussex R H 1 0  2 A X ,  En g land . 
Seikagaku Corp.: 1-5, N ihonbash i-hon cho  2-chom e, C h u o-k u , T o k y o  103, Japan.
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Southern Biotechnology: 1 6 0 A  O x m o o r B ou levard , B irm in gh am , A la b am a  35209,
U .S .A .
Vector Labs.: B u rlin gam e, C a lifo rn ia  94010, U .S .A .
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2.4 Biological Solutions
Th e  fo llo w in g  solutions are referred to in  the text, b y  nam e only . T h e  final 
concentration o f  constituents, in  the fo llo w in g  solutions, are g iven  in  appendix C .
2.4.1 Mammalian cell culture 
Phosphate-Buffered Saline (PBS)
T h is  alw ays refers to  D u lbecco's A  P B S , 0 .14M , p H  7.2-7.4. T h e  com ponents w ere  
obtained prem ixed as tablets and d isso lved  in  the correct vo lu m e o f  d istilled  H 2O  
(d H 20 ).
2.4.1.1 Splenocyte preparations:
Dissection Hanks Balanced Salt Solution (DHBSS)
C a C l2.H 20 00.194g
K C 1 00.400g
K2HPO4 00.060g
M g C l2 00.046g
MgSC>4 00.049g
N a C l 08.000g
N a 2H P 0 4 00.048g
D -G lu c o s e 01.000g
P h en o l R ed OO.OlOg
com ponents w ere d issolved in 1 L  o f  ultra-pure H 2O  ( U P H 20 ) , adding
C a C k .H z O  last, and autoclaved. T h e  resulting solution w as supplem ented w ith  
gentam icin and am photericin, to  fin a l concentrations o f  50ng/ml and 2.5|ag/ml, 
respectively. Th e  solution w as stored at -20°C.
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Geys Haemolytic Solution
G e y s  H a e m o lytic  So lu tion  w as made up  as fo llo w s  not m ore then 30 m in. before  
use:
d H 20  14.6m l
G e y s  A  04.000m l
G e y s B  01.000m l
G e y s  C  00.400m l
G e y s  A :
N H 4CI 35.000g
K C 1  01.850g
K 2H P O 4 O O . l l lg
D -G lu c o s e  05.000g
P heno l R e d  00.050g
G elatin  25.000g
T h e  com ponents w ere d issolved  in  1 L  o f  d H 20 ,  autoclaved, and stored at room  
temperature (R T ).
G e ys  B :
M g C l2 01.970g
M g S 0 4 00.749g
C a C l2.2 H 20  04.500g
T h e  com ponents w ere d issolved  in  1 L  o f  d H 20 ,  autoclaved, and stored at R T .
G e y s  C:
5.6% (w/v) so lution (sterile-filtered) o f  N a H C 0 3  in  d H 20, stored at 4°C.
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2.4.2 Molecular biology
Tris/EDTA (TE) Buffer
T h is  alw ays refers to  a lO m M  T r is .C l (p H  8.0) solution contain ing lm M  E D T A ,  
prepared in  U P H 2O , autoclaved, and stored at R T .
2.4.2.2 DNA minipreps:
Alkaline-lysis Solution 1
A n  autoclaved 2 5 m M  T r is .C l (p H  8.0) solution is supplem ented as fo llow s. It is 
m ade up to 5 0 m M  glucose from  a 20% (w/v) autoclaved g lucose solution. It is 
m ade u p  to lO m M  E D T A ,  from  a 0 .5 M  E D T A  (p H  8.0) stock, and stored at 4°C.
Alkaline-lysis Solution 2
T h e  com ponents w ere d issolved  in  100ml o f  ultra-pure H 2O , autoclaved, and stored
N a O H 00.8g
01.000gSod ium  D o d e c y l Sulphate (S D S )
at 4°C.
Alkaline-lysis Solution 3
5M K C 2H 3O 2 
G la c ia l acetic acid  
d H 20
60.0m l
11.5ml
28.5m l
Th e  com ponents w ere m ixed  thoroughly  and stored at 4°C.
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2.4.2.2 T4 DNA polymerase-based cloning o f  polymerase chain reaction (PCR) product:
Cut-back Buffer
T ris  00.799g
KC2H3O2 (p H  7.9) 01.315g
M g C 2H 30 2 .4 H 2 0  00.429g
dithiothreitol (d T T )  00.154g
T h e  com ponents w ere d issolved  in  100m l U P H 20 ,  and sterilised. T h is  so lution  
w as then supplem ented w ith  5m l o f  2% (w/v) gelatin, and 400^1 o f  either lO O m M  
deoxythym id ine triphosphate (d T T P )  or lO O m M  deoxyadenosine triphosphate  
(d A T P ) , fo r cut-back o f  the vecto r o r P C R  product, respectively. T h e  b u ffer w as 
stored at -20°C.
Ligation buffer
T r is .C l (p H  7.8) 01.21 lg
M g C l2 00.095g
d T T  00.308g
T h e  com ponents w ere d issolved  in  100m l U P H 2O  and sterilised. 20|a.l o f  a 
lO O m M  stock o f  d A T P  w as added per 1ml o f  solution. T h e  buffer w as stored at 
-20°C.
2.4.2.3 Genomic DNA preparation:
PCR Lysis Solution
lO x  P C R  B u ffe r  (Taq or Pwo) 0 0 .100ml
U P H 2O  00.891m l
N P -4 0  00.005m l
Tw een-20 00.005m l
T h e  com ponents w ere m ixed thoroughly, and stored at 4°C.
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Proteinase K
A  10mg/ml so lution o f  Proteinase K  in  U P H 20 ,  w as incubated at 37°C  fo r  2 hrs, 
and stored at -20°C.
2.4.3 Biochemistry
2.4.3.1 Solid-phase immunoassays:
2-Amino-2-Methyl-l-Propanol (AMP) Buffer
M g C l2 
T rito n  X -4 0 5  
N aN ?
00.070g
00.100m l
01.000g
T h e  com ponents w ere d issolved  in  50m l d H 20 .  98.5m l o f  A M P  w as s lo w ly  added, 
w h ile  stirring. T h e  vo lum e w as brought to 900m l w ith  d H 20  and the p H  adjusted to 
10.25, w ith conc. HC1. T h e  p H  w as left to  equilibrate overnight and then readjusted  
to 10.25. Th e  vo lum e w as brought to 1L, and stored at 4°C.
Coating Buffer
K2HPO4
K H 2P O 4
N a 2E D T A .2 H 20
N a C l
N a N 3
01.742g
00.680g
00.186g
04.000g
00.250g
Th e  com ponents w ere d issolved  in  500m l d H 20 ,  and stored at 4°C.
Wash Buffer
T r is .C l (p H  7.4) 
N a C l  
Tw een  20  
Thim erosa l
01.21 lg  
08.766g  
01.000m l
00.050g
T h e  com ponents w ere d issolved in  1 L  o f  d H 20 ,  and stored at 4°C.
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2.4.3.2 Immunoblots and related techniques:
Coomassie Blue Stain Solution
C oom assie  blue R -250  01 .OOOg
M eth an o l 450m l
d H 20  450m l
G lac ia l acetic acid  100ml
The com ponents w ere d issolved  and m ixed  thoroughly, and stored at R T .
Destain Solution
M eth an o l 100ml
G la c ia l acetic acid  100ml
d H 20  800m l
Th e  above com ponents w ere m ixed, thoroughly, and stored at R T .
Electrophoresis Buffer
T ris  03.OOOg
G ly c in e  14.400g
S D S  01.OOOg
T h e  com ponents w ere d issolved  in  1L  o f  d tfeO , and stored at R T .
Homogenising Buffer
T r is .C l (p H  6.8) 00.363g
d T T  00.77 lg
E D T A  00.015g
10% (w/v) S D S  10.0ml
T h e  com ponents w ere d issolved in  o r m ixed  w ith  sufficient dH^O to bring the final 
volum e to 50ml. T h is  solution w as supplem ented w ith  aprotin in  to a fin a l conc. o f  
1 (J-g/ml, pepstatin to  a final conc. o f  l^g/m l and T L C K  to a final conc. o f  50|j.g/ml, 
and stored at 4°C.
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Lysis Buffer
T r is .C l (p H  8.0) 01.21 lg
K C 1  00.746g
M g C l2 00.050g
N P -4 0  00.500m l
T h e  com ponents w ere m ixed  and d isso lved  in  100m l U P H 2O . T h is  so lution w as 
supplem ented w ith  aprotinin to a final conc. o f  lu g/m l, pepstatin to  a fin a l conc. o f  
lUg/m l and I L C K  to  a final conc. o f  50|ig/ml, and stored at 4°C.
Sample Buffer
1 M  T r is .C l (p H  6.8) 00.600m l
50% (v/v) G ly ce ro l 05.000m l
10% (w/v) S D S  02.000m l
2 - M E  (2-M ercaptoethanol) 00.500m l
1% (w/v) B rom op h en o l b lue 00.900m l
T h e  com ponents w ere thoroughly m ixed  together, and stored at -20°C.
Solution A
A c ry la m id e  29.200g
B isa cry la m id e  00.800g
T h e  com ponents w ere d issolved  in  100m l d H 20, and stored in  the dark at 4°C.
Solution B
2 M  T r is - H C l (p H  8.8) 75.0m l
10% (w/v) S D S  04.0m l
d H 20 21.0m l
T h e  com ponents w ere thoroughly m ixed  together, and stored at 4°C.
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Solution C
I M  T r is .C l (p H  6.8) 50.0m l
10% (w/v) S D S  04. Orni
d H 20  4 6 .Orni
T h e  com ponents w ere thoroughly m ixed  together, and stored at 4°C.
Transfer Buffer
T ris  
G ly c in e  
M eth an o l
T h e  com ponents w ere d isso lved  in  1 L  o f  d H 20 ,  and
2.4.3.3 In situ ß-galactosidase staining
Fix Solution
25% (w/v) G lutaraldehyde 00.400m l
0 .5 M  phosphate b u ffe r (p H  7.3) 10.0ml
0 .1 M  E G T A  (p H  8.0) 02.500m l
1 .0 M M g C l2 00.100m l
d H 20  37.0m l
T h e  com ponents w ere m ixed, thoroughly, and stored at R T
Rinse Solution
0 .5 M  phosphate b u ffe r (p H  7.3) 40 .0m l
d H 20  160.0ml
1. 0 M  M g C l2 0.400m l
Sod ium  deoxycholate 0.020g
N P -4 0  0.040m l
T h e  com ponents w ere d issolved  and m ixed  thoroughly, and stored at R T .
03.100g  
14.400g  
200m l 
stored at R T .
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Stain Solution
Rinse so lution JU
5-brom o-4-ch loro-3-indoly l 0 -D -galactopyranoside  (25m g/m l in  d im ethyl 
form am ide) 0 .400m l
Potassium  Ferricyan ide  0.0165g
Potassium  Ferrocyanide 0 .0165g
The com ponents were dissolved and mixed just before use.
2.5 Mammalian cell Culture
A l l  m am m alian ce ll cultures w ere g row n in  a 5% C O 2 atmosphere, at 37°C. A l l  ce ll 
counts w ere m ade using  a N eu bauer C ou n tin g  Cham ber. V ia b le  ce ll counts w ere  
obtained b y  m ix in g  cells, w ith  a 1/4 vo lum e o f  a com m ercia l 0.4% (w/v) isoton ic  
T ryp a n  blue solution. D e a d  cells w ere stained blue. T h e  v iab le  ce ll count w as 
carried out w ith in 5 m in. o f  the addition o f  T ryp a n  blue. C e lls  w ere v isu a lised  w ith  
a phase contrast m icroscope. A l l  ce lls w ere pelleted b y  centrifugation and all 
centrifugations w ere at 200-250g fo r 5 m in. unless otherw ise stated.
2.5.1 Mammalian cell culture media:
2.5.1.1 DMEM. 500m l o f  1 x  D M E M  (D u lbecco 's m od ification  o f  Eag le 's  m edium ) w as 
supplem ented w ith  2 m M  1-glutamine, 2 0 m M  H E P E S  and 25 (ig/ml gentam icin.
2.5.1.2 LINO. Th e  fo llo w in g  solutions w ere added to 500m l o f  I M D M  (Iscove's 
m odification  o f  D u lb ecco 's  m edium ):
0 .5m l o f  a fresh 2.5m g/m l so lution o f  B o v in e  Serum  A lb u m in  ( B S A )  in  I M D M
0.5m l o f  a 0.5% (w/v) solution o f  bovin e  in su lin  in  0 .0 1 N  HC1. T h is  so lution w as 
prepared in  advance, and stored at -8 0 °C .
5m l o f  a 0.35%  (w/v) solution o f  hum an transferrin in  P B S . T h is  solution w as 
prepared in  advance, and stored at -2 0 °C .
100|il o f  each o f  0.5%  (w/v) solutions o f  p a lm itic  acid , o le ic  acid  and lin o le ic  acid  
in  absolute ethanol. Fresh  preparations w ere used.
0.5m l o f  a fresh 2 x lO '2M  solution o f  ethanolam ine in  P B S .
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T h is  m edium  w as stored at -8 0 ° C , and supplem ented w ith  5x1 O'5 M  2- 
m ercaptoethanol (2 -M E ), non-essential am ino acids ( N E A A )  and I m M  sodium  
pyruvate before use.
2.5.1.3HAT: D M E M  supplem ented w ith N E A A ,  I m M  sodium  pyruvate, 100|iM  
hypoxanthine, 4 0 0 n M  am inopterin, 16 |iM  th ym id ine  and 10% (v/v) fetal c a lf  serum  
(F C S ).
2.5.1.4 HT: H T  m edium  w as prepared essentially as described fo r H A T  m edium  (section  
2.5.1.3), but am inopterin w as omitted.
2.5.2 Growth of cell lines
2.5.2.1. Suspension cell lines: C e lls  stored in  liq u id  nitrogen, in  cryovia ls, w ere 
thawed at 37°C. T h e  cell suspension, w as transferred to a 50m l centrifuge tube and 
10m l o f  culture m edium  w as added slow ly. T h e  cells w ere pelleted, and 
resuspended in  5 m l o f  culture m edium . T h e  resulting ce ll suspension w as cultured  
in  a T -25  flask. T o  subculture cells, they w ere flushed o f f  the surface o f  the flask  
using a pasteur pipette, into a larger vo lu m e o f  fresh culture m edium , w h ich  w as 
d iv ided  into the required num ber o f  flasks. F o r  large cell quantities, ce lls w ere  
grow n in  T -75  flasks at 15ml per flask.
2.5.2.2 Adherent cell lines: Adherent cell lines w ere grow n in  the same fash ion  as the 
suspension ce ll lines, w ith  the exception o f  subculture. T o  subculture, culture  
m edium  w as decanted from  the flask  and the flask  w as brie fly  w ashed w ith  P B S .  
C e lls  w ere exposed to l-2 m l o f  a so lution o f  P B S  contain ing trypsin  (0.25%  (w/v)) 
and E D T A  (0.2mg/ml), until ce lls  w ere seen to detach fro m  the p lastic surface. 
C ulture  m edium  (10m l per m l o f  try p s in / E D T A )  w as added to  the resulting cell 
suspension and the cells w ere pelleted b y  centrifugation at 250g fo r 10 m in. Th e  
resulting pellet w as resuspended in  the required vo lu m e o f  fresh culture m edium , 
w h ich  w as d iv id ed  into the required num ber o f  flasks.
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2.5.3 Storage of cell lines
C e lls  w ere harvested, from  the surface o f  lx T -7 5  flask, b y  flu sh ing  or trypsin izing , 
and pelleted. Pellets w ere resuspended in  4 m l o f  a  10% (v/v) solution o f  D M S O  
(D im eth yl sulphoxide) in  F C S ,  and d iv ided  into 4 cryovia ls. A  freezing-tray w as  
used to gradually co o l the cells, over a 2.5 hr. period, in  the vapour-phase o f  liq u id  
nitrogen. T h e y  w ere then im m ersed in  the liqu id-phase fo r long-term  storage.
2.5.4 Cell lines
2.5.4.1 Suspension cell lines: Sp2/0 ( A T C C  C R L  1581), E L 4  ( A T C C  T I B  39) and M y c l-  
9 E 1 0  ( E C A C C  85102202). These ce ll lines w ere cultured in  D M E M  contain ing  
10% (v/v) F C S . T h e y  w ere subcultured, using a split ratio o f  1:4, at approxim ately  
70% confluency. Th e  term  split ratio is used as defined  b y  Freshney, 1983: "the 
d iv isor o f  the d ilu tion  ratio o f  a ce ll cu lture at subculture, e.g., one flask  d iv ided  into  
fou r or 100ml up to 400m l w o u ld  be a split ratio o f  4."
2.5.4.2 Adherent cell lines N I H 3 T 3  ( A T C C  C R L  1658) and B H K  ( A T C C  C C L  10) w ere  
cultured in  D M E M  contain ing 10% (v/v) F C S . T h e y  w ere subcultured, at a split 
ratio o f  1:6, at approxim ately 90% confluency. T h e  culture m edium  w as changed at 
least every second day. C H O  ( A T C C  C C L  61) w as cultured in  D M E M  contain ing  
10% (v/v) F C S  and N E A A ,  but, otherwise, w as treated in  the same fash ion as the 
other adherent ce ll lines.
2.5.5 Conditioned media
2.5.5.1 Thymocyte-conditioned media (TCM): 4 x 3 - 4  w eek o ld  B a lb /C  m ice w ere  
sacrificed, b y  cervica l d islocation, and their thym us' w ere rem oved. A  thym ocyte  
suspension w as prepared, in  D H B S S ,  b y  cutting the thym us' in  tw o and gently  
teasing the cells out into 20m l D H B S S ,  through a 60 m esh m etal screen. L a rg e  
particulate matter w as rem oved, b y  centrifuging  at 80g fo r 30 sec.
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T h e  cells w ere pelleted, from  the resulting suspension, and resuspended in  
2m l o f  a 5% (v/v) solution o f  F C S  in  D H B S S .  10ml o f  G e y s  haem olytic solution  
w as added, and the ce ll suspension w as placed o n  ice fo r 5 m in. T h e  ce ll 
suspension w as underlaid  w ith  2 .5m l o f  F C S  and centrifuged at 300g fo r 10 m in. 
T h e  pellet w as w ashed once in  10m l o f  5% (v/v) F C S  in  D H B S S .
T h e  pellet w as resuspended in  L I N O , at 5x107 cells/m l and cultured in  25m l 
volum es in  T -75  flasks fo r 48 hrs. T h e  supernatant w as harvested, b y  
centrifugation, sterile-filtered, and stored at -8 0 °C .
2.5.5.2Mixed lymphocyte reaction (sMLR): Th ym ocytes w ere harvested from  th ym us’ 
donated b y  an equal num ber o f  B a lb/C  and C 5 7 B L\1 0  m ice , and erythrocytes lysed, 
as per section 2.5.5.1. T h e  fin a l ce ll pellet w as resuspended in  D M E M  contain ing  
2% (v/v) rabbit serum  (R S ) and 50jjM  2 -M E . C e lls  w ere cultured fo r 48 hrs in  50m l 
volum es in  T-75  flasks. T h e  supernatant w as harvested, sterile-filtered, and stored at 
-8 0 °C .
2.5.5.3 EL4-conditioned media (s E L 4 E L 4  cells w ere routinely  cultured in  D M E M  
contain ing 10% (v/v) F C S . C e lls  w ere harvested, and w ashed using  20m l o f  
D M E M  containing N E A A ,  I m M  sodium  pyruvate and 1% (v/v) R S . C e lls  w ere  
resuspended, at lx lO 6 cells/ml, in  the latter m edium . P h orb o l 12-m yristate 13- 
acetate ( P M A )  w as added, to a fin a l concentration o f  lOng/m l, from  a concentrated  
stock in  absolute ethanol. C e lls  w ere cultured fo r 40  hrs, in  20m l volum es, in  T -7 5  
flasks. T h e  supernatant w as harvested, sterile-filtered, and stored at -8 0 °C .
2.5.6 In vitro immunisations
2.5.6.1 Method o f Ossendorp et al (1986): T h e  desired num ber o f  6-8 w eek o ld  B a lb/C  
m ice (approxim ately 1 x  B a lb /C  per 2 0 m l o f  fin a l IV I  culture) w ere sacrificed and 
their spleens rem oved. N u cleated  splenocytes w ere prepared in  the same fash ion as 
w ere thym ocytes (section 2.5.5.1), except fo r the fact, that splenocytes w ere
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rem oved from  the spleen, b y  flu sh ing  D H B S S  through the spleen capsule w ith  a 
21g lance and a 1ml syringe.
Th e  final nucleated splenocyte pellet w as resuspended in  L I N O  at lx lO 7 
cells/ml. A n  equal vo lu m e o f  T C M  w as added. F in a lly , the desired am ount o f  
im m unogen w as added, from  a concentrated stock in  P B S . T h e  resulting  
suspension w as cultured in  6 w e ll plates at 2m l per w ell.
2.5.6.2 Method of Borrebaeck and Moller (1986). N u cleated  splenocytes w ere prepared as 
per section 2.5.6.1. T h e  final nucleated splenocyte pellet w as resuspended, at 5x106 
cells/ml, in  the fo llo w in g  m edium . I f  the fin a l vo lu m e  was to be X  m l, the ce ll 
pellet w as resuspended in  X/3 m l o f  D M E M  contain ing  10% (v/v) R S , N E A A ,  
I m M  sodium  pyruvate and 50|iM  2 -M E . X/3 m l o f  s M L R  and X/4 m l o f  s E L 4  
w ere added and the vo lu m e w as adjusted to X  m l w ith  D M E M  contain ing 2% (v/v) 
R S , N E A A ,  I m M  sodium  pyruvate and 50|jM  2 -M E . A n tig en  w as added, as 
desired, from  a concentrated stock in  P B S . T h e  ce ll suspension w as cultured, in  
10ml volum es, in  T -25  flasks.
2.5.7 Hybridoma isolation
2.5.7.1 Somatic cell fusion. Sp2/0  cells w ere grow n fo r  at least tw o weeks, p rio r to fusion. 
C e lls  w ere not grow n above 50% confluency, and w ere subcultured at a split ratio  
o f  1:2 the day before fusion. O n  the day o f  fusion, the m edium  w as poured o f f  the 
Sp2/0 cells, and D M E M  lack in g  H E P E S  w as added. C e lls  w ere resuspended and  
counted. T h e  cells w ere stored on ice until required.
Splenocytes, from  an in vitro im m unisation , w ere resuspended and counted. 
Splenocytes and Sp2/0  ce lls  w ere m ixed  to g ive  a cell ratio o f  10 splenocytes per 
Sp2/0 cell. T h is  ce ll m ixture was pelleted and w ashed 4 tim es w ith  5m ls o f  D M E M  
lack ing  H E P E S .
A l l  o f  the supernatant, from  the final w ash, w as rem oved, except fo r 50- 
100(j.l (sim p ly  pouring  o f  the supernatant sufficed), and the cells w ere resuspended  
b y  tapping. Th e  ce ll suspension w as placed in  an ice/water bath, and 1.5ml o f  50%
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(v/v) P E G  (polyethylene g ly co l)  w as added to it, over a 1 m in. period, w hile  
sw irling. S w irlin g  was m aintained fo r  another 1.5 m in. T h e  centrifuge tube was 
rem oved, from  the w ater bath, and enclosed in  the palm  o f  the hand. 20m l o f  pre­
w arm ed (37°C) D M E M  lack in g  H E P E S  w as then added over 5 m in. w ith  constant, 
slow , sw irling. T h e  resulting suspension w as p laced  at 37°C  fo r 15-20 min.
T h e  suspension w as centrifuged, at 200g fo r  10 m in., and the cells w ere  
resuspended at 1 .2 x l0 6 cells/ml, in  H A T  supplem ented w ith  5% (v/v) B ric lo n e . 
T h e  suspension w as plated, in  96 w ell plates, at 0 .1m l per w ell, and incubated fo r 7 
days. O n  day 7, 50jj,1 o f  fresh H A T  w ith  5% (v/v) B ric lo n e  w as added to each w ell. 
O n  day 8, 50|o,l o f  spent m edium  w as rem oved and fresh m edium  w as added. W e lls  
w ere then fed as required.
2.5.7.2 Screening for antigen-reactive wells: O u tgrow n w ells, from  the m asterplates, w ere  
screened b y  an E L Is p o t assay (2.8.1.2.). B rie f ly , h a lf  the ce lls  from  a w ell, w h ich  
contained v is ib le  co lon ies, w ere placed into  an eppendorf tube and w ashed in  three 
volum es o f  fresh H A T  m edium . T h e  cells, then, w ere resuspended in  a lOOjj.1 
volum e o f  H A T  m edium , and used as a test sam ple in  the E L Is p o t assay, as per 
section 2.8.1.2.
2.5.7.3 Cloning of antigen-reactive hybridomas: C e lls  from  w ells, w h ich  tested positive  in  
the E L Is p o t assay, w ere expanded in  H A T  m edium , from  96 w ell plates, to  24 w ell 
plates and fin a lly  to 6 w ell plates.
C e lls  w ere cloned, b y  lim itin g  d ilution, w hen they had  reached 50%  
confluency. B rie f ly , ce lls w ere resuspended, and diluted to 100 cells/ml in  H T  
supplem ented w ith  5% (v/v) B ric lo n e . T h e  cell suspension w as plated, then, at 
100(il/well in  96 w ell plates. A fte r  7 days, 50^1 o f  fresh H T  contain ing 5% (v/v) 
B ric lo n e  w as added, and on  day 8 h a lf  the m edium  w as changed. W e lls  w ere fed as 
required. Screening fo r positive  w ells  proceeded, as per section 2.5.7.2, o r using an 
E L I S A  as per section 2.8.1.1, using  neat m edium  from  the w ell, as the test sample.
P ositive  w ells  w ere expanded, as already described, and recloned  tw ice  at 10 
cells/ml. T h e  second tim e, ce lls  w ere cloned in  D M E M  contain ing  10% (v/v) F C S ,
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N E A A  and I m M  sodium  pyruvate rather then in  H T  m edium . P o sitive  w ells at this 
stage w ere considered, statistically, to be m onoclonal. T h e  resulting hybridom as  
w ere routinely g row n in  the above m edium . O n  occasion, they w ere g row n in  a 
com m ercia l serum -free m edium , H y b r id o m a -S F M ™ .
2.5.8 Eukaryotic cell transfections
2.5.81 Transient transfections. 7 .5x10s cells, in  10m l o f  m edium , w ere plated in  60m m  
tissue culture dishes, one day p rio r to transfection. Transfection  w as carried  out 
using either T fx -5 0 ™  or T fic-1 0 ™  reagent according  to the m anufacturer's 
instructions.
2.5.8.2 Stable transfections. Tran sien tly  transfected ce lls  w ere trypsinised, after 48hrs, and 
subcultured at a split ratio o f  1:15 into  60m m  tissue culture dishes contain ing  
m edium  supplem ented w ith  geneticin. (Th e  concentration o f  geneticin  required, w as 
determined, b y  splitting a confluent d ish o f  the parental ce ll line  1:15, into m edium  
containing various concentrations o f  geneticin. T h e  m in im al concentration o f  
geneticin required, to  com pletely inhib it co lo n y  outgrow th, w as used to select stable 
transfectants). M e d iu m  w as replaced, w ith  fresh m edium , every fou r days.
C o lo n ie s  w ere p icked  w hen they contained approxim ately 500 cells (see F ig . 
4.12). T h e  fo llo w in g  procedure w as fo llow ed. T h e  m edium  w as drained from  the 
dish using  a pasteur pipette. C o lon ies cou ld  be seen, b y  ho ld ing  the d ish  at an angle  
to the light, as opaque patches o n  the d ish  surface. C o lo n ie s  w ere rem oved using a 
P200 tip attached to a G ilso n  pipetteman. T h e  tip w as scraped over the co lo n y  
w h ile  the p lunger w as s low ly  released. Gathered cells w ere expelled into  fresh  
m edium  (1m l in  a w ell o f  a 24 w ell plate) b y  v ig o ro u s ly  pipetting up  and dow n the 
P200 tip. B e fo re  p ick in g  any other co lon ies the dish w as w ashed w ith  2 volum es o f  
P B S  to rem ove any lo ose ly  adherent o r floating cells. C o lo n ies  w ere considered to  
be m onoclonal (see F ig . 4.12), and the resulting stable transfectant cell lines w ere  
routinely g row n in  m edium  supplem ented w ith  geneticin.
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I2.6 Microbiology
2.6.1 Bacterial strains:
E. coli H B 2 1 5 1 : hsdA 5thiA(lac-proAB) F '[traD36proAB + laclq lacZ/SMXS]
E. coli T G I : supE hsdA 5thiA(lac-proAB) F '\traD36proAB + laclq /acZzlM 15]
E.coliD H 5 a :  supE44 A/acU 169 (<|)80 Z a c Z A M I 5) hsdRXl recAX endAl gyrA96 
thi- 1 relA\
E. coli T O P I O F ’ : F'|7acl q7w lO (Tet mcrA A(mrr-hsdRMS-mcrBC )
<I>80/acZAM15 MacXIA deoR recAl araD 13 9 A(ara-leu)7697 galU 
galK rpsL endAl nupG
E. coli X L - 1  B lu e  M R F ':  A(/wcrA)183 A(mcrCB-/i5<iSMR-/w/'/'y) 173 e« i/A l
5M/?E44 thi-l recAl gyrA96 relAl lac F '[ p r o A B  lacl qZ A M 1 5  T n lO  
( T e t 1)]
E. coli X L - 1  B lue: supE44 hsdRl7 recAl endAl gyrA46 thi relAl lac
F  '\proAB+ laclq lacZMA.15 TnlO (tetr)]
2.6.2 Culture media
L B  Broth: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) N a C l.
S O B  (a): 2% (w/v) tryptone, 0.5% (w/v) yeast extract, lO m M  N a C l,  2 .5 m M
KC1.
S O C  (a): S O B  (a) supplem ented w ith  lO m M  M g C U , 2 0 m M  glucose.
S O B  (b): 2% (w/v) tryptone, 0.5% (w/v) yeast extract, lO m M  N a C l,  lO m M
M g C l2, 1 0 m M M g S 0 4 .
S O C  (b): S O B  (b) supplem ented w ith  0.4% (w/v) glucose.
2 x T Y : 1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) N a C l.
T e rr ific  B roth: 4.7% (w/v) terrific  m edium , 0.8% (v/v) g lycero l.
2.6.3 Bacterial culture
Bacteria l strains w ere m aintained as g lycero l stocks (bacterial pellets resuspended in
10% (v/v) g lycero l in  U P H 2O ) and stored at -2 0 °C . 5|il o f  g lycero l stock was
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streaked on  an agar plate (broth supplem ented w ith 1.5% (w/v) agar and antibiotic) 
and grow n overnight at 37°C. T h e  next m orning, a co lo n y  w as p icked, and 
transferred to 10ml o f  the relevant broth (containing antibiotic) in  a 20m l un iversal 
container. T h is  culture w as grow n, during the day, at 37°C  in  an orbital shaker at 
100-200rpm. I f  necessary, the 10ml culture w as used to inoculate 500m l o f  fresh  
m edium , w h ich  w as grow n fo r  approxim ately 12 hrs under the same conditions.
2.6.4 anti-NIP ScFv production
A  10ml culture o f  E. coli H B 2 1 5 1  anti-NIP, in  2 x T Y  supplem ented w ith g lucose  
and carben ic illin  to  final concentrations o f  1% (w/v) and 100|xg/ml, respectively, 
was grow n at 37°C overnight. T h e  fo llo w in g  m orning, 500m l o f  fresh m edium  w as 
inoculated w ith  5m l o f  th is culture, and grow n at 37°C. T h e  optical density at 
600nm  o f  the culture w as tested, period ica lly , and w hen it reached 0.6, the cells 
w ere harvested by centrifugation at 4000g fo r 20 m in. at R T .
T h e  bacterial pellet w as w ashed once in  2 x T Y , pre-w arm ed to 30°C, and 
resuspended in  500m l o f  2 x T Y  (again pre-w arm ed to 30°C) supplem ented w ith  
carben ic illin  to  a final concentration o f  100(j,g/ml. 120mg o f  so lid  isopropyl P -D -  
thiogalactopyranoside (IP T G )  w as added and the culture w as grow n overnight at 
30°C.
T h e  fo llo w in g  m orning, the culture was cooled on ice  fo r 15 min. and one  
drop o f  antifoam  A  w as added to it. Th e  culture supernatant w as harvested by  
centrifugation at 6000g fo r 10 m in. at 4°C. S o lid  streptom ycin w as added to the 
supernatant to a final concentration o f  0.15%  (w/v) and the supernatant w as filtered  
through a sintered-glass filter and stored at 4°C  as a source o f  ScFv.
A  perip lasm ic lysate w as prepared from  the cell pellet as a second potential 
source o f  ScFv. T h e  pellet w as resuspended in  10ml o f  P B S  supplem ented w ith  
O .lm M  phenyl m ethyl su lphonyl flu oride  (P M S F )  and 0.15%  (w/v) streptom ycin. 
Th e  pellet was freeze-thaw ed b y  storing at -20°C fo r lh r. p rior to thaw ing out under 
a co ld  tap. T h is  w as repeated tw ice and the supernatant harvested by centrifugation  
at 6000g fo r 0.5hr at 4°C. T h e  supernatant was sterile filtered and stored at 4°C.
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2.7 Molecular Biology
2.7.1. General Molecular Biological Techniques
A s  per Sam brook etal. (1989) except as described below .
2.7.2 DNA preparations
2.7.2.1 Minipreps: B acteria  w ere harvested, from  a 10ml culture, b y  centrifugation at 
lOOOg fo r 10 m in. T h e  pellet w as 'dried', b y  centrifugation at lOOOg fo r 30 sec. 
fo llow ed  b y  rem oval o f  any traces o f  supernatant w ith  a pipette. T h e  pellet w as 
resuspended in  200(j.l o f  a lka line-lysis solution 1, by vortexing, and w as left o n  ice  
fo r 4 m in. 400^1 o f  a lka line-lysis  so lution 2 w as added, and they w ere m ixed  b y  
rotation and left on  ice  fo r 4 m in. T o  this, 300|il o f  a lka line-lysis 3 so lution w as 
added, m ixed b y  vortex ing  and left on ice fo r  4 min. 600|il o f  the resulting m ixture  
was transferred to an eppen dorf tube, spun at 12000rpm  in  a m icrofiige  fo r 5 m in. 
and the supernatant w as transferred to a fresh ep pen d orf tube.
Th e  supernatant w as 'extracted' b y  adding an equal vo lum e o f  50% (v/v) 
equilibrated phenol/50% (v/v) ch loroform  (hereafter referred to as phenol- 
chloroform ) to it. T h e  em ulsion  w as m ixed  b y  v ig orou s vortexing and the tw o  
layers separated b y  m icrofuge centrifugation (hereafter referred to as 'm icrofuging') 
at 12000rpm fo r 2 m in. T h e  top layer was transferred to a new  eppendorf tube.
A n  equal vo lu m e o f  isopropanol w as added to the eppendorf tube, w h ich  
w as left on ice fo r 10 m in. A  d ry  crude preparation o f  D N A  w as recovered, b y  
m icrofug ing  at 12000rpm  fo r 5 m in. T h e  pellet w as rinsed in  1ml o f  a 70% (v/v) 
solution o f  ethanol, left to dry, and resuspended in  50|ol o f  sterile U P H 2O . 1 unit (u) 
o f  R N ase  1 w as added to the solution o f  D N A  in  order to destroy any contam inating  
R N A .
U ltrapure D N A  w as prepared, i f  required, from  the above preparation, b y  gel 
extraction using  a Q ia e x  II gel extraction kit according  to the m anufacturer's 
instructions.
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2.7.2.2 Maxipreps : M a x ip re p s  o f  u ltrapure D N A  w ere prepared using a Q iagen  M a x ip re p  
D N A  kit according  to  the m anufacturer's instructions.
2.7.2.3 from eukaryotic cells: G e n o m ic  D N A  w as prepared fro m  eukaryotic ce lls  according  
to either one o f  the fo llo w in g  tw o protocols.
i) C e lls  w ere harvested from  1 x  T-75  flask, and w ashed in  tw o volum es o f  P B S . 
T h e  cells w ere resuspended in  1ml o f  U P H 2O  and bo iled  fo r tw o  minutes. T h e  
supernatant w as harvested b y  m icrofug ing  at 13000g fo r 10 m in., and w as used as a 
source o f  genom ic D N A .
ii) C e lls  w ere harvested from  1 x  T -75  flask, and w ashed in  tw o volum es o f  P B S . 
T h e  cells w ere resuspended in  lOOp.1 o f  P C R  lys is bu ffer, and 1 j_il o f  proteinase K  
was added. Th e  ce ll suspension w as incubated at 65 °C  fo r  10 m in. A  further l| il o f  
proteinase K  w as added and the incubation w as continued fo r a further 50 m in. Th e  
solution w as then incubated at 95°C fo r 10 m in. T h e  supernatant w as harvested b y  
m icrofug ing  at 13000g fo r 10 m in. and used as a source o f  genom ic D N A .
2.7.3 Polymerase chain reactions (PCR)
2.7.3.1 PCR with Taq polymerase: T h e  fo llow in g  P C R  m aster m ix  w as prepared: 5.5^1 o f  
4 0 m M  stocks o f  each d N T P , 59|il o f  2 5 m M  M g C l2, 100pl o f  lO x  Taq reaction  
buffer and 819^1 U P H 20 .
P C R  reactions w ere set up as fo llow s: 90(il P C R  master m ix , 3|il o f  forw ard  
prim er (20nm oles), 3(il o f  reverse p rim er (20nm oles), 3(j.l o f  tem plate D N A  ( lx lO 6 
m olecules) and 0.5(j,l Taq polym erase ( lu ) .
Th e  fo llo w in g  tem perature profile  w as used fo r therm ocycling: 94°C  fo r  1 
min. fo llow ed b y  30 cyc les of: 94°C fo r 1.5 m in., 55°C fo r 1 min. and 72°C fo r  3 
m in. F in a lly , the reaction product w as extended at 72°C  fo r 7 min.
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2.7.3.2 PCR with Pwopolymerase. T h e  fo llo w in g  P C R  m aster m ix  w as prepared: 5 .5 fil o f  
4 0 m M  stocks o f  each d N T P  and 478(il o f  U P H 20 .
P C R  reactions w ere set up as fo llow s: 50|o.l P C R  master m ix , 3 0 p l U P H 2O , 
10(il o f  lO x  Pwo buffer, 3|il o f  forw ard prim er (20nm oles), 3(j,l o f  reverse prim er  
(20nm oles), 3 p l o f  tem plate D N A  ( lx lO 6 m olecules) and 0.5(il Pwo polym erase  
( lu ) .
Th e  same tem perature profile , as in  section 2 .7 .3 .1 , w as used.
2.7.4 TA cloning and transformation of PCR product
P C R  reaction product produced w ith Taq polym erase w as d irectly  ligated into  the 
vector p C R ™ 3 - U n i provided  w ith  the eukaryotic T A  clon in g  kit, according  to  the 
m anufacturer's instructions. Transform ation  o f  the liga tio n  m ix  into E. coli T o p lO F  
chem ically-com petent ce lls (provided w ith  the kit) w as carried out according  to  the 
m anufacturer's instructions.
2.7.5 T4 DNA polymerase-mediated-cloning and transformation of PCR product
2.7.5.1 Creation of vector pMIK. T h e  vector p c D N A 3 .1 +  w as restricted as fo llow s. 10j_il 
p c D N A 3 .1 +  ( l( ig ) , 6\x\ U P H 20 ,  2(j,l S u R E 1 cut buffer B ,  ljj.1 HindUl ( lO u ) and 1 jj.1 
EcoRl ( lO u ) w ere m ixed incubated at 37°C  fo r 4 hours.
2 3 0 p l o f  U P H 20  w as added to the restriction digest, w h ich  w as extracted  
w ith an equal vo lu m e o f  phenol-chloroform . T h e  top layer w as rem oved, and 25 ¡ul 
o f  3 M  sodium  acetate and 2(il o f  a 2% (w/v) g lyco g en  so lution w ere added to it.
500|_il o f  absolute ethanol w as added and the m ixture incubated at - 2 0 ° C  fo r  
1 hour. T h e  precipitated, restricted p c D N A 3 .1 +  w as pelleted, b y  m icro fu g in g  at 
13000rpm  fo r 10 m in ., washed once in  70% (v/v) ethanol, left to  air-dry and 
resuspended in  15(0.1 o f  U P H 2O .
1 SuRE cut buffers are a series of reaction buffers, produced by Boehringer Mannheim, and optimised for use 
with their restriction enzymes. The recipes for these buffers are available in the Boehringer Mannheim 
catalogue.
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T h e  fo llo w in g  ligation reaction w as set up and incubated at 14°C overnight. 
Ijj.1 o f  restricted p c D N A 3 .1 +  (20fm oles), l|j,l o f  synthetic duplex D N A  (see fig. 5.1) 
(40fm oles), 1(^ 1 o f  lO x  ligation  buffer, 6|jl o f  U P H 2O  and l|J.l o f  T 4  D N A  
polym erase.
T h e  ligation  m ix  w as electroporated, into electrocom petent E. coli X L 1 -  
B lu e , as fo llow s. In a co ld  eppen dorf tube, 300jil o f  the ce ll suspension w as m ixed  
w ith 2|il o f  the ligation  reaction and left on  ice  fo r  30 sec. T h is  m ixture w as 
transferred to a cold, 0 .2cm  electroporation cuvette. T h e  cuvette w as placed into the 
ch illed  safety cham ber slide and pulsed once at the fo llo w in g  settings: 25|iF, 
2 .48kV and  2 0 0 Q . T h e  cuvette w as im m ediately rem oved, 3m l o f  S O C  (a) m edium  
added, and q u ick ly  m ixed, w ith  the contents. T h e  resulting ce ll suspension, w as 
transferred to a 20m l un iversal tube, and incubated at 37°C fo r 1 hour w h ile  shaking  
at 225rpm.
T h e  transfection m ix  w as plated on  L B  agar ( L B  broth w ith 1.5% (w/v) agar 
and lOO^g/ml carben ic illin ) and cultured overnight. 10 colon ies w ere p icked  and 
grow n in  10ml o f  L B  broth w ith lOO^g/ml carben ic illin . D N A  w as prepared b y  
m iniprep (2.7.2.1.) from  h a lf  o f  each culture, and a g lycero l stock o f  the rem aining  
h a lf  w as also prepared. E a c h  D N A  preparation w as analysed b y  restiction digest. A  
plasm id g iv in g  the correct restriction pattern w as nam ed p M I K .
2.7. S. 2 Restriction of pMIK. U ltrapure  p M I K , prepared b y  m axiprep, w as restricted as 
fo llow s. 40(il p M I K  (50|ig), 20|J £ c o R I  (200u), 20jj1 S u R E  cut bu ffer H  and 120|il 
o f  U P H 2O  w ere m ixed  in  an eppen dorf tube and incubated at 37°C  fo r 4 hours. 
Subsequently, 200(il o f  T E  buffer w as added, and the solution w as tw ice  extracted 
w ith phenol-chloroform . 400(il o f  so lution w as recovered after extraction. T o  this, 
40ul o f  3 M  sodium  acetate and 1ml o f  absolute ethanol w as added, and incubated  
on ice fo r 30 m in. Th e  D N A  w as pelleted, by m icro fu g in g  at 13000g fo r 10 m in., 
washed in  70% (v/v) ethanol, air-dryed and resuspended in  40(j,l o f  U P H 2O.
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2.7.5.3 pMIK cut back. T w o  o f  the fo llo w in g  reactions w ere set up and incubated fo r  1 hr 
at 15°C. 25(j,l cut back  buffer, 5^1 T 4  D N A  polym erase (5u), 5(0.1 o f  restricted p M I K  
(6.25|ig) and 15(xl o f  U P H 20 .  B o th  reactions w ere com bined  and 50(ol o f  T E  buffer 
added to them. Th e  solution w as tw ice extracted w ith  pheno 1-chloroform  and 150(il 
w as recovered. T h is  w as extracted w ith  150(ol o f  ch lo ro form , from  w h ich  100|il 
was recovered. 10(j.l o f  3 m M  sodium  acetate, 1 jj.1 2% (w/v) g lycogen  and 250^1 o f  
absolute ethanol w ere added and incubated on  ice fo r  15 m in. A  pellet o f  D N A  was 
recovered b y  centrifugation at 13000rpm  fo r 10 m in., w ashed in  70% (v/v) ethanol, 
air-dried and resuspended in  40(j,l o f  U P H 2O .
2.7.5.4PCR cut back: T h e  P C R  product w as first purified  using a P C R  cleanup kit 
(Boehringer M an n h eim ) according to the m anufacturer's instructions. T w o  reactions 
were set up as fo llow s, and incubated at 15°C fo r  1 hr. 40(il cut back buffer, 4fj.l T 4  
D N A  polym erase (4u), 8|il U P H 2O  and 8jol purified  P C R  product (lp.g). B oth  
reactions w ere com bined  and 70[il o f  T E  buffer added to them. T h is  so lution was 
then treated as per section 2.7.5.3.
2.7.5.5 Ligation : F o u r o f  the fo llow in g  ligation  reactions w ere set up, and incubated at 5°C  
overnight. 25|il ligation  buffer, 5(il cut back vector (200ng), 5(ol cut back P C R  
product (200ng), 5[_il U P H 2O , 5|ol T 4  polynucleotide  kinase (50u) and 5(jl T 4  D N A  
ligase (5u). T h e  ligation  reactions w ere pooled  (180j_il) and heated to 65°C fo r 15 
min. Th e  reaction w as phenol-ch loroform  extracted and 180|il recovered. 18(il o f  
3 M  sodium  acetate, l|_il o f  2% (w/v) g lycog en  and 450(ol o f  absolute ethanol were 
added, and incubated on ice  fo r 1 hour. D N A  w as pelleted b y  m icro fu g in g  at 
13,000rpm  for 15 m in., rinsed in  70% ethanol, air-dried fo r 10 m in. and 
resuspended in 2(il o f  T E  buffer.
2.7.5.6 Transformation: T h e  electroporation cham ber and a 0 .1cm  electroporation cuvette, 
were pre-ch illed  on  ice. E. coli X L  1-B lu e  M R F '  electroporation-com petent cells 
w ere thawed on ice. 960|il o f  S O C  (b) m edium  w as pre-heated to 37°C.
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40(0,1 o f  the ce ll suspension w as m ixed, w ith  l|ol o f  the purified  ligation  
reaction in  an eppen dorf tube, on ice. T h is  m ixture w as transferred to the cuvette, 
w h ich  w as p laced  in  the cham ber, and pulsed  once at 1 .7kV , 2 0 0 Q  and 25 (oF. 
960|ol o f  pre-w arm ed S O C  (b) w as im m ediate ly  added to and m ixed  w ith , the 
contents o f  the cuvette. T h e  contents w ere transferred to a 20m l un iversal tube, and 
incubated at 37°C  at 200rpm  fo r 1 hour.
A  sm all am ount o f  the ce ll suspension w as then taken to determine the 
num ber o f  transform ants present, b y  plating. T h e  rem ainder w as added to 10ml o f  
terrific broth supplem ented w ith  20|og/ml tetracycline and 50|og/ml carben ic illin , 
and incubated fo r 1 hour at 37°C and 200rpm . 1ml o f  this culture w as added into  
each o f  10 20m l un iversal tubes contain ing 10m l terrific  broth supplem ented w ith  
100(og/ml carben ic illin , and cultured overnight. T h e  next m orning  the bacteria w ere 
harvested from  a ll 10 cultures and the com bined  bacteria  w ere resuspended in  1ml 
o f  a 10% (v/v) solution o f  g lycero l in  U P H 2O  and this g lycero l stock w as stored at -  
20°C.
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2.8 Biochemistry
2.8.1 Solid phase immunoassays
2.8.1.1 ELISAs for titration of antibody activity: 100|il o f  a solution o f  antigen in  coating  
buffer (a phosphate buffer, p H  7.6 - see section 2.4.3.1), w as added to w ells, o f  a 
N u n c  m axisorp plate, and incubated at room  tem perature fo r  at least 8 hours.
W e lls  w ere w ashed w ith  3 x  20 0 jil and 1 x  400(j.l o f  w ash buffer, and 100^1 
o f  a 5% (v/v) so lution o f  F C S  in  coating buffer w as added to each w ell, and 
incubated fo r at least 1 hour at room  tem perature. T h is  w as to 'block' any rem aining  
adsorption sites on  the plastic surface.
W e lls  w ere then w ashed out w ith  4 x  200|j,l and 1 x  400^.1 o f  w ash buffer 
and test sam ples (100|il per w ell) w ere added to the plate. I f  necessary sam ples 
were diluted in P B S  containing 0.05%  (v/v) T w een  20 and 5% (v/v) F C S  (diluent 
buffer). Sam ples w ere incubated fo r  5 hrs. at room  temperature.
W e lls  w ere w ashed w ith  4 x  200|xl and 2 x  400(il o f  w ash buffer, 100|il o f  
secondary antibody (alkaline phosphatase conjugated to a goat anti-m ouse antibody  
or a goat anti-rabbit antibody), d iluted as required in  d iluent buffer, w as added to 
each w ell and incubated fo r 2 hours at room  temperature.
W e lls  w ere w ashed w ith  4 x  200|ol and 3 x  400jj.l o f  w ash bu ffer and 200|il 
o f  substrate was added per w ell. T h e  substrate used w as para-nitrophenyl phosphate 
(pN P P ) provided  in tablet fo rm  and d isso lved  in  the required vo lum e o f  d H 20  just 
p rio r to  use. Substrate was left to  develop in  the dark at room  temperature. O ptica l 
densities w ere read at 405nm  using  a titertek plate reader.
2.8.1.2 ELIspot assay for enumeration of antibody secreting cells. N u n c  m axisorp  plates 
w ere coated and b locked  as per section 2.8.1.1.
W e lls  w ere washed w ith 4 x  2 0 0 n l and 1 x  400|xl o f  w ash buffer fo llow ed  
by 4 x  400|j,l P B S . T h e  population o f  ce lls  to  be analysed, w ere harvested, washed  
in  three vo lum es o f  fresh m edium , and resuspended in  fresh m edium  and counted.
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K n o w n  am ounts o f  cells, in  lO O jil o f  fresh m edium  w ere added per w ell, and 
incubated at 37°C  fo r 6 hours, in  a 5% C O 2 atmosphere.
W e lls  w ere w ashed out w ith  4 x  200^1 and 2 x  400)0,1 o f  w ash buffer, and 
developm ent w ith  secondary antibody (alkaline phosphatase conjugated to a goat 
anti-m ouse antibody) proceeded as per section 2.8.1.1.
W e lls  w ere w ashed out w ith  4 x  200(il and 3 x  400(il o f  w ash buffer, and 
100(il o f  substrate w as added per w ell. T h e  substrate used w as 5-brom o-4-chloro-3- 
in d o ly l phosphate, para-toluidene salt (B C IP )  at 1 mg/ml in  A M P  b u ffer and was 
prepared fresh. Substrate w as left to develop overnight in  the dark at room  
temperature.
T h e  fo llo w in g  m orning w ells w ere w ashed w ith  4 x  200jol and 3 x  400j_il o f  
d H 2 0  and the plate w as left to air-dry. T h e  num ber o f  b lue plaques in  each w ell 
w ere counted, under 40x m agnification, and the frequency o f  ce lls secreting  
antigen-reactive antibody w as calculated, b y  regression analysis, o f  the num ber o f  
plaques per w ell versus the num ber o f  ce lls per well.
2.8.1.3 Affinity analysis using ELISA. T h e  m ethod o f  Frigu et et al., (1984) w as em ployed. 
B rie fly , the day before the E L I S A  analysis, a series o f  antibody-antigen m ixtures 
were prepared in  w ells o f  a 96 w e ll plate. These  solutions each contained a constant 
but unknow n concentration o f  antibody. T h is  concentration w as n o m in a lly  referred  
to as "1". These solutions each contained vary in g  but know n concentrations o f  
antigen ([A]). These various antibody-antigen solutions w ere left overnight at R T ,  
to reach equilibrium .
T h e  fo llo w in g  m orning, the nom inal concentration o f  free antibody in  each 
solution was determ ined b y  E L I S A ,  as per section 2.8.1.1. O D  405nm  values were 
related to nom inal concentration values b y  reference to a standard curve o f  nom inal 
concentration versus O D  405nm .
T h e  fraction o f  total antibody, bound b y  antigen (v), w as calculated fo r each 
antigen concentration. The  slope o f  a p lo t o f  1/v versus 1/[A] (K lo tz  plot) gave the 
dissociation constant fo r the interaction.
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2.8.2 Cytochemistry
2.8.2.1 In situ /3-gal staining: C e ll m onolayers w ere w ashed tw ice w ith  P B S  (500|ol per 
w ell o f  24 w ell plate). 300^,1 o f  f ix  so lution w as added to each w ell, fo r 10 m in., 
and then poured off. T h is  w as done tw ice. 300|ol o f  rinse so lution w as added to 
each w e ll and left fo r 10 m inutes before pouring  off. T h is  w as done twice. 150(ol 
o f  stain solution was added to each w ell and left overnight at 37°C. C e lls  
expressing 3-galactosidase w ere stained blue.
2.8.2.2 In situ c-myc staining: T ransiently  transfected ce lls  (section 2 .5.8.1.) were 
resuspended at lx lO 6 cells/ml in  culture m edium . 50|ol vo lum es w ere cytospun onto 
glass slides using  the Heraeus labofuge A e  system  at 750rpm  fo r 5 min. The  
resulting ce ll smears w ere fixed  and perm eabilised, using  either o f  the tw o  
fo llo w in g  procedures.
i) Sm ears w ere left air d ry  fo r  3-5 m in., p laced in  m ethanol fo r 5 m in. fo llow ed  b y  
acetone fo r 1.75 m in., (both solvents at -20°C). S lide preparations w ere left d ry  
overnight before use.
ii) A lternative ly , smears w ere left a ir d ry  fo r 3-5 m in. before adding a drop o f  4%  
(w/v) paraform aldehyde in  P B S  to each cell smear. A fte r 10 m in. slides were 
w ashed fo r 9 m in. w ith  3 changes o f  P B S  and then p laced  in  a 0.2% (v/v) solution  
o f  T rito n  X -1 0 0  in  P B S . A fte r  10 m in. the slides w ere w ashed as before, and w ere  
then ready fo r use.
30(0.1 o f  a ffin ity-purified  (section 2.8.4.2.) anti-c-m yc antibody (mouse IgG , 
produced b y  clone M y c -9 E 1 0 ), diluted in  P B S  contain ing 5% (v/v) F C S ,  w as added 
to fixed  and perm eabilised smears, and the slides w ere incubated in a hum id  
cham ber at 4 °C  fo r 1 hour. S lides w ere washed w ith  3 changes o f  P B S  fo r 9 min. 
and 100(0.1 o f  a suitable d ilu tion  o f  a F IT C -g o a t anti-m ouse I g G  conjugate (again in  
P B S  w ith  5% (v/v) F C S )  w as added to each smear. Slides w ere replaced in  the
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hum id  cham ber at 4°C  fo r 1 hour. Subsequently, slides w ere w ashed fo r 9 min. 
w ith 3 changes o f  P B S  and w ere left a ir d ry  fo r 5-10 m in. C o vers lip s  w ere mounted  
on the glass slides w ith  V ectash ie ld  m ounting m edium , and stored in  the dark prior 
to m icroscop ic analysis w ith  a fluorescent L e itz  L a b o r lu x  K  m icroscope. C e lls  
expressing c-m yc fluoresce green.
2.8.3 Immunoblots and related techniques
2.8.3.1 Cell cytoplasm extracts: C e lls  were harvested from  1 x  T -75  flask, w ashed in tw o  
volum es o f  P B S , resuspended at 5 x l0 7 cells/m l in  ly s is  buffer, and incubated on ice  
fo r 30-60 m in.. T h e  nucle i w ere rem oved b y  m icrofu g in g  at 250g fo r 10 min. Th e  
supernatant (lysate) was clarified  by m icrofu g in g  at lOOOOg fo r 30 m in. Th e  lysate  
was pretreated to rem ove proteins w h ich  m ay b in d  b o v in e  serum, m ouse I g G  or  
goat IgG . 10(j.l o f  bovine serum -agarose, 10|il o f  m ouse IgG -agarose and IOjj.1 o f  
goat I g G  -agarose w ere added per 200|il o f  lysate, incubated at 0-5°C fo r 1 hr., prior 
to being rem oved b y  m icrofu g in g  at 200g fo r 5 min. T h e  supernatant w as stored at 
-20°C.
2.8.3.2 Organ extracts: Extracts w ere prepared from  the fo llo w in g  B a lb /C  organs: heart, 
liver, lung and spleen. Th e  relevant organ w as rem oved, from  the required num ber 
o f  m ice, and rou gh ly  m inced w ith  a scalpel. A p p ro x im ate ly  600m g o f  the m inced  
organ w as added to 10ml o f  hom ogen ising  buffer, in  a 20m l un iversal tube, and w as 
disrupted w ith  a hom ogeniser fo r  4 minutes. T h e  resulting m ixture w as clarified  b y  
centrifugation at 6000g fo r 10 minutes. T h e  supernatant w as aliquotted and stored 
at -20°C. Th e  protein concentration w as determ ined spectrophotom etrically, using  
the fo llo w in g  form ula  (Peterson, 1983):
conc. (mg/ml) = O D  205nm/ [27 + 120(Q D  28Qnm /OD 205nm )]
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2.8.3.3 SDS-PAGE: A  5% (w/v) stacking/10% (w/v) reso lv ing  S D S - P A G E  gel was 
prepared using an A tto  dual m in islab  electrophoresis system. R e so lv in g  gel: 1.98m l 
solution A ,  1.5ml solution B ,  2.52m l d H 20 ,  50(il 0.5% (w/v) am m onium  persulfate  
and 5|il T E M E D .  Stacking gel: 0 .33m l so lution A ,  0 .5m l solution C ,  1.15m l d H 20 ,  
30(j,l 0.5% (w/v) am m onium  persulfate and 5|il T E M E D .  T h e  gel w as poured  
according  to the m anufacturer's instructions w ith  the fo llo w in g  exception. W e lls , in  
general, w ere created in the stacking gel b y  insertion o f  a com b in  the 
unpolym erised gel. F o r  running organ extracts through the gel, how ever, a level 
interface w as created b y  pouring  ethanol on  top o f  the unpolym erised  stacking gel. 
A fte r polym erisation, the ethanol w as poured  o f f  to  leave a leve l interface.
600|og o f  the relevant organ extract (in a vo lu m e o f  less than 100(il) w as 
m ixed  w ith  Va volum e o f  sam ple buffer, bo iled  fo r tw o m inutes and loaded a long the 
entire length o f  the top o f  the gel. O ther protein sam ples w ere m ixed w ith  V* vo lum e  
o f  sam ple buffer, bo iled  fo r tw o m in. and 10(j,l w as loaded into in d iv idu a l w ells. 
T h e  sam ples w ere run through the stacking gel at an am page o f  1 5 m A  and through  
the resolving  gel at an ampage o f  2 0 m A .
S D S - P A G E  gels w ere either stained directly, o r transferred to nitrocellu lose  
(N C )  (see section 2.8.3.4). G e ls  w ere stained b y  incubating  in  C o om assie  B lu e  
stain solution at R T  fo r 1 hr. on a rocker platform . T h e  gel was then destained b y  
incubating at R T  fo r a couple o f  days in  m ultip le  changes o f  destain solution, w h ile  
constantly rockin g  on  a rocker platform . Protein bands stain b lu e  against a clear 
background.
2.8.3.4 Electrotransfer: T h e  B io -ra d  Tran s-b lot cell w as used fo r electrotransfer o f  
proteins, from  the S D S - P A G E  gel, to n itrocellu lose membranes. T h e  S D S - P A G E  
gel w as rem oved from  between the glass plates and incubated fo r five  m inutes, w ith  
rocking, in  five  changes o f  transfer buffer. E lectrotransfer w as then carried out 
overnight, at 3 0 V  and 100m A, accord ing  to the m anufacturer's instructions.
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2.8.3.5 Immunoblotting: T h e  n itrocellu lose w as rem oved from  the T ran s-b lot cell, and w as 
blocked  fo r 0.5 hours w ith P B S  contain ing 0.3% (v/v) N P 4 0  fo llo w ed  b y  P B S  w ith  
0.1% (v/v) Tw een 20, fo r 2 hrs, w h ile  shaking on  a ro ck er platform .
T h e  b locked n itrocellu lose was, in  general, probed w ith  p rim ary  antibody  
(m ouse antibody d iluted as required in  P B S  contain ing  0.05%  (v/v) Tw een-20) fo r 2 
hrs at R T  w ith constant rocking. O rgan  extracts, transferred to N C ,  w ere probed  
w ith the aid o f  a m iniblotter. T h is  is a m ultichannel instrum ent, w h ich  a llow ed  
incubation, in  paralle l, and sim ultaneously, o f  m any probes w ith  the one 
n itrocellu lose m embrane, w h ile  m in im is in g  the am ount o f  probe required. P rim ary  
antibodies were incubated w ith  the b lot fo r 4 hours at R T ,  w h ile  the m inib lotter w as 
rocked  at 6 tilts per minute.
T h e  blot was, subsequently, washed fo r a ha lf-hour w ith  6 changes o f  P B S  
w ith  0.05%  (v/v) Tw een  20, w h ile  rock in g  constantly. T h e  b lo t w as then probed  
w ith a secondary (alkaline phosphatase conjugated to goat anti-m ouse antibody) 
antibody, diluted in  P B S  w ith  0.05%  (v/v) Tw een  20 and 5% (v/v) F C S . Incubation  
was fo r 2 hours at R T  w ith constant rocking.
T h e  b lot w as then w ashed fo r h a lf  an hour, w ith  6 changes o f  P B S  w ith  
0.05%  (v/v) Tw een 20, p rio r to addition o f  substrate to the blot. Substrate w as 
0.2mg/ml B C I P  and 0.2m g/m l N B T  (nitroblue tetrazolium ) d issolved  in  A M P  
buffer. Substrate w as incubated w ith  the b lot at R T ,  until su ffic ient co lou r had  
developed, and the reaction w as then term inated, by w ash in g  the b lot w ith  water.
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2.8.4. Protein G affinity purification of IgGs
2.8.4.1 Concentration of tissue culture supernatant: 200m l o f  spent supernatant from  the 
elevant hybridom a ce ll line  w as collected over a period  o f  tim e, supplem ented w ith  
sodium  azide to a final concentration o f  0.02%  (w/v) and stored at 4°C.
T h e  supernatant w as ultrafiltered to a fin a l v o lu m e  o f  20m l, using a stirred 
ultrafiltration cell w ith  a 76m m  d ia flo  ultrafilter m em brane w ith  a m olecular w eight 
cu t-o ff o f  100,000 daltons. T h e  concentrate w as stored at 4°C.
2.8.4.2 Affinity purification: 1ml o f  a suspension o f  im m o b ilise d  protein G  (im m obilised  
on Sepharose 4 B ) w as packed in  a chrom atography co lum n. T h e  co lu m n (stored in  
P B S  containing 20% (v/v) ethanol) w as pre-equilibrated w ith  20m l o f  P B S .
E ither, 1ml o f  serum  o r 20m l o f  concentrated supernatant w as passed  
through the colum n. T h e  flow -through w as co llected  and a llow ed to flo w  through  
the co lu m n a second time.
25m l o f  P B S  w as passed through the co lu m n and, subsequently, the retained  
protein w as eluted w ith  0 .1 M  g lyc in e  buffer (p H  2.7). 0.9m l fractions o f  eluate 
were collected in ep pen d orf tubes, and neutralised w ith  0 .1m l o f  1 M  T r is .C l  buffer 
(p H  8.7.).
Th e  optical density o f  each fraction, at 280nm , w as measured. Those  
fractions containing sign ificant protein w ere pooled, d ia lysed  against P B S  w ith  
0 .5 M N a C l,  and stored at 4°C.
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2.8.5 Generation of affinity columns
Cyanogen  brom ide (C N B r)-activa ted  Sepharose 4 B  w as sw ollen in  0 .1 M  H C1 fo r  1 
hr. It was sucked dry on  a B u ch n e r funnel, and w ashed (on  the B u ch n e r funnel) 
tw ice w ith  250m l o f  P B S . 6g (dry-w eight) o f  the gel can be expected to g ive 20m l 
o f  w et gel.
T h e  ligand w as d issolved  in  cou pling  b u ffer (0 .1 M  carbonate buffer (p H  8.3) 
containing 0 .5 M  N a C l) , in  general, at l-10m g/m l. A  sm all vo lum e w as kept fo r  
later analysis. E q u a l volum es o f  ligand so lution and w et gel w ere m ixed, and 
incubated overnight at 4°C , w ith  constant rotation.
Th e  gel w as let fa ll out o f  suspension, and a sm all sam ple o f  so lution w as 
taken. Spectrophotom etric com parison  o f  this so lution w ith  the solution taken p rio r  
to in cu b a tio n , allow ed one to calculate, rough ly h ow  m uch o f  the ligand had bound  
to the Sepharose.
Th e  gel w as w ashed sequentially (on a B u ch n e r funnel), w ith  200m ls o f  
0 .1 M  carbonate buffer (p H  8.5), P B S  and P B S  contain ing l M N a C l .
T h e  gel w as incubated w ith  1 M  ethanolam ine (p H  9.0), fo r 2 hrs. at R T ,  
w ith  constant rotation.
Th e  gel w as washed sequentially w ith  200m ls o f  0 .1 M  N a A ceta te  buffer (p H  
4.0), 0 .5 M  N a C l and cou p lin g  buffer. The  a ffin ity  co lu m n  w as stored in  P B S  w ith  
0.02%  (w/v) N a N 3 at 4°C.
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2.8.6 Affinity purification of mouse IgM from hybridoma supernatants
A  com m ercia l preparation o f  affin ity-pu rified  anti-m ouse I g M  (developed in  
sheep), w as coupled to C N B r-activated  Sepharose 4 B , fo r the purposes o f  p u rify in g  
m ouse IgM . T h e  basic protoco l o f  section 2.8.5 w as used, and exact details are 
g iven  in  section 3.3.2.2. T h e  final lO m ls o f  w et gel w ere packed into  a 
chrom atography co lu m n and the final I g M  p u rification  schem e, chosen, is described  
below .
T h e  co lum n w as equilibrated, b y  passing 60m l o f  P B S  through it. 10ml o f  
concentrated hybridom a supernatant (see section 2.8 .4 .1) w as passed through the 
colum n, fo llow ed  b y  60m l o f  P B S . Protein retained on  the co lum n w ere eluted by  
slow ly  passing 30m l o f  0 .1 M  g lyc in e  bu ffer (p H  2.2) through it and co llecting  1ml 
fractions. These fractions w ere neutralised b y  adding lO O jil o f  1 M  T r is .C l (p H  8.7). 
60m l o f  elution buffer w as then q u ick ly  passed through the co lum n to rem ove any 
rem aining IgM . 100ml o f  P B S  w as then fin a lly  passed through the colum n, w h ich  
w as stored in  P B S  + 0.02%  N a N 3, at 4°C.
T h e  optical density o f  each fraction w as determ ined spectrophotom etrically  
at 280nm , and fractions contain ing sign ificant am ounts o f  protein w ere pooled, 
dialysed against P B S  w ith  0 .5 M  N a C l,  and stored at 4°C.
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2.8.7 'Real-time' Biomolecular Interaction Analysis
T h e  B ia c o re ™  w ith  C M 5  chips, w as used fo r  all real-tim e analyses. F o r  a 
detailed description o f  the theory and practice o f  th is instrum ent, the reader is 
referred to Jonnson et al., (1991). A l l  the experim ents, to be described herein, 
relied on  N H S / E D C  cou pling  chem istry, to im m o b ilise  ligand  on  the dextran m atrix  
at the surface o f  the chip.
T h e  ligand w as d issolved  at between 5-50^ig/ml in  0 .0 1 M  N a A ce ta te  buffer, 
at a range o f  p H 's  between 4-5. These w ere passed, sequentially, over an 
underivatised ch ip  surface, and that p H  g iv in g  the greatest mass (m easured in  terms 
o f  response units (R U ))  pre-concentrated at the surface o f  the ch ip , w as used fo r 
ligand im m obilisation.
T h e  ch ip  surface w as activated, b y  passing 35(il o f  a so lution contain ing  
0 .0 5 M  N H S  and 0 .2 M  E D C  in U P H 2O , over the ch ip  surface at a f lo w  rate o f  
5|il/min. 35(j,l o f  a solution o f  the ligand, in  the chosen buffer, w as passed over the 
surface at a flo w  rate o f  5(il/min. R em ain in g  active sites w ere deactivated, by  
passing 35(j,l o f  a 1 M  ethanolam ine (p H  8.5) solution over the surface at a flo w  rate 
o f  5pl/min. Th e  surface w as then used, to  analyse b iom olecu lar interactions 
in vo lv in g  that particular ligand.
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2.9 Animal experimentation
2.9.1 Mice
A l l  B a lb/C  m ice  used in  these studies w ere housed in  the D C U  anim al house and 
cared fo r b y  a qualified  vet. A l l  C 5 7 B L U 0  m ice  w ere purchased, freshly k illed , 
from  the U C D  B io m e d ic a l Fa c ility , D u b lin .
2.9.2 Rabbits
O n e N Z W  rabbit w as used during the course o f  these studies fo r im m unisation  
purposes. Th e  rabbit w as purchased from  the T r in ity  B ioresou rces U n it, D u b lin , 
and cared fo r b y  a q u a lified  vet in  the D C U  anim al house w here all experim entation  
took  place. These studies w ere carried out under licen ce  from  the D epartm ent o f  
Health. Th e  im m unisation  protocol used is reproduced here
Day 1: Im m unise rabbit b y  intraderm al in jection  w ith  an em ulsion  (1m l) consisting  
o f  a 200(j,g/ml so lution o f  the im m unogen m ixed  1:1 w ith Freu nds C om plete  
Adjuvant.
Day 21: R em ove  a 1ml b lo o d  sam ple from  the ear ve in  (prim ary bleed) and titrate 
its anti-im m unogen activity.
Day 31: R e-im m unise  the rabbit as before using  Freu nds Incom plete A djuvant.
D a y  41: O btain  b lo o d  sam ple as before (secondary bleed) and titrate as before. 
Antiserum recovery:
T h e  above cycle  o f  b lo o d  sam pling/titration and re-im m unisation is carried out at 10 
day intervals until the activ ity  is seen to plateau. A t  this stage the anim al is 
sacrificed and the b lo o d  recovered b y  cardiac puncture.
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CHAPTER 3
I N  V I T R O  IM M UNISATION AND ANTIBODY  
POLYREACTIVITY
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One o f the main areas o f interest in the laboratory has, and continues to 
be, the use o f alternative methods, to in vivo immunisation, for the production 
o f monoclonal antibodies. Antibody-library technologies have been exploited 
to produce, for example, anti-coumarin ScFv antibodies (Killard et al, 1997). 
Another method, frequently employed, is in vitro immunisation (IVI). 
Nonetheless, at the outset o f this project, a review o f the literature (discussed 
in section 1.3.2.2) suggested, not only that many o f the supposed advantages o f 
this technique, over in vivo immunisation, were more apparent than real, but 
that a solid case could be made in favour o f the hypothesis that Mabs produced 
in this fashion may suffer from polyreactivity.
This hypothesis was predicated on one fact, re: IVIs, in general, only 
result in primary immune responses. It was also based on the idea, that B la  
cells may be preferentially activated during IVI. This notion was justified by a 
review of the literature, i) Direct evidence has been published, that an IVI 
culture system did result in preferential activation o f CD5+ B cells (Feeney et 
al, 1984). ii) A number o f reports have indicated that no requirement exists in 
vitro for either antigen-specific T cells (Feeney et al, 1984) or, indeed, any T 
cells (Borrebaeck and Moller, 1986). IVI responses to unconjugated haptens 
have even been reported, in vitro (Stahl et al, 1995; Bonwick et al, 1997). 
These observations dovetail nicely with the finding, that murine B la  cells but 
not B2 cells, proliferate and secrete antibody in response to IL-5, in a T cell 
independent fashion (Kasaian and Casali, 1993). iii) finally, CD5+ B cells 
appear hardier than conventional B cells, in vitro, and survive longer (Pritsch 
etal, 1997).
In order to test the hypothesis, a number o f splenocyte culture systems 
were initially investigated to ascertain, whether they supported a humoral 
immune response (section 3.1). One culture system, which supported an 
immune response was used to produce a panel o f 9 hybridomas (section 3.2). 
Finally, a series o f studies aimed at analysing the binding-characteristics o f 
their respective Mabs were carried out (section 3.3). These studies, in their 
entirety, allow a number o f conclusions to be drawn. In particular, the 
evidence is strongly in favour o f  the notion, that IVI tends to produce 
polyreactive Mabs.
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3.1 IN  VITRO IMMUNISATIONS
As mentioned in section 1.3.2.2, the reproducibility o f IVIs was questioned. 
Therefore, two IVI systems were investigated to determine whether they 
actually supported an antigen-reactive, antigen-induced, humoral immune 
response, this being defined as a variation in the frequency o f cells secreting 
antibody against the antigen, upon exposure to it. Initial studies (section 3.1.2) 
focussed on an IVI system for murine splenocytes, originally published by 
Ossendorp e ta l. (1986). This was chosen as it had been successfully adapted 
and used in the laboratory previously (Carroll et al., 1991). The second, a 
system for murine splenocytes originally published by Borrebaeck and Moller 
(1986), was chosen at random. Studies o f this system are reported in section 
3.1.3. First, the development o f an ELIspot assay, in order to facilitate the 
analysis o f these two IVI culture systems, is reported (section 3.1.1).
3.1.1 E L Ispot assays: ELIspot assays (reviewed by Sedgewick and Holt, 1986; see 
also Fig. 3.1) allow enumeration o f the frequency o f cells secreting antibody 
reactive with a given antigen and, hence, allow evaluation o f humoral immune 
responses at the cellular level.
In order to develop and validate an ELIspot assay, an IVI was set up as 
described in section 2.5.6.1, with no added antigen, and cultured for 42 hrs. 
The frequency o f cells in this population, secreting anti-dinitrophenol-human 
albumin1 (DNP) was evaluated by an ELIspot assay, essentially as described in 
section 2.8.1.2. DNP was used as the coating antigen at 100, 10 and 0|ig/ml. 
Alkaline phosphatase, conjugated to goat anti-mouse polyvalent 
immunoglobulin, was used as the secondary antibody, at some or all o f the 
following dilutions: 1:400, 1:800, 1:1600, 1:3200, 1:6400 and, also, with no 
secondary antibody (referred to as a dilution o f '1 infinity'). The results are 
depicted in Figs. 3.2-3.5.
1 Throughout this chapter, anti-antigen refers to antibody against that antigen.
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F ig . 3.1: ELI spot assays allow the enumeration of the number of cells 
secreting antibody against an antigen of interest. In order to carry out an 
ELIspot assay, the wells of a 96-well plate are coated with the antigen of 
interest (A) and then blocked (B). The cells to be tested are washed and added 
to the well, where they fall out of suspension and form a monolayer on the 
coated surface of the well (C). If any cell is secreting antibody, reactive with 
the coating antigen, it is bound locally in the vicinity o f  the cell (C). The 
bound antibody is visualised, subsequently, in a two-step process. Firstly, the 
primary antibody is bound by a secondary antibody (an antibody against the 
primary antibody, conjugated to alkaline phosphatase) (D and E). Finally, a 
solution of 5-bromo-4-chloro-3-indolyl phosphate, p-toluidene salt (BCIP), a 
substrate for alkaline phosphatase is added to the wells. When acted upon by 
the enzyme, BCIP is converted to an insoluble product. This insoluble product 
precipitates out locally in the vicinity o f  the cell to form what is termed a 
'plaque' (F). Many blue plaques are shown in the photograph (G). Each 
plaque is assumed to be the result of one cell, only, secreting antibody against 
the coating antigen. The number of plaques per well corresponds to the 
number of cells per well secreting antibody against the coating antigen. A plot 
of the number of plaques per well versus the number of cells per well should, 
as a result, give a straight line through the origin. The slope of the resulting 
'best-fit-line' indicates the fraction of the cell population secreting antibody 
against the coating antigen.
I l l
F ig s . 3 .2-3.S co n tin u e d : DNP-human albumin (100, 10 and 0/j.g/ml) and 
dilution of secondary antibody. Frequencies are measured as antibody- 
secreting cells (ASC) per 1x106 splenocytes. The values for ASC/lxlO6 
splenocytes were determined from a linear regression analysis of all the trend 
lines, of plaques versus cells, depicted in Figs. 3.2-3.4. Such a regression 
analysis gives one the mean ± the standard deviation of the slope of the 'best- 
fit-line’ to the trend. The depicted values for ASC/lxlO6 splenocytes are then 
calculated by multiplying the mean ±the standard deviation by lx l 06.
These 'ASC/lxlO6 splenocytes' values were considered a valid, albeit 
imperfect measure of the frequency of cells secreting anti-DNP antibody. 
Quite clearly, as plaque numbers were linearly related to cell numbers, and as 
plaque formation was completely dependent upon the use of secondary 
antibody (see Figs. 3.2-3.4), plaque formation was causally linked to the 
secretion of antibody by cells. In this sense, the assay was valid.
However, although all plaques were due to the secretion of antibody by 
cells, it was equally clear, that not all plaques could be attributed to cells 
secreting anti-DNP antibody. In wells, which were blocked only, significant 
numbers of plaques developed (Fig. 3.4). This was not surprising and was 
attributed to cells secreting antibody against the blocking agent (FCS) or, 
perhaps, the plastic. The number of plaques developed in uncoated, blocked 
wells could not be significantly reduced by suspending the test cells in medium 
spiked with 10% (v/v) FCS. Given that wells coated with DNP may also 
contain adsorbed FCS and, by definition, contain a plastic solid phase, some 
of the plaques developed in these wells may not be attributable to cells 
secreting anti-DNP. Unfortunately, there was no way of determining the 
fraction of the plaques developed in DNP-coated wells, which were due to 
cells secreting antibody against DNP, and in this sense, the assay was 
imperfect. Hence, the 'ASC/lxlO6 splenocytes' values were referred to as the 
'apparent frequency' of cells secreting antibody against DNP.
The above considerations indicated that a 100fjg/ml solution of coating 
antigen was optimal. Not only did this coating concentration give the greatest 
apparent frequency of cells secreting anti-DNP; it would be expected to 
reduce the amount of FCS adsorbed onto the plastic surface.
11 2
These results (Fig. 3.5) clearly demonstrated that a coating 
concentration o f 100|ig/ml DNP-human albumin, (DNP), gave the greatest 
sensitivity, i.e. the greatest apparent frequency o f cells secreting anti-DNP. 
Subsequent ELIspots always used coating antigen at this concentration, unless 
explicitly stated otherwise.
While, ostensibly, these results (Fig. 3.5) appeared to suggest that 
higher concentrations o f the secondary antibody may be useful, this was not 
so. As presented, these results give no indication o f the problem o f artifactual 
('background') colour development, which hindered counting o f plaques. A 
visual examination o f the developed wells resulted in a 1:3200 dilution o f the 
secondary antibody being chosen as optimal and was used in all subsequent 
ELIspot experiments.
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3.1.2  E v a lu a t io n  o f  th e  m e th o d  o f  O s s e n d o rp  et a l (1986): To determine, whether 
the method o f Ossendorp e t a l (1986) facilitated an antigen-reactive, antigen- 
induced, immune response, the effect o f the concentration o f GIgG in the 
splenocyte culture, on the frequency o f cells secreting anti-GIgG, was 
investigated. This was investigated directly, at the single-B cell level, using 
the ELIspot assay (section 3.1.2.1). It was also analysed indirectly, by 
immortalising the cultured splenocytes, as hybridomas, and screening the 
resulting hybridoma populations for anti-GIgG secretion (section 3.1.2.2).
GIgG was chosen as the antigen after an ELIspot analysis o f  the 
apparent frequency o f naturally activated splenic B cells (see section 1.2.2) 
secreting antibody against a variety o f antigens. Antigens used were DNP- 
human albumin (DNP), digoxigen-keyhole limpet haemocyanin (KLH), 7- 
hydroxycoumarin-ovalbumin (7-OHC), porcine thyroglobulin (Thyr), goat IgG 
(GIgG) and lipopolysaccharide from E. coli 055:B5 (LPS). An antigen, which 
in this thesis is referred to as M6149, was also used. M6149 refers to the IgG 
fraction, purified by protein G affinity chromatography (section 2.4.8.2), o f an 
antiserum reactive with mouse polyvalent immunoglobulins. This antigen 
could act as a capture antigen for any mouse antibody, regardless o f  its 
subclass or idiotype, and was used to determine the frequency o f cells 
secreting antibody.
The results from this experiment are depicted in Fig. 3.6. The natural 
response to GIgG was very low (the apparent frequency o f  cells secreting anti- 
GIgG was only 20 ASC/lxlO6 splenocytes, at a coating concentration of 
100ng/ml o f GIgG). Because o f this low natural response to GIgG, it was 
decided to use this antigen as a model antigen in all studies.
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3.1.2.1 D ir e c t  an a lysis: A series o f IVIs were set up as described in section 2.5.6.1. 
Each individual culture received a different concentration o f GIgG (0, 0.01, 
0.1,1 or 10ng/ml). After 72 hrs., the apparent frequency o f cells secreting any 
antibody, antibody against GIgG or antibody against DNP was determined for 
each culture. These apparent frequencies are plotted in Fig. 3.7 as a function 
o f the concentration o f GIgG.
If  an antigen-reactive, antigen-induced immune response occurred in 
the culture system, the anti-GIgG cellular response would be expected to vary 
with the concentration o f GIgG in the culture. The anti-DNP response and the 
total number o f cells secreting antibody would be expected to be invariant with 
changing GIgG concentration. Analysis o f variance o f the data presented in 
Fig. 3.7 (Ostle and Malone, 1988) using a 95% confidence limit indicated, that 
the apparent frequency o f cells secreting anti-GIgG was independent o f the 
concentration o f GIgG in the culture. In other words, there was no evidence to 
suggest that an antigen-reactive, antigen-induced, immune response was 
occurring in this culture system. Surprisingly analysis o f  variance indicated 
that, the apparent frequency o f cells secreting anti-DNP did depend upon the 
concentration o f GIgG used. This was most likely due to the response at a 
GIgG concentration o f 0.01(j,g/ml. This response may be an outlier and no 
practical significance was attached to this statistical finding. In subsequent 
experiments, this finding could not be repeated. The apparent frequency of 
antibody-secreting cells was, as expected, invariant with GIgG concentration.
While no specific immune response was obtained, a polyclonal 
immune response obviously occurred in this culture system. Under 
microscopic analysis colonies o f proliferating cells were evident (Fig. 3.8). 
Also, the frequency o f antibody-secreting cells was higher after the 72 hr. 
culture period, than it was prior to culture (approximately 8000 ASC/lxlO6 
splenocytes, versus 3180 ASC/lxlO6 splenocytes prior to culture).
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Fig. 3.6: Splenocytes were obtained from unimmunised Balb/C mice as described in 
section 2.5.6.1 and the apparent frequency o f  cells secreting antibody, reactive with a 
number o f  different antigens, was determined by ELIspot assay. It was evident that, 
the natural immune response varied greatly against different antigens. The natural 
immune response against GlgG appeared very low (20 ±  2 ASC /lxl ( f  splenocytes, at 
a coating concentration o f  100jug/ml).
ELIspot: The ELIspot assay was carried out as described in section 2.8.1.2. 
Coating antigens were used at a concentration o f  100 (black), 10 (red) or 0/ug/ml 
(green). DNP: DNP-human albumin; KLH: digoxigen-keyhole limpet haemocyanin; 
7-OHC: 7-OHC-ovalbumin; Thyr: porcine thyroglobulin; GlgG: goat
immunoglobulin G; LPS: lipopolysaccharide from E. colt 055:B5. An alkaline 
phosphatase, conjugated to goat anti-mouse polyvalent immunoglobulin, was used as 
the secondary antibody a t a dilution o f 1:3200
Fig. 3.7 : IVIs were set up, as described in section 2.5.6.1, using different amounts o f  
GlgG as antigen, and cultured fo r  72 hrs. The apparent frequencies o f  immunised 
splenocytes secreting anti-GIgG, anti-DNP or antibody, was determined by an 
ELIspot assay and plotted as a junction o f  GlgG conc. No evidence was obtained to 
suggest that an immune response had occurred against GlgG
ELIspot assays .These were carried out as described in section 2.8.1.2. Either 
GlgG (anti-GIgG), DNP (anti-DNP) or M 6 149 (antibody), at 100pg/ml were used as 
the coating antigen. An alkaline phosphatase, conjugated to goat anti-mouse 
polyvalent immunoglobulins, was used as the secondary antibody, at a dilution o f  
1:3200.
1 1 6
F ig . 3.8 : Colonies of proliferating cells are clearly visible in the above two 
photographs (40x magnification). A small colony of proliferating cells is 
visible in the top photograph. A much larger colony, with an associated 
adherent cell (presumably macrophage) colony, is visible in the bottom 
photograph.
117
3.1.2.2 F u s io n  analyses: To corroborate the results reported in section 3.1.2.1, which 
suggested that no antigen-reactive, antigen-induced humoral immune response 
was occurring in culture, IVIs were set up as described in section 2.5.6.1, 
utilising GIgG as antigen at 0, 0.01, 0.1, 1 and lOjag/ml. After 72 hrs, 
individual cultures were fused as described in section 2.5.7.1. Poisson 
distribution analysis (see De Bias et al., 1981) o f fusion masterplates, on day 7 
after fusion, indicated that the hybridomas were outgrowing at statistical 
monoclonality. Thus, individual wells were treated, and referred to, as clones. 
Clones were screened by ELIspot assay, as described in section 2.5.7.2, for 
both antibody secretion and anti-GIgG activity. (The reasons for choosing this 
screening system and its validation are discussed below). The decision to 
classify a clone as positive or negative was made as follows. If  a clone gave 
absolutely no plaques, it was to be considered negative. Even the presence of 
one plaque was taken as indicating that the clone was positive. Fig. 3.9 shows 
the percentage o f antibody-secreting clones, which secreted anti-GIgG, as a 
function of GIgG concentration. This percentage was invariant (0%) with 
GIgG concentration and, hence, this analysis clearly indicated that no antigen- 
dependent, antigen-reactive, immune response occurred in culture.
The decision to utilise an ELIspot screen rather than the more 
conventional ELISA screen was made for two reasons. Firstly, as the humoral 
immune response was being directly investigated by screening B cells for 
antibody secretion at the single-B cell level, it seemed sensible and consistent 
to screen hybridoma clones in the same fashion. Secondly, Spira and Sharff 
(1992) reported that an ELIspot assay was less prone to false positives than an 
ELISA, in screening for hybridoma subclones, which had undergone an 
isotype switch.
This screen was validated as follows. Firstly, as masterwells contain 
dying splenocytes as well as hybridoma cells, it was necessary to demonstrate 
that only hybridoma cells could generate plaques. This was demonstrated by 
showing that mock fusions (fusion in the absence o f Sp2/0s) did not result in 
any plaque formation (results not shown). Thus, plaque formation was due to 
antibody secretion by hybridomas and not splenocytes. Secondly, although the 
decision to classify a clone as positive or negative based on the presence or
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absence o f only one plaque may suggest that this particular screen should be 
susceptible to many false positives and negatives due to random error, this was 
not so. In practice, clones subsequently classified as positive always gave rise 
to significant numbers o f plaques (>10), and clones subsequently classified as 
negative always gave rise to no plaques. Thus, a clear discrimination between 
positive and negative wells was achieved with this assay and it was considered 
very unlikely that, random error generated false positive or negatives. Finally, 
although the possibility o f  false negatives due to systemic error was not 
considered, the possibility o f  false positives due to systemic error was. 
Evidence, presented more fully in section 3.2, suggests that there was no 
significant problem with false positives. O f 10 clones identified, using the 
ELIspot screen, as positive for anti-GIgG secretion, 9 were shown using an 
independent ELISA-based assay, to have significant affinity for GIgG.
0.01 0.1 1 
GIgG conc. (microg/ml)
Fig. 3.9 : IVIs were set up as described in the legend to Fig. 3 .7, fused according to 
section 2.5.7, and the resulting clones were analysed by ELIspot assay, fo r  both 
antibody secretion, and anti-GIgG activity. The percentage o f  antibody-secreting 
clones, secreting anti-GIgG was calculated, in each case, from  analyses o f  a t least 33 
antibody-secreting clones.
ELIspot: the ELIspot assay was carried out essentially as described in section 
2.5.7.2. Either GIgG (anti-GIgG) or M6149 (antibody secretion) were used as 
coating antigens at 100fj,g/ml. An alkaline phosphatase, conjugated to goat anti­
mouse polyvalent immunoglobulin was used as secondary antibody, at a  dilution o f  
1:3200. A well was considered positive fo r  either anti-GIgG secretion or antibody 
secretion, i f  one or more plaques developed.
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3.1.3  E v a lu a t io n  o f  th e  m e th o d  o f  B o rre b a e c k  a n d  M o l le r  (1986): The negative 
results presented in section 3.1.2 indicated that it was necessary to try another 
variant o f the IVI technique, and that published in the above reference was 
chosen. A  series o f splenocyte cultures were set up as described in section
2.5.6.2. Each culture received a different amount o f GIgG (0, 0.1, 1 or 
10|ig/ml) as an antigen and was cultured for a period o f 5 days. At the end o f 
this period, the apparent frequency o f cells secreting anti-GIgG, anti-DNP or 
antibody was determined for each culture, by ELIspot assay. The results are 
depicted in Fig. 3.10.
A significant increase in the apparent frequency o f cells secreting anti- 
GIgG was evident with increasing concentration o f GIgG. Quite clearly, this 
culture system did allow an antigen-dependent, antigen-reactive, immune 
response. O f note, this response was superimposed on a large polyclonal 
immune response. This is indicated by the very large apparent frequency o f 
antibody-secreting cells on day 5, for all GIgG concentrations (« 220,000 
ASC/lxlO6 splenocytes compared to »  2,500 ASC/lxlO6 splenocytes, prior to 
culture). Indeed, significantly greater proliferation occurred in this culture 
system (Fig. 3.11) than in the previous system (Fig. 3.8).
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F ig s . 3.10: IVIs were set up as per section 2.5.6.2. GlgG was used as antigen 
at concs. of 0, 0.1, 1 and 10/jg/ml. The splenocytes were cultured for 5 days 
prior to analysis, by ELlspot assay, of the cellular response to M6149, DNP 
and GlgG. The results are plotted as a function of GlgG conc. The cellular 
response to GlgG was obviously dependent upon the concentration of GlgG 
added to the culture; a clear humoral immune response had occurred in this 
culture system.
ELlspot: The ELlspot assay was carried out as described in the legend 
to Fig. 3.7.
F ig .  3.11: Two photographs (40x magnification) are presented of splenocytes 
cultured for 5 days as described by Borrebaeck and Moller (1986). A great 
degree of cell proliferation was evident in this culture system.
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3.2 P ro d u c t io n  o f  a  p a n e l o f  M a b s  re a ctiv e  w ith  G o a t  I g G
Having established that the splenocyte culture system o f Borrebaeck and 
Moller (1986) facilitated an immune response, it was used to produce a panel 
o f hybridomas secreting anti-GIgG. An IVI was set up as per section 2.5.6.2 
using GIgG as antigen at l|ig/ml. After a culture period o f 5 days, the cells 
were fused as described in section 2.5.7.1. Masterwells were screened on day 
9 after fusion, as described in section 3.1.2.2, for both antibody secretion and 
anti-GIgG activity. O f 219 masterwells secreting antibody, 39 (18%) showed 
anti-GIgG activity. (An IVI was also set up without any GIgG and 
subsequently was treated as the above IVI was. In this instance, o f 101 wells 
in which antibody secretion was demonstrable, only 1 (1%) showed any anti- 
GIgG activity. Thus, as expected, based on the results presented in section
3.1.3.1, the presence o f GIgG in the IVI increased the frequency o f 
hybridomas secreting anti-GIgG).
O f the 39 positive wells, 13 hybridomas in total were cloned as 
described in section 2.5.7.3. These were named G l, G3, G4, G7, G9, G i l ,  
G18, G19, G22, G24, G30, G31 and G33. G7, G9 and G22 proved unstable 
and were not used in any analyses. G 31 proved unreactive with GIgG when 
the affinity o f  their interaction was measured (see section 3.3.1). The reason 
for this false positive is unknown but probably may be attributed to reactivity 
with the blocking agent used during the screening assay. The remaining 9 
hybridomas were subsequently characterised.
3.2.1 T it ra t io n  a n d  is o ty p in g  o f  M a b s :  Supernatants were harvested from all 9 
hybridomas. Both the quantity o f Mab and the anti-GIgG activity possessed 
by each supernatant, were titrated by ELISA (Figs. 3.12-3.22). These ELISAs 
served two functions. Firstly, they allowed a crude comparison o f  the anti- 
GIgG activity o f each supernatant. Secondly they allowed the isotyping o f the 
Mabs heavy chains.
The ELISA results obtained with a G l supernatant are depicted in Figs.
3.12-3.14. Surprisingly this Mab appeared to be o f  both [j. and y isotypes (see 
Figs. 3.12 and 3.13). Further experimentation (results not shown) indicated, 
however, that the anti-y conjugate was just as reactive with mouse IgM as it
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F ig . 3.14
F ig s  3.12-3.14: The quantity of
3
Mab and the anti-GIgG activity of 
a G1 supernatant were titred by 2
ELISA. The ELISA was carried I
Sr 1
out as described in section 0
2.8.1.1. Either a 10/jg/ml °
solution of GIgG (to titrate the 
anti-GIgG activity) or a lOjug/ml 
solution of M6149 (to titrate the 
quantity of Mab) were used as coating antigens. Alkaline phosphatase 
conjugated to either goat anti-mouse IgM (Fig. 3.12), goat anti-mouse IgG 
(Fig. 3.13) or goat anti-mouse IgA (Fig. 3.14) were used as secondary 
antibodies, at the manufacturer's recommended dilution.
This Mab showed equally good titres with the anti-p and anti-y 
secondary antibodies, ostensibly indicating that this Mab was a mixture of 
both isotypes, or possibly, not a true monoclonal antibody preparation. 
Another surprising aspect of this assay was the very low activity of this 
supernatant against GIgG.
M 6149
V  G IgG
0  0001  0.001  0.01 0.1 1 
dilution of supernatant
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was with IgG. Subsequently, positive results with both the anti-|i and anti-y 
conjugates was taken as indicating that the Mab was o f the |x isotype. All 
other Mabs were positive with the anti-jx conjugate (see Figs. 3.15-3.22) and 
negative with the anti-a conjugate (results not shown). Thus, all Mabs were 
considered to be o f the [i isotype. Subsequently, all Mabs were isotyped with 
regard to their light chain using the same strategy as employed for their heavy 
chain (results not shown). These experiments clearly indicated that all Mabs 
were o f the k  isotype.
With regard to Figs. 3.12 and 3.15-3.22 it was immediately apparent 
that the Mabs were broadly classifiable into two groups. G 11 was the sole 
member o f one group and showed considerable anti-GIgG activity. The 
remaining Mabs constituted the second group and showed low to non-existent 
(G3 and G30) anti-GIgG activities. The low-to-negative activities in the 
ELISA assay contrasted sharply with the positive activities obtained with the 
ELIspot assays used during the screening and cloning of these hybridomas. 
They were not due to low quantities o f Mab in the supernatants (compare the 
ELISA titration curves, obtained for each supernatant, on M6149-coated 
wells). Thus, at first glance, these ELISA results appeared to contradict the 
ELIspot results and suggested that, none o f the second group o f Mabs were 
significantly reactive with GIgG.
This apparent contradiction was easily resolvable, however, if  one was 
receptive to the possibility that binding sites may be polyreactive. To see why 
this is so, imagine 2 Mabs, equally reactive with GIgG, that is to say, the 
affinities o f their respective interactions with GIgG are identical. However, 
one Mab is highly monoreactive; the second is highly polyreactive. 
Supernatants are highly complex matrices and in any hybridoma supernatant a 
dynamic equilibrium must exist between Mab, media components (MC) and 
Mab-MC complexes:
Mab + MC Mab-MC 
In the case o f the monoreactive Mab, the equilibrium will exist far to the left. 
Hence, the anti-GIgG activity o f the supernatant, which when detected by 
ELISA is dependent on the [Mab], will be high. In the case o f the polyreactive 
Mab, the equilibrium may exist far to the right and, as a result, the anti-GIgG
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activity o f  that supernatant may appear low-to-non-existent. Viewed from this 
perspective, the anti-GIgG activity o f any supernatant must be considered a 
very poor indicator o f the reactivity o f the corresponding Mab with GIgG. 
Equally, this perspective suggests that the anti-GIgG activity as detected by 
ELIspot, is a much better indicator o f the reactivity o f the Mab with GIgG. 
This is due to the fact that, the ELIspot assay differs fundamentally from the 
ELISA in that, it detects freshly secreted antibody. This being the case, the 
dynamic equilibrium cannot be established to the right regardless o f the nature 
o f the binding site in question.
This interpretation o f the results led to a number o f working 
hypotheses. Firstly, the second group o f Mabs were bound in solution by 
media components; these Mabs were tentatively classified as polyreactive. 
G i l  was considered to be monoreactive. Secondly, if  one could affinity- 
purify the polyreactive Mabs, they should show a higher specific anti-GIgG 
activity, as determined by ELISA, than their corresponding supernatants, as all 
the Mab in affinity-purified form should exist free in solution. Thirdly, if  the 
polyreactive Mabs were bound in solution by media components, antigen 
affinity-purification would not be a useful means o f purifying the Mabs. 
These hypotheses were tested and the results are reported in the section 3.3.
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Figs. 3.15-3.22: The quantities ofM ab and the anti-GIgG activities o f  a series 
o f supernatants from  the G3, G4, G il, G18, G19, G24, G30 and G33 
hybridomas were titrated by ELISA (figs. 3.15-3.22, respectively). The G il  
supernatant was the only supernatant which showed significant anti-GIgG  
activity (see also fig . 3,12).
ELISA: The ELISAs were carried out as described in the legend to Fig.
3.12-3.14, but only using an alkaline-phosphatase conjugated to goat anti­
mouse LgM as a secondary antibody.
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Analysis of Mab polyreactivity
At the start o f this chapter, the hypothesis that IVI would result in polyreactive 
Mabs was advocated based on a review o f the literature. This contention was 
strenghted by the fact, that a polyreactive rather than a monoreactive model o f 
antibody binding sites, appeared better able to explain the data for 8 o f the 9 
hybridomas, presented in section 3.2.1. Reported in this section, are the results 
obtained using three different modes o f analysis o f  the putative polyreactivity 
of the G l, G3, G4, G i l ,  G18, G19, G24, G30 and G33 Mabs.
One approach used was to purify each Mab and compare its specific 
activity with that o f its corresponding supernatant. An increase in specific 
activity was to be taken as indicative o f a polyreactive binding profile. (This 
approach was based on the notion that polyreactive M abs should show a  
higher specific activity as their purity increases (see section 3.2.1). Although, 
it may be argued that the opposite argument (i.e. that an increase in specific 
activity is indicative o f polyreactivity) does not necessarily hold, one can think 
o f no other reasonable explanation fo r  an increase in specific activity with 
increasing purity. This would be especially true i f  the percentage increase in 
specific activity was a  characteristic peculiar to each M ab and, hence, most 
probably linked to its variable region). Studies on IgM purification and 
specific activity determinations are reported in section 3.3.2. A second, more 
formal, approach used was to measure the affinity o f the Mabs for a small 
panel o f antigens, other than GIgG. Obviously, any detectable affinities were 
indicative o f polyreactivity. This line o f investigation is the subject o f section
3.3.1. This approach was considered to be limited in its ability to  discriminate 
between polyreactive and monoreactive antibodies, due to the limited numbers 
o f antigens employed (see section 1.2.2). Thus, a third approach was used 
(reported in section 3.3.3), based on immunoblotting. In this approach, crude 
protein extracts are separated by SDS-PAGE and electrotransferred onto nitro­
cellulose to provide an array o f many hundreds o f separated proteins. 
Antibodies, to be analysed for polyreactivity, are used as primary probes in an 
immunoblot o f the nitro-cellulose. Thus, the antibodies are tested for their 
activity against many hundreds o f  antigens, simultaneously. Upon subsequent 
development of the immunoblot with a secondary antibody and substrate, the 
presence o f bands indicate polyreactivity.
3.3.1 M ethod of Friguet et al. (1985): An ELISA-based approach originally 
published by Friguet et al. (1985) was used to measure the affinity o f the Mabs 
for GIgG and a panel o f 6 other antigens (DNP-human albumin (DNP), 
thyroglobulin (Thyr.), phosphorylcholine (PC), single-stranded DNA 
(ssDNA), bovine insulin (BI) and bovine serum albumin (BSA)). The theory 
o f this method is fully described in the above reference. Briefly, an unknown 
but constant concentration o f antibody is incubated with known, varying, 
concentrations o f the antigen of interest. At equilibrium, a certain fraction o f 
the antibody (v) will be bound in solution by the antigen. This fraction is 
dependent upon the concentration o f antigen ([A]). The following equation 
can be shown to hold:
v '1 = Kd [A]'1 + 1 Eq. 3.1
where Kd is the equilibrium constant for the interaction. Thus, a Klotz plot 
(v '1 versus [A]'1) should be a straight line giving a y-intercept o f 1. The slope 
o f the ’best-fit-line1 is equal to the equilibrium constant for the interaction.
In order to calculate Kd, one must be able to calculate the values o f  v ' 1 
(as the values o f [A] are at the discretion o f the experimenter, they will be 
known). This is easily accomplished. Bear in mind that, if  one can calculate 
the concentration o f free antibody remaining in each equilibrium solution, one 
can calculate v and, hence, v'1. The concentration o f free antibody can be 
easily determined. As mentioned in section 3.2.1, the anti-GIgG activity o f  a 
solution (quantified by an ELISA as an OD 405nm measurement) is related to 
the concentration o f free antibody in that solution. It should, thus, be self- 
evident, that the values o f v '1 can be obtained by determining the anti-GIgG 
activity remaining in each antibody-antigen mixture at equilibrium. This 
activity is then related to the concentration o f free Mab by reference to a 
standard curve o f optical density versus concentration of free antibody. The 
application o f this technique to determine the equilibrium constant for the 
interaction between G11 Mab and GIgG is explained in more detail in section
3.3.1.1.
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Two points must be borne in mind, if  this technique is to be used 
correctly. Firstly, during the ELISA, the equilibrium established in solution 
will be interfered with, as free antibody in solution becomes bound to the solid 
phase. It is necessary that this interference be minimised, by ensuring that 
only a small fraction o f free antibody in solution binds to the solid phase. It is 
possible to experimentally determine that this is so (Fig. 3.23). Secondly, it 
should be noted, that there is one assumption inherent in the mathematical 
treatment leading to equation 3.1. This is that the concentration o f antigen is at 
least 10 times greater than that o f the antibody. This was not formally proved. 
Nonetheless, this condition is likely to have been fulfilled. This is based on 
the assumption that, the antibody concentrations in the supernatants are 
10(ig/ml as conventionally found. For I g M ,  this roughly translates as a 
molarity o f  1x 1 0 '8M .  As all supernatants were used at a dilution o f at least 
1 :1 0 , in practice, a concentration o f antigen greater than or equal to 1x 1 0 '8M  
was required. This condition was met for all experiments.
In total, this technique was used to characterise the interaction between 
63 different antibody-antigen pairs (9 antibodies and 7 antigens). The data 
obtained is presented in section 3.3.1.1 and, in section 3.3.1.2, this data is used 
to classify the Mabs as polyreactive or otherwise.
3.3.1.1 Affinity determinations: Only for 17 o f the 63 interactions analysed, were the 
interactions strong enough to characterise. For the particular interaction of 
G i l  Mab with GIgG, Figs. 3.24-3.25 and Table 3.1 explain in great detail, the 
raw data obtained, and the subsequent data manipulation required, to derive 
the Klotz plot from which the Kd value for this interaction was determined. 
For the remaining 16 interactions, only the deduced Klotz plots are presented 
(Figs. 3.26-3.41). The derived affinity constants, characterising all 63 
interactions, are listed in Table 3.2.
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Fig. 3.23: The cmti-GIgG activity o f a G il  supernatant was titrated by ELISA. 
Post-ELISA, the anti-GIgG activity remaining in the supernatant was 
determined. The accompanying graph depicts the activity (quantified as an 
OD 405nm measurements) o f the supernatant before ('first half-hour') and  
after ('second half-hour') the ELISA assay. Both titration curves were very 
similar. It was inferred from  this that, only a sm all fraction o f the free  M ab in 
solution had become bound to the solid  phase during the ELISA.
It should be noted that, it was only necessary to demonstrate fo r  G il, 
that a small fraction o f the solution phase antibody became bound to the solid  
phase during the ELISA. That this held true fo r  the remaining M abs, was 
amply proved by Figs. 3.12 and 3.15-3.22.
ELISA: The anti-GIgG activities were determined by ELISAs, 
essentially as described in section 2.8.1.1, but the test samples were only 
incubated in the wells fo r  0.5 hrs. GIgG was used at lOjug/ml as the coating 
antigen. An alkaline phosphatase conjugated to goat anti-mouse IgM  was 
used as the secondary antibody at the manufacturer's recommended dilution.
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nominal conc. of antibody
Fig. 3.24: To utilise the method o f Friguet et al. (1985) to determine the 
equilibrium constant fo r  the interaction o f G il  M ab with GIgG, one required 
a standard curve relating anti-GIgG activities to concentrations o f  free Mab.
The concentration o f free  M ab in a G il  supernatant was unknown. To 
sim plify this discussion, its concentration in a 1:100 dilution o f the 
supernatant was referred to as a 'nominal concentration' o f 1. A series o f 
dilutions o f the supernatant were prepared to give fina l nominal 
concentrations o f 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.015625, 0.0078125, 
0.00390625 and 0. The anti-GIgG activity in each dilution was assayed in 
triplicate by ELISA and Fig. 3.24 depicts the resulting optical densities as a 
function o f concentration o f free antibody. (Each po in t represents the mean ±  
standard deviation o f the triplicate measurements).
A linear relationship was expected and obtained between OD 405nm 
values and the free antibody concentration. The red line represents the best- 
fit-line; the black lines represent the corresponding 95% confidence intervals. 
The equation o f the regression line is shown within the graph. This equation 
could then be used to determine the concentration o f  fre e  G il M ab in any 
solution, fro m  an E L ISA  carried out in an identical fa sh ion  to that used to 
generate the standard curve.
ELISA: The basic ELISA protocol o f section 2.8.1.1 was used, but test 
samples were incubated fo r  0.5 hr s. rather than the stated 5 hr s. GIgG was 
used as the coating antigen at lOpg/ml and an alkaline phosphatase 
conjugated to a goat anti-mouse IgM  was used as the secondary antibody at 
the manufacturer's recommended dilution.
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[G IgG ]1 (M-1)
« A r t
OD 405nm NC* NCo+/[NCo-NC]
( v 1)
3.2xlOb
6.4x106
1.28xl07 0.161 0.113 1.14
2.56xl07 0.182 0.172 1.23
5.13xl07 0.3 0.505 2.24
1.02xl08 0.399 0.717 4.71
2.04x108 0.405 0.802 8.42
4.08x10s 0.421 0.847 14.44
8.16xl08 0.423 0.853 15.96
oo 0.443 0.91
* Nominal concentration o f free antibody
t  Nominal concentration of free antibody in the absence o f antigen.
Table 3.1: A series o f G il  M ab-GIgG mixtures were prepared in triplicate, 
and allowed to equilibrate fo r  a t least 12 hrs. Each solution contained Mab at 
a nominal concentration o f 1. Solutions contained different concentrations o f 
GIgG as listed in the table.
The follow ing morning, the nominal concentration o f free  antibody, 
remaining in each mixture, was determined by an ELISA assay, carried out in 
an identical fashion (actually, a t the same time and in the same plate) as that 
used to generate the standard curve o f Fig. 3.24. 7 he mean OD 405nm values 
obtained from  the triplicate measurements are shown as a function o f GIgG  
concentration in the above table. The equation o f the regression line o f the 
standard curve depicted in Fig. 3.24 allowed one to convert these mean values 
into nom inal concentration values.
I t was then possible to calculate v 1from  these nominal concentrations.
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[A]’1
Fig. 3.25: The Klotz plot ( v 1 versus [A]  ') used to characterise the interaction 
o f GIgG with G il  M ab is shown above. The values o f [ A / 1 and the 
corresponding values o f  v ' were obtained from  Table 3 .1. The equation o f the 
regression line gives the affinity o f the interaction as 3.5 (±  0.1) x  1 O'8 M.
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Fig. 3.26: G l Mab-GIgG Fig. 3.27: G3 Mab-GIgG
V 1 = (2.0ßx10-'+/-3x10>[A]~' + (0.976+/-0.008), R2 = 1.000
1 e + 6  2  e + 6  3 e + 6  4 e + 6  5 e + 6
[A]’1
v 1= (3.04X108+/-6X10-10)X[A3'1 + (1.10+/-0.03), R2= 0.997
O.OefO 2.0e+7 4.0e+7 8 0e+7 Büm -7 12ef0
[Ar1
Fig. 3.28: G4 M ab-GIgG Fig. 3.29: G18 M ab-GIgG
V ' = (32x10 '+M X10“)X[A]’'  + (1 02+A003). R* = 0 998
OfrriJ 1*+6 2<H6 36it« 4e+6 5e+8
V 1 = (1.88X10 , +/-3x10 a)x[A]J| + (0 86W-0.06), R’  =
[Ar1
Fig. 3.30: G19 M ab-GIgG Fig. 3.31: G24 M ab-GIgG
V1 = (8xt0 +/-1x10 )x[A] +  (2.0+/-0.2), 0,982
O.Oe+O B.Oa+5 1.Obhh0 1.5®-w§ 20646 2.5046 3,De+6 3.5*46
[Ar1
= (5.9x10,-t/-3x10F-)x[A]-1 +  (147+/-0 29), R2 = 0.990
1&+7 2&t-7 2W7 3*+7 3#+7
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Fig. 3.38: G1 Mab-Thyr. Fig. 3.39: G18 Mab-Thyr.
M1
Fig. 3.40: G24 Mab-Thyr. Fig. 3.41: G4 M ab-BI
w' [ai1
Figs. 3.26-3.41: The K lotz p lo ts ( v 1 versus [A] ’)  used to deduce the 
equilibrium constants fo r  the interactions between a variety o f  antibody- 
antigen pairs are presented. The details o f the antibody-antigen pairs are 
provided with each graph. GIgG: goat IgG, DNP: DNP-human albumin, 
Thyr.: thyroglobulin, BI: bovine insulin.
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GIgG DNP Thyr
G1 2.08 (± 0.03) xlO"7 7.2 (±0.8) xlO'7 4.95 (± 0.08) xlO*6
G3* 3.04 (± 0.08) xlO’8 CLOD CLOD
G4 3.2 (± 0.1) xlO’7 CLOD CLOD
G i l 3.5 (± 0.1) xlO"8 CLOD CLOD
G18 1.88 (± 0.03) xlO'7 3.65 (± 0.07) x l0 ‘8 7.0 (± 0.2) xlO’7
G19 8 (± 1) xlO’7 2.9 (± 0.2) xlO"8 CLOD
G24 5.9 (± 0.3) xlO"7 9.6 (±0 .1) xlO'9 2.08 (± 0.06) xlO’7
G30* 3.1 (± 0.3) xlO"8 CLOD CLOD
G33 7.7 (± 0.1) xlO"8 CLOD CLOD
PC ssDNA BI BSA
<LOD CLOD CLOD CLOD
<LOD CLOD CLOD CLOD
<LOD CLOD 1.39 (± 0.05) xlO'7 CLOD
<LOD CLOD CLOD CLOD
<LOD CLOD CLOD CLOD
CLOD CLOD CLOD CLOD
CLOD CLOD CLOD CLOD
CLOD CLOD CLOD CLOD
CLOD CLOD CLOD CLOD
* The affinity data for these Mabs were calculated from affinity-purified Mabs
(see section 3.3.2) rather than hybridoma supernatants.
Table 3.2: The equilibrium constants characterising the interaction between 
63 antibody (grey)-antigen (purple) pa irs ( 9 x 7 )  are listed in the above table. 
These constants are listed as the mean + standard deviation and are measured 
in terms o f M olarity' (M). <LOD refers to calculated affinities, where the 
mean minus three times the standard deviation was less than zero.
GIgG: goat IgG, DNP: DNP-human albumin, Thyr: thyroglobulin, PC: 
phosphoryl choline, ssDNA:single-stranded DNA, BI: bovine insulin, BSA: 
bovine serum albumin.
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3.3.1.2 Affinity m easurem ents and polyreactivity: The data presented in Table 3.2 
clearly and formally indicated, that G l, G4, G18 and G24 were polyreactive. 
They reacted with at least one o f the six antigens (GIgG was excluded from the 
analysis as this was the antigen against which the Mabs were raised) against 
which they were tested. However, the data is equivocal with regard to whether 
the remaining Mabs were polyreactive. Although these Mabs did not react 
with any o f the six antigens, Fig. 3.42 indicates that this may purely be due to 
chance. In short, this approach to polyreactivity analysis was not sufficiently 
sensitive, to rule out the possibility that the remaining Mabs were polyreactive.
Fig. 3.42: Based on the data 
presented in Table 3.2, M abs 
were classified as reacting with 
from  0-6 o f the antigens. They 
were reactive i f  their 
interaction with the antigen in 
question could be quantified by 
an equilibrium constant; 
otherwise they were unreactive.
The above graph depicts the 
observed mtmbers o f M abs reacting with 0, 1, 2, 3, 4, 5, or 6 o f the antigens.
The question was then asked. D id this data support the null hypothesis, 
that the M abs were equally polyreactive?
Under the null hypothesis, the expected numbers o f M abs reacting with 
from  0-6 antigens was calculated using a binomial model (Mabs were either 
reactive or not reactive) and 17/63 as the probability o f an antibody reacting 
with an antigen. The 'goodness-of-fit' o f the observed values with expected 
values cannot be calculated using a '% goodness-of-fit test' as the frequency 
values were too low. Nonetheless, visually, there does not appear to be a  huge 
difference between the observed and expected values. Thus, the null 
hypothesis could not be rejected.
I observed 
I expected
E 2
II I
0 1 2 3 4 5
number of reactivities
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3.3.2 The purification of Mabs and the determination of their specific activities:
The purification o f monoclonal antibody from each o f 9 hybridoma 
supernatants (G l, G3, G4, G i l ,  G18, G19, G24, G30 and G33), was 
undertaken to test the postulate (section 3.2.1) that, with the exception of G i l  
Mab, the purified Mabs would have a higher specific anti-GIgG activity than 
their corresponding supernatants.
A number o f approaches to IgM purification were conceivable. Firstly 
gel filtration, the conventional method used to purify IgM, was considered. It 
was rejected as it is most suited to situations o f low volume/ high 
concentration. Supernatants from hybridomas do not meet this criterion. Also 
bovine IgM would co-purify. An attempt was made, however, to utilise 
ultrafiltration through a 300,000 Da cut-off membrane. The rationale for this 
was that in SDS-PAGE analyses o f serum, the vast majority o f serum proteins 
appear o f 70,000 Da or less. However, attempts to purify IgM in this manner 
failed (results not shown) as the vast majority o f serum proteins were retained 
by the membrane as indicated by SDS-PAGE analyses.
Affinity chromatography using any one o f four different ligands was 
then considered. These ligands were mannose binding protein (MBP), protein 
L, GIgG and anti-mouse p, chain (anti-p,). A commercial MBP column was 
available for IgM purification. However, the purification procedure was not 
optimised for purification from tissue culture supernatants. Also some degree 
o f uncertainty was felt with regards to the specificity o f this ligand. This 
approach was rejected. Protein L binds specifically to  k  light chains and was 
rejected for this very reason. It could not be used to purify an IgM antibody of 
the A, isotype.
Although convinced that it would not work for reasons already 
discussed (section 3.2.1), an attempt was made to use a commercial GlgG- 
agarose column to purify the IgMs. 0.2ml o f  G l supernatant was applied to 
the column, followed by 10ml o f  PBS and 5ml o f  elution buffer (0.1M glycine, 
pH 2.7). 15 x 1ml fractions were collected and fractions 11-15 (eluted
fractions) were neutralised with 0.1ml o f 1M Tris.Cl, pH 8.7, and dialysed 
overnight against PBS. The quantities o f murine IgM and the anti-GIgG 
activities o f  each fraction were determined by ELISA (Figs. 3.43 and 3.44,
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respectively). It was obvious that the major murine IgM peak and the only 
observable peak o f anti-GIgG activity, which emerged from the column, 
centred about the second fraction. A SDS-PAGE analysis o f each fraction 
(result not shown) indicated, that this was the fraction where the vast majority 
o f the FCS-derived proteins were found. It was inferred from these 
observations, that the majority o f the IgM passed straight through the column; 
only a small fraction was retained by the column and, subsequently, was 
eluted; hence the small quantity o f mouse IgM in fraction 13.
While there is no theoretical reason why a monoreactive G1 Mab 
should pass through the column in such a bimodal fashion, this is exactly what 
one might expect if  it was polyreactive. Using this model, it is to be expected 
that, at equilibrium, only a small fraction o f the G1 Mab would remain free in 
the supernatant. This amount could bind to the affinity column and later 
appear in the eluate. The majority, however, would pass straight through the 
column and appear with the FCS-derived proteins. This experiment not only 
provided more supporting evidence for the view that the G1 Mab was 
polyreactive. It also indicated, given the belief that only G il  Mab was 
monoreactive, that an anti-p. column was the only sensible approach for the 
purification o f these Mabs.
For this purpose, a commercial preparation o f anti-p was procured. For 
this to be an effective affinity ligand it was essential that, its interaction with 
IgM was regenerable. This was evaluated using the BIAcore™. This system 
was used for the simple reason that, it allows easy visualisation o f interactions 
between biomolecules, within a short experimental timeframe.
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Fig. 3.43: 0.2ml o f G1 supernatant was passed through a GIgG-agarose 
column. 10ml o f PBS, fo llow ed by 5ml o f elution buffer (0.1M  glycine, p H  2.7) 
were passed through the column. 15 x  1ml fractions were collected and the 
quantities o f  murine IgM  in each fraction were determ ined by ELISA, as 
described in section 2.8.1.1, with a lO pg/m l solution o f M 6149 as coating 
antigen. An alkaline phosphatase conjugated to goat anti-mouse IgM  was 
used as the secondary antibody, a t the manufacturer's recommended dilution. 
One major peak emerged from  the column with PBS; a minor peak eluted o ff 
the column.
Figs. 3.44: The anti-GIgG activities in each o f the 15 x  lm l fractions 
mentioned in the legend to Fig. 3.43, were determ ined by ELISA. The ELISA 
was carried out essentially as described in section 2.8.1.1, w ith a 10pg/ml 
solution o f GIgG as coating antigen. A n alkaline phosphatase conjugated to 
goat anti-mouse IgM  was used as the secondary antibody, a t the 
manufacturer's recommended dilution. A ll the observable anti-GIgG activity 
em ergedfrom  the column with the PBS.
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3.3.2.1 BIAcore™ studies: To allow an appreciation of the results obtained with the 
BIAcore™, the system will be briefly introduced. For a detailed introduction, 
however, the reader is referred to Jonnson et a/.( 1991).
The BIAcore™ is a commercially available biosensor, allowing 'real­
time Biomolecular Interaction Analysis (BIA)1. The system makes use o f 
specialised, disposable 'chips'. These chips, referred to as 'CM5 chips', contain 
a layer o f carboxy-methylated dextran (referred to  as the 'dextran matrix') 
attached to a gold layer. When inserted into the hardware o f the system, they 
are juxtaposed with a flow cell, which allows one to  pass solutions over and 
through the dextran matrix. Surface plasmon resonance, which is the basis for 
measurements with Biacore™, is an optical phenomenon arising in thin metal 
films under conditions o f total internal reflection. This phenomenon produces a 
sharp dip in the intensity o f reflected light at a specific angle (known as the 
resonance angle). This resonance angle is a function o f the refractive index o f 
the medium close to the non-illuminated side o f the metal film. The Biacore™ 
measures the resonance angle (in terms o f response units) as a function of time 
to produce a sensorgram. Changes in response units are then interpreted in 
terms o f changes in the refractive index in the dextran matrix. Interpretation o f 
sensorgrams will be introduced using Fig. 3.45 as a specific example.
For BIA, one o f the pair o f interacting molecules must be immobilised 
in the dextran matrix. In the experiment, which led to  the sensorgram depicted 
in Fig. 3.45, anti-(i was immobilised. A fresh CM5 chip was inserted into the 
BIAcore™. An isotonic salt solution, referred to as 'running buffer', was 
passed over the surface. Running buffer is the default flow solution, and at 
position 1 in the sensorgram, running buffer is still flowing over the surface o f 
the chip. A constant response (RU) is obtained because its refractive index is 
constant. This response is given a nominal value o f 0 RU as all changes in 
response will be measured relative to this baseline. At position 2, running 
buffer is again being passed over the surface. However, a net, perm anent 
change in response o f 147 RU is apparent. A sharp, transient change in  
response is evident, also, between position 1 and 2. This transient change is 
caused by a switch from running buffer to a solution o f NHS/EDC. As this
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Fig. 3.45: This sensorgram depicts the immobilisation o f anti-fi to the dextran 
matrix o f a CM5 chip. Between position 1 and 2, a NHS/EDC solution was 
passed over the chip surface, to activate the carboxy-methyl groups o f  the 
dextran matrix. This resulted in a sm all change in response, relative to 
position 1 (the baseline), o f 147 RU. Between positions 2 and 3, a 50jug/ml 
solution o f anti-p  was passed over the surface. Anti-fx became bound to the 
carboxy-methyl groups o f  the dextran matrix, via its amine groups; hence, a 
large change in response o f 24,664 R U  was observed. Finally, between 
positions 3 and 4, a solution o f 0.1M  ethanolamine, p H  9.0, was passed over 
the surface. This was to deactivate any rem aining activated carboxy-methyl 
groups. A  slight decrease in response was evident post-ethanolamine. This 
was attributed to removal o f loosely adherent anti-jx, from  the matrix, by the 
basic solution.
solution has a different refractive index to running buffer, one gets a transient 
increase in response, which disappears upon reversion to running buffer. To 
understand the residual permanent change in response, which is unaffected by 
reversion to running buffer, one must understand the role of the NHS/EDC 
solution. This solution results in the chemical modification and activation of
143
the carboxy-methyl groups in the dextran. This modification permanently 
changes the refractive index in the matrix.
At position 3 running buffer is again passing over the dextran surface 
and a further net, permanent change in response o f 25000 RU has accrued. 
Between position 2 and 3, a 50(ig/ml solution o f anti-|i in 0.01M NaAc, pH 
4.7, was passed over the surface. Under these conditions, anti-(i is attached via 
its amine groups, to the activated carboxy-methyl groups, hence, immobilising 
it within the dextran matrix. Again, it is the resulting change in the chemical 
constitution o f the dextran matrix that underlies the permanent change in 
response. All that is now required, prior to engaging in BIA with anti-n, is 
deactivation o f any remaining activated carboxy-methyl groups. This is 
achieved by passing a solution o f 0.1M ethanolamine, pH 9.0, over the surface. 
In the sensorgram depicted in Fig. 3.45, this occurs between positions 3 and 4. 
The small decrease in response, evident post-ethanolamine, is due to this 
solution removing loosely bound anti-(i from the dextran matrix. This surface 
is now ready for BIA o f the interaction o f anti-jo., with its ligand, mouse IgM.
G1 supernatant was passed over this derivatised surface (Fig. 3.46). An 
increase in response o f over 1000 RU was obtained, attributed to binding of 
IgM by the anti-(j.. In an attempt to regenerate the surface (i.e. disrupt the 
binding of IgM by anti-ja), a series o f acid glycine buffers were, sequentially, 
passed over the surface (Fig. 3.46). In order to evaluate the regenerative 
capacity o f the various buffers one assumption was made. This was, that the 
change in response was due, solely, to changes in the mass o f IgM bound in the 
dextran matrix. This assumption allowed one, to calculate the amount o f IgM 
remaining in the dextran matrix using the following theoretically derived 
relationship. Any change in response due to changes in the mass o f protein 
bound within the dextran matrix, is directly proportional to the mass 
change. The application o f this model indicated, that even the harshest buffer 
appeared to leave 74% of the IgM bound by anti-(j,. Thus, an initial analysis of 
these results appeared to confirm that this batch o f anti-jx was not suited to the 
requirements o f affinity purification. Subsequently, however, it was calculated 
that the 20000 RU o f anti-n immobilised corresponded to a concentration of
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Fig. 3.46: In  the above sensorgratn, G1 supernatant was passed over the anti- 
p  surface. This occurred between positions 1 and 2, and an increase in 
response o f 1138 R U  was obtained. This was attributed to binding o f G l Mab, 
by the anti-ft in the dextran matrix, as fresh  G l culture medium d id  not lead to 
any increase in response when passed over this surface. Between positions 2 
and 3, 0.1M  glycine, pH  2.9, was passed over the surface in an attem pt to 
disrupt the interaction between the M ab and anti-p. The response, relative to 
the baseline, decreases to 1075. This decrease in response was attributed to a 
decrease in m ass o f  M ab bound in the dextran m atrix by anti-p. This simple 
model suggested that 94% o f the M ab was still retained by the anti-p. 0 .1M  
glycine buffers (pH's 2.6, 2.4 and 2.2) were passed over the surface between 
positions 2 and 3, 3 and 4, and 4 and 5, respectively. Even using the harshest 
buffer, 74% o f the M ab appeared to be retained by the anti-fx
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anti-|i in the dextran matrix o f > lOOmg/ml. This did not accurately reflect the 
situation on affinity columns where in general proteinaceous ligand 
concentrations o f < lOmg/ml are used. It was considered that the high 
concentration o f anti-p, in the dextran matrix may have contributed to  the 
difficulty in regenerating the surface. Therefore, it was decided to make one 
more attempt at regenerating the interaction on the BIAcore™, by immobilising 
less anti-fj, on the surface.
1000 RU o f anti-(I were immobilised on a new chip surface (result not 
shown). As depicted in Fig. 3.47 and described in the corresponding legend, 
the interaction o f IgM with anti-p proved even more refractory to regeneration 
in this experiment, than the initial experiment, contrary to expectation. Not 
only did the sensorgram suggest that no regeneration was taking place, it also 
indicated an increase in RU after passing 0.1M glycine, pH 2.2, over the 
surface. This apparent increase in refractive index was inexplicable, in terms o f 
the assumption that changes in response were due, solely, to changes in mass o f 
bound protein in the dextran matrix. Some other factor was obviously causing 
an increase in response and, provisionally, this was attributed to a contraction 
o f the dextran matrix upon exposure to this particular regeneration buffer. 
Regardless o f the exact cause, it was obvious that the model being used to 
evaluate the extent of regeneration was flawed. Most likely, it was 
underestimating the extent o f regeneration. In order that the model could be 
successfully applied, it was decided to use a different low pH solution, in the 
hope that, it would indicate a greater regenerative effect o f low pH on the 
protein interaction.
As indicated in Fig. 3.48, approximately 2000 RU of anti-p. was 
immobilised on a fresh CM5 chip, G1 supernatant was passed over the chip, 
and an increase in response o f 215 RU was obtained. lOmM, 20mM, 30mM 
and 40mM HC1 (corresponding to pH s o f 2.25, 2.15, 2 and 1.85, respectively) 
were successively passed over the surface (Fig. 3.48). lOmM HC1 did not 
result in any regeneration. 20mM HC1 apparently only left 18% o f the IgM on 
the surface. After 30mM HC1 only 8% o f the IgM appeared to remain upon the 
surface and this was reduced to 5% after passing 40mM HC1 over it. This
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Fig. 3.47: 1000 R U  o f anti-p were immobilised on a fresh  CM5 chip, and 90 
R U  o f M ab was bound by it, from  G l supernatant, prior to running this 
sensorgram. Between positions 1 and 2, 0.1M  glycine, p H  2.2, was passed  
over the surface. Rather than the expected decrease in response, due to 
disruption o f the anti-p  : M ab interaction, a slight increase in response was 
noted. Between positions 2 and 3, G l supernatant was, again, passed over the 
surface. A slight increase in response, o f  54 RU, was noted, due presumably 
to binding o f M ab by the anti-p. Between positions 3 and 4, 0.1M  glycine, pH
2.2, was passed over the surface. Unexpectedly, this led to a very large 
increase in response o f 750 RU, which was inexplicable in terms o f changes in 
the mass o f protein bound within the dextran matrix.
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experiment led one to conclude that, low pH solutions could be used to 
regenerate the particular interaction being analysed.
However for the anti-p to be an effective affinity ligand, it was 
necessary to demonstrate that it retained activity after exposure to low pH. To 
evaluate retention o f activity, 1500 RU o f anti-ji was immobilised on the chip 
surface. Then the analyte (G1 supernatant) followed by the regeneration 
solution (40mM HC1) were successively and repeatedly passed over ('cycled') 
the surface. The responses post-analyte and post- regeneration were plotted 
(Fig. 3.49) as a function o f cycle number. Although the post-regeneration 
response did increase with cycle number, anti-p activity (i.e. post-analyte 
response) appeared to be completely retained even after 7 regeneration cycles. 
The increase in the baseline response was probably attributable to retention of 
some IgM by anti-u after each cycle.
Finally, the effect o f low pH on the immunoreactivity o f IgM itself was 
analysed. To do this, 5000 RU o f normal mouse IgM was immobilised on a 
chip surface. Analyte (lOpg/ml solution o f anti-p in PBS) and 30mM HC1 were 
successively cycled over this surface. The responses post-analyte and post­
regeneration are depicted in Fig. 3.50. A one-off decrease in the 
immunoreactivity o f the surface was evident after the first cycle but, thereafter, 
the immunoreactivity remained constant
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Fig. 3.48: This sensorgram depicts the immobilisation o f 2000 R U  o f anti-/j, 
on a  CM5 chip surface. G l supernatant was then passed over the surface and  
215 R U  o f M ob was bound by the anti-jx. lOmM, 20mM, 30mM  and 40mM  
H Cl were then successively passed over the surface. 40mM  H C l appeared to 
leave only 5% (11/215) o f  the M ab bound by the anti-/j. This was taken as 
indicating that, this interaction could be successfully regenerated using low 
pH  solutions.
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Fig. 3.49: Retention o f  anti-ft activity, after exposure to low pH, was evaluated 
by successively cycling analyte (G1 supernatant) and regeneration solution 
(40mM  HCl) over a dextran matrix containing immobilised anti-ju. The 
responses were measured post-analyte and post-regeneration and p lo tted  as a  
function o f cycle number. There was no apparent reduction in anti-ju activity 
as indicated by the constant post-analyte response.
Fig. 3.50: The retention o f  mouse IgM  activity after exposure to low p H  was 
evaluated by successively cycling analyte (anti-fj) and regeneration solution 
(30mM  HCl) over a dextran matrix containing im m obilised mouse IgM. A  
one-o ff decrease in the activity o f  the IgM  was evident, in that, there was a 
decrease in the analyte response between the fir s t and second cycle. 
Thereafter the post-cmalyte response was more-or-less constant.
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3.3.2.2  Creation of an anti-jo, affinity column: The studies described in section 
3.3.2.1 were sufficiently successful to make affinity purification o f IgM, using 
anti-|i as the capture ligand, an attractive proposition. The basic protocol of 
section 2.8.5 was used to immobilise anti-jx on a Sepharose 4B solid phase. 3g 
of Sepharose 4B was pre-swollen and added to 6mg (determined 
spectrophotometrically) o f anti-jj, dissolved in 5ml o f coupling buffer. After 
incubation o f the suspension for 36 hrs, a spectrophotometric analysis indicated 
that only 58% of the anti-p had bound to the Sepharose. The reason for this 
low value was not readily apparent. The 10ml o f wet gel, subsequently, was 
packed in a commercial chromatography column.
3.3.2.3  IgM  purification: Prior to purification, supernatants from all hybridomas were 
harvested and concentrated as per section 2.8.4.1. This concentrate was 
referred to as supernatant (conc.). In the cases o f  G l, G4, G i l  and G18, 
hybridomas were adapted to grow in a serum-free formulation and supernatants 
were harvested, only when the percentage o f FCS in the media was less than 
0.01% (v/v).
Initially, an attempt was made to purify IgM from 10ml o f G il  
supernatant (conc.). This was passed through the affinity column followed by 
20ml o f PBS. Elution o f retained protein was attempted with 20ml o f 0.1 M 
glycine buffer, pH 2.2 followed by 10ml o f 0.1 M  glycine, pH 1.85; eluate was 
collected in 1 ml fractions. A total o f 35 fractions were collected and 0.1 ml o f 
neutralising buffer (1M Tris.Cl, pH 8.7) was added to each. The quantity of 
protein in each fraction was then determined spectrophotometrically at 280nm 
(Fig. 3 .51). A rather broad protein peak, which tailed-off rather slowly, eluted 
of the column. This was probably due to the geometry (short, fat) of the 
column used. Notably, only one peak appeared to elute off the column. This 
was taken to indicate that, the vast majority o f the IgM eluted with the 0 .1M 
glycine, pH 2.2, and it was determined not to use the pH 1.85 solution in future 
purifications.
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Fig. 3.51: G il supernatant was passed through the anti-ju-Sepharose 4B 
column, and retained protein was eluted with 20m l o f  0.1M  glycine, p H  2.2, 
and 15ml o f  0.1M  glycine, p H  1.85. The eluate was collected in 35 x  lm l 
volumes and the quantity o f protein in each fraction was determined 
spectrophotometrically a t 280nm. One protein peak eluted o ff the column, 
with a substantial degree o f tailing. This was attributed to the column 
geometry (short and broad column).
Fig. 3.52: The IgM  fractions purified  from  G19, G18, G i l ,  G4, G3 and G1 
(lanes 1-6 respectively) were run through a  SDS-PAGE gel, under reducing 
conditions, and stained with Coomassie blue. M olecular weight (Mw) markers 
were also run: Carbonic anhydrase (29,000 Da), Ovalbumin (45,000 Da), 
Bovine serum albumin (66,000 Da), Phosphorylase b (97,400 Da), (3- 
galactosidase (116,000 Da) and M yosin (205,000 Da). The banding-patterns 
obtainedfor the IgM  fractions from  G1 and G3 appeared very fa in t and could 
not be interpreted. Nonetheless, the remaining IgM  fractions show two clear 
bands, which occurred where one would expect to fin d  polypeptides o f & 
23,000 Da and & 70,000 Da. These were tentatively identified as an antibody 
light chain, and a ¡u heavy chain, respectively. There was no indication o f a J  
chain.
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Fractions 11-17 were pooled and dialysed overnight against PBS containing 
0.5M NaCl. This fraction was referred to as the IgM fraction. This fraction 
(along with a number o f IgM fractions purified from the supernatants o f other 
hybridomas) were analysed for purity by SDS-PAGE as per section 2.8.3.2 
(Fig. 3.52). For most o f the IgM fractions, two bands were apparent upon 
staining with Coomassie blue. They roughly correspond to the molecular 
weight o f a ji-chain («70,000) and a light chain («23,000). No band was 
evident where one would expect to find a J-chain. This was presumably due to 
its low abundance and, possibly, its staining characteristics.
In order to evaluate and compare the specific anti-GIgG activity in the 
G 11 supernatant (conc.) and the IgM fraction, the concentration o f Mab in both 
was determined, by standard addition. Standard addition refers to an analytical 
technique, where a series o f known amounts o f analyte are added to the 
unknown. In each case, the total amount o f analyte (unknown plus standard) is 
quantitated as, e.g., an absorbance value. A graph o f absorbance versus 
concentration o f added standard is plotted. The absolute value o f the x- 
intercept o f the regression line is equal to the concentration o f unknown 
(Harris, 1991). The main advantage o f this technique is that the matrix remains 
constant for all samples. Using this technique, the concentrations o f Mab in 
both the G il  supernatant (conc.) and its corresponding IgM fraction were 
determined as 1.5mg/ml and 0.39mg/ml, respectively (Fig. 3.53).
The anti-GIgG activities o f both samples were titrated by ELISA, and 
plotted as a function o f concentration o f Mab (Fig. 3.54). Specific anti-GIgG 
activity, then, was defined as the slope o f the regression line to the linear 
portion of a plot of anti-GIgG activity, versus concentration of Mab. The 
specific anti-GIgG activity o f the supernatant (conc.) was 0.0337 ± 0.0007 
ml/|ig and that of the IgM fraction was 0.034 ± 0.002 ml/pg. These specific 
activities were almost identical. This led one to the conclusion that the affinity 
purification had been very successful, as it was accomplished without any 
apparent diminution in Mab activity.
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Fig. 3.53: A 1:100000 dilution o f  G i l  supernatant (conc.) and a 1:20000 dilution o f  
its corresponding IgM  fraction were prepared. The quantities o f  Mab in both 
unknowns were determined by standard addition, to the unknowns, o f  a series o f  
known amounts o f  normal mouse IgM  (0-50ng/ml'). The total amount o f  mouse IgM, 
in each sample, was quantified by ELISA, and plotted versus the concentration o f  
added standard.
The absolute value at the intersection o f  the regression line with the x-axis, 
was taken as the concentration o f  IgM in the unknown. For the 1:100000 dilution o f  
G il  supernatant (conc.), this value was 15 ng/ml. Thus, the conc. o f  IgM  in the 
undiluted G i l  supernatant (conc.) was 1.5 mg/ml. The concentration o f  IgM in the 
corresponding IgM fraction was calculated as 0.39 mg/ml.
ELISA: This was carried out as described in section 2.8.1.1. A 10ng/ml 
solution o f  M6149 was used as the coating antigen, and an alkaline phosphatase 
conjugated to goat anti-mouse IgM was used as the secondary antibody, a t the 
manufacturer's recommended dilution.
Fig. 3.54: The anti-GIgG activities o f  both G i l  supernatant (conc.) and G i l  IgM  
fraction were titred by ELISA, and plotted as a function o f  Mab concentration. The 
specific activities o f  both the supernatant (conc.) (0.0337 ± 0 .0007  ml fig'1)  and the 
IgM  fraction (0.034 ±  0.002 ml f jg 1)  were defined as the slopes o f  the regression 
lines to the linear portion o f  both curves.
ELISA: as described in the legend to Fig. 3.53, but a 10¡ug/ml o f  GlgG was 
used as the coating antigen.
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3.3.2.4 Specific anti-GIgG activity as a measure of poly reactivity: All the
remaining Mabs were purified, as described in the previous section for G il  
Mab. In each case, the quantities o f Mab in both the supernatant (conc.) and 
corresponding IgM fraction were determined by standard addition, and the anti- 
GIgG activities, in both, titred by ELISA. The anti-GIgG activities were 
plotted versus concentration o f Mab (see Fig. 3.55-3.62), and the specific anti- 
GIgG activities o f each supernatant (conc.) and its corresponding IgM fraction 
were calculated, as described for G i l  Mab (section 3.3.2.3). The specific 
activities are tabulated in Table 3.3.
It was immediately evident that, as predicted in section 3.2.1, all Mabs 
segregated in one o f two groups. G i l  Mab was the sole occupant o f one 
group, distinguished by the similarity o f its specific activity in supernatant 
(conc.) form to that as an IgM fraction. G i l  Mab was said to be 
'monoreactive' as a term-of-convenience. The remaining Mabs constituted the 
second group and were distinguished by the large increases in specific activity 
attendant upon purification. These Mabs were considered to be polyreactive.
155
OD
 
40
5n
m
Fig. 3.61 Fig. 3.62
IgM (jigAnl) IgM (fig/tnl)
Fig. 3.55-3.62: M abs were purified from  supernatants o f  the G l, G3, G4, G18, 
G19, G24, G30 and G33 hybridomas, as described in section 3.3.2.3. The 
quantities o f M ab in each supernatant and its corresponding IgM  fraction  
were determined by standard addition, as described in section 3.3.2.3, and  
their anti-GIgG activities were determined by ELISA. In each case, the anti- 
GlgG activity was p lo tted  as a function o f M ab concentration, and the specific 
activity o f each solution was deduced from  the slope o f  the regression line to 
the linear portion o f  each curve. These specific activities are tabulated in 
Table 3.3.
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Specific acti'i it\ of 
supernatant (conc.)
Specific activity of the I«M 
fraction
Percentage increase in 
specific activity
G1 0.0228 ± 0.0009 1.28 ±0.09 5,500%
G3 <LOD 0.18 ±0.02 ND
G4 0.0108 + 0.0003 0.081 ±0.003 650%
G il 0.0337 ±0.0007 0.034 ± 0.002 0.9%
G18 0.066 ±0.001 0.760 ± 0.007 1,050%
G19 0.0045 ± 0.0004 0.7 ±0.1 14,500%
G24 0.0065 ± 0.0003 2.20 ±0.03 33,700%
G30 0.015 ±0.001 24.8 ±0.5 164,300%
G33 0.84 ±0.04 21.8 ±0.23 2,400%
Table 3.3: The specific activities o f a ll hybridoma supernatants and their 
corresponding IgM  fractions are depicted above (all measured in m l jug1). 
The increase in specific activity refers to that o f  the IgM  fraction over the 
supernatant. This was calculated by dividing the mean specific activity o f the 
IgM  fraction by that o f  the corresponding supernatant.
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3.3.3 Im m unoblots:
For the final test o f polyreactivity-the immunoblot-it seemed sensible to  use the 
affinity-purified Mabs rather than the hybridoma supernatants. In this form, all 
the binding-sites were considered to be free and could interact with the proteins 
immobilised on the nitro-cellulose. On the otherhand, in supernatant form, the 
percentage o f Mab, which remained free, was probably very limited. For 
example, the specific activity determinations for G30 Mab (Table 3.3) 
suggested that, only, 0.06% (0.015x100/24.8) o f the total Mab remained free in 
the supernatant. This sequestration was expected to be very deleterious to the 
sensitivity o f the assay.
In an initial experiment, G l, G4, G i l ,  G18 and G19 affinity-purified 
Mabs were used to probe a template o f size-fractionated liver proteins, 
immobilised on nitro-cellulose. Two purified mouse IgM monoclonal 
antibodies, produced independently o f the studies reported in this chapter, were 
also used to probe this blot, in the expectation that they would serve as 
negative controls. Clone E51.87 is an anti-CD5, produced by in vivo 
immunisation (Mark et a l, 1981). Clone 11E10 is an anti-lipopolysaccharide 
IgM, also produced by in vivo immunisation (Southern Biotechnology 
Technical Division, personal communication). Upon development with 
secondary antibody and substrate, the blot depicted in Fig. 3.63 was obtained. 
The result was very unexpected. All the Mabs produced for this study, 
including G i l ,  appeared to be polyreactive in that, they all resulted in a similar 
multi-band staining pattern. Clones E51.87 and 11E10, while not completely 
negative on this blot, at least gave much less intense staining patterns, than the 
Mabs generated by IVI. This evidence in favour o f a polyreactive G l 1 Mab 
was directly opposed to the evidence, presented in section 3.3.2, o f the specific 
activity determinations.
In an attempt to resolve this apparent contradiction, it was noted that,
the intensity o f the staining pattern developed on the blot was related to the
harshness o f the procedure used to purify the Mab. All the Mabs generated
during the course o f this study had been purified by elution from an affinity
matrix, using low pH. The remaining two Mabs had been purified, however, by
size-exclusion chromatography followed by anion-exchange chromatography -
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a much gentler procedure. It was considered possible that, the exposure to  low 
pH had in some way disturbed in a minor fashion, the binding sites o f each 
Mab. In the case of G l 1 Mab, this had converted a monoreactive Mab into, 
ostensibly, a polyreactive one. To test this, advantage was taken o f the similar 
specific activities o f G l 1 supernatant and its corresponding IgM fraction, both 
of which were used to probe a template o f liver proteins resulting in the blot of 
Fig. 3.64. This experiment clearly revealed, that exposure to the low pH had 
changed the binding-characteri sties o f  this Mab, at least as revealed by the 
immunoblot assay. Quite clearly, one had no choice if one wanted to avoid 
artifactual observations, but to use the hybridoma supernatants for this assay.
These concentrated supernatants were used to probe a template o f size- 
fractionated liver proteins and the blot, which resulted, is presented in Fig. 3.65. 
There are a number o f noteworthy aspects to this blot. Firstly, the staining 
patterns observed were the result o f binding by the Mabs to liver proteins. Two 
observations lead to this conclusion. The first is that the secondary antibody 
only weakly reacted with the liver proteins (only a weak staining pattern was 
evident in regions o f the blot between the lanes in which the supernatants were 
run). The second is that although the staining patterns observed in each lane 
are similar, in terms of the bands stained, the relative intensity with which they 
are stained is a characteristic peculiar to each supernatant.
The second noteworthy point is that the G l 1 Mab was the only Mab,
which did not react with the template o f liver proteins. It is true that many of
the other Mabs reacted weakly on the blot. This may be attributed, at least in
part, to the very low concentrations o f free Mab in each supernatant. (Table 3.4
lists the concentrations of Mab in the concentrated supernatants from the G l,
G3, G4, G i l ,  G18, G19, G24, G30 and G33 hybridomas. Related values,
referred to as the concentrations o f free Mab are also quoted. These are
determined from the actual concentrations using the specific activity
measurements tabulated in Table 3.3. The calculation o f the free
concentrations (see Table 3.4) is based on the assumption that the differences in
specific activity o f an affinity-purified Mab and its corresponding hybridoma
supernatant are attributable to a reduction in the fraction o f total Mab which
remains free in the supernatant). The exception is the G l 1 Mab, whose free
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concentration was very high in the supernatant used to probe the blot; the lack 
of staining is all the more remarkable for this. This evidence was taken as 
corroborating the conclusions reached with the specific activity determinations. 
G11 Mab was monoreactive and the remaining Mabs were polyreactive.
A final point o f interest is that the differences with which the 
polyreactive Mabs reacted on the blot cannot be solely attributed to differences 
in their concentrations. G18 and G19 Mabs stained the blot with an intensity 
markedly higher than did the remaining Mabs even though most Mabs were 
used at similar concentrations to probe the blot. This difference may be a 
reflection o f varying degrees o f polyreactivity. However, it may be argued in 
this case that one should observe a reduction in the number o f bands stained not 
in the intensity with which bands are stained. One other possibility is based on 
the suggestion, that monoclonal polyreactive antibodies might be 'organ- 
specific' (A. Nobrega, UFJR, Rio de Janeiro, Brasil, personal communication). 
Perhaps, the G18 and G19 Mabs are particularly reactive with liver proteins. 
To test this possibility it would be o f interest to use all Mabs to probe size- 
fractionated proteins sourced from organs other than the liver. However, at 
present, the significance (if any) o f this observation remains obscure.
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Concentration of Mab Concentration o f  Tree- Mab
G1 166 3
G3 106 <LOD
G4 460 61
G i l 1500 1487
G18 1720 149
G19 950 6
G24 570 2
G30 96 0.06
G 33 390 15
Table 3.4: The concentrations o f Mab, in each o f 9 hybridoma supernatants, 
are tabulated above. These values were determ ined by standard addition as 
described in section 3.3.2.3. The related values fo r  the concentrations o f free  
Mab were calculated by m ultiplying the concentrations determ ined by 
standard addition by the specific activity o f  the supernatant; the resulting 
value was divided by the specific activity o f  the affinity purified Mab. (The 
relevant specific activity values are given in Table 3.3). A ll concentrations 
are related in fig/ml.
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Fig. 3.63: A liver extract (section 2.8.3.2) was run through a SDS-PAGE gel 
(section 2.8.3.3) and the size-fractionated proteins were electro-transferred 
onto nitro-cellulose (section 2.8.3.4). The nitro-cellulose was then probed  
with 20jug/ml solutions o f the IgM  fractions o f G l, G4, G i l ,  G18 and G19 
supernatants (lanes 1-5, respectively) and with mouse IgM  from  clones 11E10 
andE 51.87 (lanes 6-7, respectively), as described in section 2.8.3.5.
The results were quite surprising. Lanes 1-5 gave very similar 
banding-patterns, which differed only in intensity. Contrary to expectation the 
IgM  fraction o f G il  supernatant gave quite a  strong banding-pattern, which 
indicated that it was multireactive.
Lanes 6-7, while not completely negative, were much less intense than 
lanes 1-5. This was as expected as these IgM fractions had been purified  from  
two hybridomas raised by in vivo immunisation. I t was, thus, expected that 
they would be monoreactive, generating a negligeable banding-pattern. The 
residual banding-patterns evident in these two lanes was attributed to the fact, 
that these two clones had been in the laboratory fo r  over two years prior to 
use, and, hence, may have been degraded to a  certain extent.
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Fig. 3.64: Liver proteins were size-fractionated and blotted onto nitro­
cellulose, as described in the legend to Fig. 3.63. The nitro-cellulose was 
probed with G il  supernatant (conc.) containing 1,500jug/ml o f G il  M ab (lane 
1). I t was also probed with solutions o f  affinity-purified G il  M ab a t 36, 72, 
145 or 390/j.g/ml (lanes 2-5, respectively). This experiment provided  
convincing evidence in favour o f the hypothesis, that affinity-purifying the 
G il M ab had converted a monoreactive antibody binding site into one, which 
was polyreactive. The affinity-purified G 1I M ab was clearly polyreactive in 
that, it gave a m ulti-band staining pattern on the blot, even at 36pg/ml, 
indicating that it was reactive with many different proteins (see lane 1). In  
contrast, when the nitro-cellulose was probed with the G il  supernatant 
containing G il  M ab a t the much higher concentration o f 1,500fig/ml, no 
bands were stained, that could not be attributed to binding by the secondary 
antibody to the liver proteins. This indicated that the G il  Mab, in what may 
be described as a more natural state, was monoreactive.
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Fig. 3.65: Liver proteins were size-fractionated and blotted onto nitro­
cellulose as described in the legend to Fig. 3.63. The nitro-cellulose was 
probed with concentrated supernatants from  the follow ing hybridomas: G l, 
G4, G3, G il, G18, G19, G24, G30 and G33 (lanes 1-9, respectively). A ll 
supernatants were used neat except those from  the G18 and G19 hybridomas, 
which were diluted 1:10 in PBS. The concentrations o f  M obs in each solution 
can be read or calculated from  Table 3.4.
The supernatants from  a ll hybridomas, excepting G i l ,  gave a multi­
band stain pattern. 7his was taken as evidence that G il  Mab was 
monoreactive and the remainder polyreactive.
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3.4 Conclusions
It was hypothesised at the outset o f  this study, that IVI would produce
polyreactive Mabs. To test this prediction, a panel o f nine hybridomas
secreting anti-GIgG (G l, G3, G4, G i l ,  G18, G19, G24, G30 and G33) was 
produced using the IVI system published by Borrebaeck and Moller (1986) 
(section 3.2). The binding characteristics o f their respective Mabs were then 
investigated, as described in section 3.3 (affinity determinations, specific 
activity determinations and immunoblots). The affinity determinations (see 
Table 3.2) formally identified G l, G4, G18 and G24 as polyreactive. They did 
not result in any classification o f the remaining Mabs. In contrast, the evidence 
o f the specific activity determinations and, also, the immunoblots (see sections
3.3.2 and 3.3.3, respectively) were in complete agreement, that 8 o f the 9 Mabs 
produced (G l, G3, G4, G18, G19, G24, G30 and G33) were polyreactive, G l 1 
being monoreactive. The fact that the affinity determinations only identified
four o f these Mabs as polyreactive is presumably due to a lack o f discriminatory
power, attributable to the limited number (6) o f antigens involved in this 
experiment. Notably, both the specific activity determinations and the 
immunoblots involved, presumably, many hundreds o f antigens (either in the 
supernatant or on the nitro-cellulose). Thus, these results provide explicit 
proof that the IVI system of Borrebaeck and Moller (1986) produces 
polyreactive Mabs. While these results cannot, obviously, be taken to infer 
that, all IVI culture systems produce polyreactive Mabs, they do at least 
indicate that it would be expedient to investigate this possibility for each 
system.
Looked at in a more general sense, these studies highlighted the 
problem o f detecting polyreactive antibodies. The possibility that conventional 
assays for detecting antibody (e.g. ELISA) would not be suitable for detecting 
polyreactive antibodies was not considered at the start o f the project. 
However, this appears to be the case. This point became very evident when 
comparing the G l 1 and the G30 Mabs. The reactivities o f these Mabs against 
GIgG were indistinguishable. G30 reacted with GIgG with an affinity constant 
of 3.1 (±0.3) xlO'8 while, G i l  reacted with GIgG with an affinity constant o f
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3.5 (±0.1) xlO'8 (see Table 3.2). Nonetheless, the supernatant o f the G30 
hybridoma had absolutely no anti-GIgG activity, as determ ined by ELISA  (see 
Fig. 3.21). In stark contrast, G i l  supernatant had a  titre o f a t least 1:10,000 
using this assay form at (Fig. 3.17). The explanation offered in this thesis, to 
account for this finding (section 3.2.1), is that when one is screening for 
reactivities in complex biological matrices (such as supernatants), polyreactive 
antibodies may be bound in solution by components o f the matrix leaving only a 
small fraction of the antibody free in solution and, hence, detectable by ELISA. 
Overall, this suggests that ELISAs or any other systems for detecting 
antibodies in highly complex matrices are inherently biased towards the 
detection o f monoreactive antibody. Screens will, as a  consequence, 
underestimate the extent o f a  potentially important class o f antibodies. This 
may lead in turn to an under-appreciation o f  the role o f  polyreactive 
antibodies in various immune (and, i f  the speculations o f  Coutinho and  
Avrameas (1992) are correct, non-immune) phenomena. In  order to eliminate 
such bias, it seems clear, that one m ust carry out screens in as simple a matrix 
as possible. Two different situations where these considerations are relevant 
are considered below.
When screening cells at the clonal level (e.g. B cells or hybridoma 
clones), the conventional approach is to harvest the supernatant from individual 
clones and assay it by ELISA. The results presented in this chapter suggest 
that this is a sub-optimal approach, ill-suited to the detection o f polyreactive 
antibodies. A far better approach would be to use an ELIspot assay. The 
coating antigen in an ELIspot assay should be better able to compete with 
matrix components for secreted polyreactive antibody as the ELIspot assay is 
based on the detection o f freshly secreted antibody. I t may also be suggested 
that, the perfect assay fo r  unbiased detection o f both monoreactive and  
polyreactive antibodies would be an ELIspot assay using cells resuspended in 
PBS, rather than, as during these studies, culture medium.
A different set o f problems present themselves when attempting to 
screen complex mixtures o f antibodies in an unbiased fashion. Screens o f 
normal serum for reactivities against hundreds o f antigens at once using
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immunoblots (e.g. Haury et al., 1994) best exemplify the problems that can 
occur. The problem can be stated as follows. The species o f  antibody present 
in normal serum can reasonably be expected to vary in the extent to which they 
show polyreactive binding profiles. Some species will be monoreactive, some 
highly polyreactive and others may lie somewhere between these two extremes. 
In a complex matrix such as serum, antibody will partition between free 
antibody and antibody bound to components o f the serum. The problem here is 
that the free antibody, that is to say the portion o f the total antibody detectable 
by immunoblot, cannot be a representative sample o f the total antibody in the 
serum. The polyreactive antibody component o f the normal serum, by its very 
nature, must preferentially exist bound to components o f  the serum; the 
monoreactive antibody component, by its very nature, must preferentially exist 
free in solution. The detectable antibody as a result must be enriched for 
monoreactive antibodies. The obvious solution is to affinity-purify the antibody 
from the serum in order to simplify the matrix in which the normal antibody is 
contained. Thus, Sigounas et al. (1994) demonstrated that normal human 
plasma contains much polyreactive IgM, which is masked in the circulation by 
antigen-binding and only revealed by affinity-purification. Bememan et al. 
(1992) showed that IgG, affinity-purified by protein G chromatography from 
normal mouse serum, was highly polyreactive. This polyreactivity was not 
evident in the serum itself.
Unfortunately, the simple expedient o f affinity-purifying antibody, in
order to reveal its polyreactive component, may itself lead to bias in that it may
generate polyreactive antibodies from monoreactive ones. This was made very
clear during the series o f experiments reported in this chapter. Specifically, the
G il  Mab, when exposed to low pH, was converted from a monoreactive
antibody to one displaying polyreactive binding characteristics as determined by
an immunoblot assay (see Fig. 3.64). That polyreactive binding evident post-
affinity-purification cannot necessarily be attributed to 'de-masking' o f bound
polyreactive antibody, but may be artifactual and due (presumably) to limited
denaturation o f monoreactive antibody should obviously be borne in mind at all
times. In fact, some observations in the literature, which have been attributed
to 'de-masking' o f polyreactive antibody may be better explained by
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denaturation o f monoreactive antibody. As noted in section 1.2.3, there is 
some dispute over the predominant isotype o f natural polyreactive antibodies. 
Casali and Schettino (1996) have indicated that IgM is the predominant isotype. 
This is disputed by Avrameas and Temynck (1995) who have claimed that IgG 
is the predominate isotype. There view is based on the observation that protein 
A-purified normal mouse IgG appears to be polyreactive, in contrast to that in 
the crude serum (Bememan et al., 1992). This effect o f purification was, 
similar to the ideas in this chapter, attributed to masking of reactivity in the 
complex biological matrix o f the serum. Curiously, however, this polyreactivity 
was only evident upon basic elution of IgG from the protein A. Under acidic 
conditions, the reactivity o f the IgG was not in evidence. This was claimed to 
be due to denaturation o f the IgG under acidic conditions. While this may very 
well be true, one other possibility deserves consideration. This is that, the 
reactivity pattern is not destroyed under acidic conditions; rather it is created 
under basic conditions. In support o f this notion, the conversion o f G 11 from 
a monoreactive to a polyreactive Mab is presented. It is also noteworthy that, 
in general, basic conditions are considered harsher on antibodies than are acidic 
conditions (John Quinn, D.C.U., personal communication). This interpretation 
o f results is in agreement with other findings in the literature. For example, 
Klinman (1994) reported, that the repertoire o f splenic B cells secreting IgG in 
normal mice was substantially less cross-reactive than the corresponding IgM 
repertoire. These observations were made with an ELIspot assay, not an 
ELISA, and as discussed earlier, should be able to detect polyreactive 
antibodies. Finally, unlike normal IgM, normal IgG production by antigen-free 
mice is extremely limited (Coutinho et al., 1995). One possible interpretation 
o f this is that normal IgG represents the product o f a conventional immune 
response to external antigens. I f  this was the case the IgG would be expected 
to be monoreactive and not polyreactive.
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CHAPTER FOUR 
THE ANTI-NIP INTRABODY
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The concept of the intrabody library and a number o f its potential 
applications were introduced in section 1.4.4.1. These applications were 
considered sufficiently attractive that a project to investigate the feasibility o f 
the intrabody library concept was undertaken and, the remainder o f this thesis 
(this chapter and chapter 5) is dedicated to this work. The choice o f this 
project, dependent as it is on antibody monospecificity, may seem rather 
incongruous when considered alongside work on antibody polyspecificity 
(chapter 3). This incongruity is more apparent than real, however. 
Polyspecific and monospecific models o f antibody binding sites are not 
mutually exclusive, and it was felt, that as long as a sufficient fraction o f the 
intrabody library consisted o f specific intrabodies, it would prove useful.
At the outset, it was decided that, the simplest approach to generate an 
intrabody library, from a technological point o f  view, would be to convert a 
pre-existing phage-displayed ScFv library to an intrabody library. The only 
such library available at that time in the laboratory was the Nissim library 
(Nissim et al., 1994); this library became the focus o f all efforts. It was also 
decided at the start that, initial studies should target intrabodies to the 
cytoplasm.
These decisions made, a generic strategy was conceived, for converting 
any ScFv into an intrabody. In chapter 5, the application o f this strategy to 
generate a 'one-shot' intrabody library is presented. In this chapter, the 
strategy is introduced and its validation reported.
Generic strategy for intrabody construction
The genetic construction o f the Nissim library was discussed in section 1.3.3.2 
and depicted in Fig. 1.8a. It contains an ORF (open reading frame) encoding a 
PelB - ScFv - c-myc - g ill fusion protein. When deciding how best to construct 
an ORF encoding an intrabody from this, the following points were noted.
i) g ill has no activity o f relevance to an intrabody.
ii) In the absence o f a leader sequence, proteins expressed in mammalian cells 
should be retained in the cytoplasm. PelB, although a bacterial leader
sequence, retains the essential feature o f mammalian leader sequences, that is 
to say, it contains a core o f hydrophobic amino acids. Therefore, the 
possibility existed that a PelB - ScFv - c-myc fusion protein would be targeted 
to the ER of a mammalian cell prior to secretion.
These considerations suggested the ScFv - c-myc fusion protein as an 
appropriate intrabody format. While the c-myc tag, like g ill, has no essential 
activity, it was retained for the purpose of analysing the intracellular location 
o f the putative intrabody. (A protein G affinity-purified anti-c-myc was 
available in the laboratory. It had been purified from the supernatant o f  the 
Mycl-9E10 hybridoma).
PCR was the obvious strategy to generate an ORF encoding a ScFv - c- 
myc protein from that encoding a PelB - ScFv - c-myc - g in  protein. The 
insertion o f a stop codon, just 3' to the c-myc sequence could be achieved 
easily using a primer referred to as MIK2 (see Fig. 4.1). O f great importance 
for the aim o f generating an intrabody library, this primer could be used to 
construct an intrabody from any ScFv in the Nissim library, or indeed, an 
intrabody library from the Nissim library. This was due, simply, to the fact 
that the sequence this primer targeted was part o f the parental plasmid used to 
construct the Nissim library (see section 1.3.3.2) and was present on every 
member o f the library.
The insertion o f a start codon just 5' to the ScFv sequence was a more 
formidable task. There were two conflicting requirements. On the one hand, it 
was desired to target the forward primer within the PelB  sequence (which is 
encoded on the parental plasmid) so that the primer would be generally 
applicable. On the other hand, there was no obvious way to introduce the 
required start codon, using a primer targeted to this region.
Fortunately, a closer look at the detailed sequence o f PelB  revealed, 
that as well as the initiator ATG codon at its 5' end, it contained an 'in-frame' 
ATG codon at its 3' end (Fig. 4.1). This codon could be used to start the ORF 
encoding the ScFv - c-myc protein. Thus, the forward primer could be 
targeted anywhere between the two ATG codons. All potential primers were
171
analysed using GeneStrider™ for the potential to form hairpin bends and 
loops. Based on this analysis, the primer named MIK1 was chosen.
Prior to applying this strategy to  create an intrabody library, it was 
validated using an anti-NIP ScFv (4-hydroxy-5-iodo-3-nitrophenylacetyl) 
isolate provided with the Nissim library. The remainder o f this chapter is 
concerned w ith the validation o f this strategy (Fig, 4.2).
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-60 -50 -40 -30
A  ATG  AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA
I— ------------------------------------------------------------------------------------Peitì
-4 -------------------------- M I K l    ►
TAC CTA TTG CCT ACG GCA GCC 
TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT
-20 -10 -1 1 2  3 4 5 6
B TTA CTC GCG GCC CAG CCG GCC A T G  GCC CAG CTG.
AAT GAG CGC CGG GTC GGC CGG TAC CGG GTC CAC
+ 1 +10
GCG GCC GCA GAA CAA
-ScFv-
CGC CGG CGT CTT GTT
+20 +30 +40 +50
D AAA CTC ATC TCA GAA GAG GAT CTG AAT GCG GCA GCA.......
---------------------------------c-myc-------------------------------------------------- 1
CTC CTA GAC TTA CCC CGT CGT A C T
<4____________________ M I K 2 _______________________ fr,
TTT GAG TAG AGT CTT CTC CTA GAC TTA CCC CGT CGT
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4.1.1 Polymerase chain reaction: Plasmid DNA from the anti-NIP ScFv isolate 
was prepared as described in section 2.7.2.1 (Fig. 4.3), restricted with £coRI 
and gel-purified according to section 2.7.2.1. This was used as the template 
DNA in a PCR, as described in section 2.7.3.1. MIK1 and MIK2 were used as 
the primers. The PCR was analysed by gel electrophoresis, as depicted in Fig. 
4.4, and was very successful, as described in the accompanying legend.
4.1.2 'TA  Cloning' of the PCR product and transformation of the resulting 
recombinant plasmid into E. coli ToplOF': Due to a nontemplate-dependent 
polymerase activity, PCR products produced using Taq polymerase contain 3' 
adenosine overhangs. As a result, they can be ligated into linearised vectors 
containing complementary 3' thymidine overhangs, a process known as 'TA- 
cloning' (Mead et al., 1991; Hengen, 1995). Although not the most efficient 
way to clone PCR products, its simplicity (it does not require purification o f 
the PCR product) makes it the most attractive methodology when its limited 
efficiency is not an issue.
A commercially available mammalian expression vector, pCR™3-Uni 
(see appendix D for plasmid map and sequence), was used for TA cloning. It 
came as part o f the 'Unidirectional TA Cloning Kit', which also provides for 
transformation o f the resulting ligation mix into E. coli ToplOF'. In total, 
120ng o f PCR product was ligated with 60ng o f pCR3™-Uni, and 36ng o f the 
resulting product was transformed into E. coli ToplOF', as instructed by the 
manufacturer's, resulting in 350 transformants.
Unfortunately, this system does not allow for selection o f transformants 
containing recombinant over non-recombinant plasmids. Nor does it allow 
selection o f recombinants containing insert in the correct orientation. Thus, 
after growth of the transformed bacteria, individual colonies must be screened 
for the presence o f a correctly oriented insert.
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Fig. 4.3 Fig. 4.4
21227bp 
5148b»
4973 and 4268bp
2027 and 1904bp 
i534bp 
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4 5 6
Fig. 4.3 : Plasmid (referred to as pHen-Vx + anti-NIP ScFv) was purified from  
an anti-NIP ScFv isolate provided with the Nissim library. It was restricted 
with EcoRI and size-fractionated by gel electrophoresis to estimate its size.
Lanes 1 and 6: M w markers as indicated in the margin (Lambda DNA 
restricted to completion with EcoRI and Hindlll).
Lanes 2 and 3: Plasmid DNA from  the anti-NIP ScFv isolate, before 
(2) and after (3) restriction with EcoRI.
Lanes 4 and 5: Parent plasm id (pHenl) before (5) and after (4) 
restriction with EcoRI.
Note that, when restricted, the plasm id from  the anti-NIP ScFv isolate 
appeared at ~  5,300bp, as one would expect (pHenl was 4,500bp and the 
insert was expected to be 780bp in size). The restricted pHen-Vx + anti-NIP 
ScFv was subsequently eluted from  the gel and used as the template DNA in a 
PCR, to create an ORF encoding an intrabody
Fig. 4.4 : A PCR was set up as described in section 2.7.3.1. Restricted, gel- 
purified pHen-Vx + anti-NIP ScFv was used as the template DNA. MIK1 and  
MIK2 were used as forw ard and reverse primers, respectively. The success o f  
the PCR was assessed by gel electrophoresis.
Lanes 1 and 7: M w markers as indicated in the margin.
Lanes 2-6: PCR product.
The PCR appeared to work very well. Only one band was evident and it 
appeared at 780bp as expected.
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Screening was carried out, by purifying the plasmid from individual 
colonies (section 2.7.2.1) and restricting it with Ncol. There was a Ncol site at 
the 5' end o f the PCR product (see Fig. 4.1, positions -8 to -3). This combined 
with the fact that, pCR3™-Uni contains three Ncol sites oriented 
asymmetrically about its multiple cloning site, allowed one to identify 
recombinant plasmids with the insert in the correct orientation, based on the 
Ncol restriction pattern (Fig. 4.5).
1000 2000 3000 4000 4994 (base-pairs)
- I — I— I— [
386 2599 3296
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386 705 3379 4076
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t t t t
386 1405 3379 4076
Fig. 4.5: A, B  and C represent schematics o f  pCR3 ™-Uni without insert, with 
insert in the correct orientation and insert in the incorrect orientation, 
respectively. Arrows indicate N col sites. A N col restriction pattern composed 
o f  4 bands o f  339, 2674, 697 and 2187 base-pairs is indicative o f  a correctly 
oriented insert. These calculations are based on an insert o f  780 base-pairs.
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Seven colonies were analysed for the presence o f a correctly oriented 
insert and the results are shown in Fig. 4.6. A clone referred to as Top6 
contained a correctly oriented insert. This plasmid was named pp6. In the 
next section, studies aimed at determining the sub-cellular location o f its gene 
product are described.
•  >• *  ,> •  * * <»
i W a
tM  '**  • • 750bf>
SOObp
300bp 
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Fig. 4.6 : Plasmids were purifiedfrom  7 transformants (Top2-Top8) according 
to section 2.7.2.1 and, subsequently, restricted with Ncol. The restriction 
fragments were size-fractionated by gel electrophoresis.
Lanes 1, 6 and 10: M w markers as indicated in the margin.
Lanes 2-5 and 7-9: Plasmids from  colonies Top2-Top8, restricted with 
Ncol.
Note that, the plasmids from  Top3 and Top6 (referred to as pp3 and pp6, 
respectively) appeared to contain the insert in the correct orientation, as 
indicated by the presence o f  a band at »  340bp.
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4.2 Transfection experiments
In order to both serologically identify, and locate at the sub-cellular level, the 
gene product expressed by pp6, it was transfected into three different cell lines, 
NIH3T3, CHO and BHK, chosen for their high transfectability. After 48 hrs, 
the transiently transfected cell populations were analysed by 
immunocytochemistry. Alternatively, stably transfected cell lines were 
selected and analysed. Stable transfectants lend themselves to 
immunocytochemical analyses using electron microscopy, which was expected 
to lead to a deeper appreciation o f the sub-cellular localisation of the gene 
product.
Two different probes were used during the immunocytochemical 
analyses including the anti-c-myc probe mentioned in section 4.1. An anti- 
NIP antiserum produced in a rabbit during the course o f these studies, was also 
used.
4.2.1 Optimisation of transfection conditions: Calcium phosphate transfection, 
DEAE-dextran transfection, electroporation and lipofection are the four major 
methods for introducing DNA into mammalian cells, o f which, lipofection is 
the most efficient (Ausubel et al., 1990). A number o f  lipofection reagents are 
available commercially, and the Tfx™ series (Tfx™-10, 20 and 50) was 
chosen at random for these studies. It is recommended that transfection 
conditions be optimised for each individual cell line. Parameters to be 
optimised include the type o f Tfx™ reagent used, the DNA concentration and 
the charge ratio o f Tfx™ : DNA in the transfection mix, and the lenght o f time 
that it is applied to the cells.
In order to optimise these parameters, pCHl 10 was transfected into the 
cell lines under the variety o f conditions suggested in Promega Technical 
Bulletin # TB 216 (DNA concentrations o f 5, 2.5, 1.25 or 0.625|ig/ml; charge 
ratio's o f 2:1, 3:1 and 4:1; time periods o f 1 or 2 hrs.). pCH llO  is a reporter 
plasmid expressing P-galactosidase (see appendices B and D), and the 
effectiveness with which it was transfected was monitored by analysing the 
percentage o f cells in the transfected population expressing this enzyme (see 
section 2.8.2.1). The optimal transfection conditions are shown in Table 4.1.
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Ttx™ DNA (ug/ml) T tx1-'1: DNA Time (hours)
NII13T3 50 2.5 3:1 1
CHO 50 5 4:1 2
BHK 10 2.5 2:1 1
Table 4.1: The optimised transfection conditions fo r  the three cell lines used 
fo r  this study are shown above. The transfection efficiency fo r  each cell line 
(% cells expressing fi-galactosidase) is visually depicted in Figs. 4.7-4.9.
Figs. 4.7-4.9 (clockwise from  top 
left): NIH3T3, CHO and BH K cells 
(Figs. 4.7-4.9, respectively), were 
transfected with pC H llO  as described 
in section 2.5.8.1 and under the 
conditions noted in Table 4.1. After 
48hrs the cells were monitored fo r  fi- 
galactosidase expression as described 
in section 2.8.2.1. 0.1%, 1% and 10%- 
30% o f  N1H3T3, CHO and BH K cells, 
galactosidase. (40x magnification).
respectively, appeared to express (3-
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4.2.2 Immunocytochemical analysis of the pp6 gene product using the anti-c- 
myc probe: A maxiprep o f pp6 was prepared as described in section 2.7.2.2. 
It was transfected into the NIH3T3 cell line, as described in section 2.5.8.1, 
under optimised conditions. The resulting cell population was analysed with 
the anti-c-myc probe as described in section 2.8.2.2. A photograph of a typical 
stained cell is presented in Fig. 4.10. The cellular distribution appeared diffuse 
and was not associated with any particular cellular structure. This is what one 
would expect for a cytosolic protein. In particular, there was no clear-cut 
exclusion from the nucleus; this again is what one would expect for a cytosolic 
protein o f 31kDa (Biocca el al., 1990). Molecules smaller than 40kDa appear 
able to diffuse into the nucleus through the nuclear pores (Biocca and 
Cattaneo, 1997). It was also noted that, in so far as one could tell visually, the 
expression level o f  the gene product appeared to be quite good1 (appendix B).
Unfortunately, when the CHO and BHK cell lines were similarly 
analysed the results were very disappointing. CHO cells transiently 
transfected with pp6 did not show any indication o f gene product expression as 
detected by anti-c-myc. While, some BHK cells did appear to express the pp6 
gene product in the cytosol (see Fig. 4.11), expression levels appeared to be 
quite poor. Only »  0.05% o f transfected BHK cells appeared to be expressing 
the gene product. This compared very unfavourably with the 10-30% of cells 
expressing P-galactosidase from pCHllO  (see appendix B). This difference 
was attributed to low expression o f the pp6 gene product compared with that 
o f pCH l 10. (It could not be attributed to a toxic effect o f the pp6 gene product 
as, when a mixture of pp6 and pC H llO  was transfected into BHK cells, no 
diminution in P-galactosidase expression was noted (result not shown)).
Overall, these results suggested that the pp6 gene product was 
expressed in the cytoplasm but at low levels. In order to confirm this sub- 
cellular location, stably transfected NIH3T3 clones were selected with 
800pg/ml o f geneticin as described in section 2.5.8.2. A typical outgrowing 
colony is depicted in Fig. 4.12.
1 The maximum number of cells per smear was 50, 000 (50|il of a lxlO6 cell/ml cell suspension was
cytospim onto a glass slide) and in general 10 cells per smear were fluorescent. As a percentage this is
0.02%. This compared relatively favourably with the 0.1% transfection efficiency observed for this cell
line with the pCHl 10 reporter plasmid.
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IFig. 4.10: An NIH3T3 cell expressing pp6 gene product is presented. The 
product was detected as described in section 2.82.2. The anti-c-myc primary 
probe was used at a dilution o f  1:50, which in a preliminary experiment was 
the highest concentration o f probe that could be used without excessive 
background non-specific staining. This probe was detected with a FITC-anti- 
mouse IgG probe used at the manufacturer’s recommended dilution. Note the 
diffuse staining throughout the entire cell, which is less intense throughout the 
nucleus. This staining pattern and, particularly, the lack o f  exclusion from  the 
nucleus is what one would expect o f  a small cytosolic protein. (lOOOx 
magnification).
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Fig. 4 .1 1 :A BHK cell expressing pp6 gene product is presented. The gene 
product was detected as described in the legend to Fig. 4.10 and the 
distribution o f the product was very similar to that o f Fig. 4.10. (lOOOx 
magnification).
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The efficiency with which cells transfected with the Tfx™ reagents 
become stably transfected has been shown to be remarkably high. Schenbom 
et al. (1995) reported that, 17% of NIH3T3 cells were transiently transfected 
by Tfx™-50 and 5% o f the cells were stably transfected. Thus, » 30% o f cells 
taking up DNA become stably transfected. The results reported here are in 
agreement with this. In one experiment, 1.5xl06 cells were transfected with 
pp6 and 48 hrs later were split 1:15 into 60mm tissue culture dishes in order to 
select for stable transformants. After 10 days, one dish was Giemsa stained in 
order to count the number o f colonies on it (Fig. 4.13). Approximately, 50 
colonies were obtained suggesting that, 750 stable transformants had resulted. 
This was 50% o f the number o f cells taking up DNA in the first instance 
(asssuming a transfection efficiency for NIH3T3 cells o f 0.1%).
In any case, 19 colonies were picked and established (see Fig. 4.14) as 
cell lines. They were named N1 - N19. To ensure that the cell lines were true 
stable transfectants, genomic DNA was prepared (section 2.7.2.3 ii) from a 
random sample o f these cell lines (N8, 9, 10 and 12) and also from the parental 
NIH3T3 cell line. Each o f these 5 samples was interrogated, by PCR, for 
integration of pp6. The genome preparations were used as template DNA, 
along with the MIK1 and MIK2 primers, in a PCR as described in section
2.7.3.1. I f  the genomic DNA contained a copy(s) o f pp6, the primers would be 
expected to amplify its 780bp ORF. The result o f this experiment is contained 
in Fig. 4.15. Quite clearly, all sub-clones gave rise to a 780bp PCR product. 
Just as importantly, the parental cell line did not. This established that, these 4 
particular sub-clones were genuine stable transfectants. It also suggested that, 
the entire panel represented stable transfectants. A 650bp band is evident in all 
5 PCRs, presumably representing the product o f amplification o f a sequence 
carried on the parental genome.
When these cell lines were analysed for expression o f the pp6 gene 
product, by immunocytochemistry with the anti-c-myc probe, all were 
negative. This suggested that, the gene product was expressed at very low 
levels and, as a result, probably ruled out the application o f electron 
microscopy techniques to further probe its sub-cellular distribution.
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Fig. 4.12: A colony 
o f NIH3T3 cells 
selected with
0.8mg/ml o f
geneticin, is
presented in the 
photograph (40x 
magnification). The 
cells towards the 
centre o f  the colony appeared to be dead. Colonies, in general, were picked  
when they had reached this size, and were treated as stably transfected clones. 
The scale-up procedure used to establish colonies as cell lines is given in Fig. 
4.14.
Fig. 4.13: A
Giemsa stained 
60mm tissue 
culture dish 
containing 
N1H3T3 colonies 
selected with 
geneticin is
depicted. The 
dish was stained
as follows. The medium was poured-off the cells, and the cell monolayer was 
washed with PBS. The cells were fix ed  fo r  15 minutes with ice-cold methanol. 
The fixed  cells were stained with a 10% (w/v) solution o f  Giemsa in methanol, 
fo r  15 minutes at RT, prior to rinsing the dish with tap-water. The above dish 
contained approximately 50 colonies.
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60mm tissue 
culture dish
24 well plate
irnmunocylochemical
analysis
store in liquid cell extract
nitrogen preparation
Fig. 4.14: The scale-up procedure used to establish stable transfectant 
colonies as cell lines is presented. Note that, the colonies were screened by 
immunocytochemistry fo r  expression o f  the pp6  gene product as soon as was 
practically possible. Also, cell extracts were prepared as described in section
2.8.3.1. Immunoblot analysis o f  the cell extracts (see section 4.2.3.3) was 
alternative to and independent o f  immunocytochemistry as a means o f  
monitoring the presence o fpp6  gene product.
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Fig. 4.15: In order to determine 
whether N8, N9, N10 and N12 
contained pp6  integrated into 
their genome, their genomic DNA 
(along with that from  the parental 
NIH3T3 cell line (p)) was purified  
(section 2.7.2.3). This DNA was 
amplified with the MIK1 and  
MIK2 primers, essentially as described in section 2.7.2.1. The PCR product 
obtained was size-fractionated by gel electrophoresis (product obtained using 
N8 was run through the gel in the lane indicated 8 etc.). Notably, all fo u r  sub­
clones contained a 780bp amplification product, which is what one would  
expect i f  they contained pp6  integrated into their genome. The parental cell 
line does not show this amplification product.
Overall, the results obtained with the anti-c-myc probe were quite 
disappointing. The pp6 gene product did appear to be expressed in the 
cytoplasm, but electron microscopy studies to confirm this could not be carried 
out due to the poor expression levels observed. Although studies to analyse 
the rates o f transcription and translation o f this ORF were not carried out, the 
reason for this poor expression is almost certainly due to rapid degradation of 
the protein. This assertion is made as pp6 contains a very active promoter 
(appendix B and D) (therefore, it is reasonable to expect high rates of 
transcription) and, as pointed out in Fig. 4.1, the ORFs start codon occurs in 
the context o f a consensus Kozak sequence (therefore, one would expect 
effective translation o f its mRNA). Rapid degradation o f cytosolic intrabodies 
has been noted by Biocca et al. (1995); these authors attributed this to poor 
folding o f the variable domain in the reducing environment o f the cytoplasm. 
Degradation is probably exacerbated by the intrabody format chosen for these 
studies. The c-myc protein (part o f which was chosen to be fused to the ScFv, 
for no better reason than aiding detection o f the gene product) is a very short­
lived protein with an intracellular half-life o f  only 0.5 hrs (Dice, 1987). It is
very possible that the c-myc tag confers this trait on the pp6 gene product.
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4.2.3 Immunocytochemical analysis of the pp6 gene product using an anti-NIP 
ScFv antiserum: An anti-NIP ScFv antiserum was raised in a rabbit for use as 
a immunocytochemical probe for the pp6 gene product. This was important 
for three reasons. Firstly, as the pp6 insert had not been sequenced, it was 
important to identify that the gene product did indeed possess, as designed, the 
anti-NIP ScFv moiety. Secondly, the possibility that the c-myc tag was being 
rapidly but selectively degraded in vivo was considered. This was possible, as 
such observations had been made in vitro (T. Killard, DCU, personal 
communication). Such selective degradation would leave the ScFv intact, but 
undetectable with the anti-c-myc probe and was considered a possible 
explanation for the poor expression levels observed with this probe. Finally, 
the presence o f such an antiserum would allow the design o f the intrabody 
without the c-myc tag, potentially improving its in vivo stability.
4.2.3.1 Purification of the anti-NIP ScFv: The anti-NIP ScFv isolate from the 
Nissim library (referred to as E. coli HB2151 anti-NIP ScFv) was cultured 
under such conditions as to express the anti-NIP ScFv (see section 2.6.4). The 
culture broth (500ml) and a periplasmic lysate (10ml) were prepared from the 
culture supernatant and corresponding cell pellet, respectively. The anti-NIP 
ScFv activity, o f the solutions, was assessed by ELISA using a BSA-NIP 
conjugate as coating antigen (kindly provided by T. Killard, DCU) (Fig. 4.16).
The ScFv was affinity-purified using BSA-NIP immobilised on 
Sepharose 4B. This solid phase was prepared essentially as described in 
section 3.3.2.2. The only difference was that BSA-NIP was used rather than 
anti-p. It was used at a concentration o f lOmg/ml in a total volume o f 10ml of 
coupling buffer. This immobilisation was more efficient than that with anti-|i.. 
The spectrophotometric analysis revealed that > 98% of the BSA-NIP was 
immobilised giving a ligand density o f lOmg protein per ml o f wet gel. 2ml o f 
the wet gel was packed in a column and used to purify the anti-NIP ScFv.
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4Dilution of solution
Fig. 4.16: A culture broth and a periplasmic lysate were prepared from  E. coli 
HB2151 anti-NIP ScFv (section 2.6.4) as a source o f  anti-NIP ScFv. The anti- 
NIP ScFv activities o f  both solutions were titrated by ELISA. Both the culture 
supernatant and the periplasmic lysate appeared to contain a  large amount o f  
the ScFv, as indicated by the presented titration curves. Although the 
periplasmic lysate appeared to have a  slightly greater concentration, the 
culture supernatant was present in greater volume and was used as the 
starting source fo r  the purification o f  the ScFv.
ELISA: The ELISA was carried out in a  similar fashion to section
2.8.1.1. A 10/ug/ml solution o f  a BSA-NIP conjugate was used as the coating 
antigen. The test solutions were incubated in the coated and blocked wells as 
described in section 2.8.1.1. A two-step process was used to detect bound 
ScFv. Firstly, a  protein G-purified mouse IgGj monoclonal anti-c-myc was 
allowed to react with the bound ScFv (1:1000 dilution o f  the monoclonal 
antibody, in PBS containing 0.05% (v/v) Tween and 5% (v/v) FCS, was 
incubated in the wells fo r  1 hr.). The bound mouse IgGi antibody was, 
subsequently, detected with alkaline phosphatase conjugated to goat anti­
mouse IgGi, followed by substrate, as described in section 2.8.1.1.
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200ml o f the culture supernatant (referred to as 'fresh supernatant') was 
passed through the column (and collected - referred to as 'spent supernatant'), 
followed by 30ml o f PBS. Optimal elution conditions were not known and the 
initial attempt at elution used 0.1M glycine, pH 2.4. 1ml fractions were 
collected, neutralised with 0.1ml o f 1M Tris.Cl, pH 8.7, and the presence of 
protein analysed spectrophotometrically (OD 280nm). The elution profile is 
shown in Fig. 4.17.
Fig. 4.17: 200ml o f  culture
supernatant containing anti-NIP 
ScFv was passed through a BSA- 
NIP column. The retained protein  
was eluted o ff the column using 
0.1M  glycine, p H  2.4, collected in 
lm l fractions and neutralised.
The quantity o f  protein in each 
fraction was determined by 
reading their optical densities at 280nm. The resulting elution profile 
indicated that one relatively sharp peak eluted o ff  the BSA-NIP column, 
presumably representing anti-NIP ScFv. Fractions 3 and 4 were pooled, 
dialysed overnight against PBS containing 0.5M NaCl and stored at 4°C. The 
anti-NIP ScFv activity o f  this fraction was analysed, subsequently, as was its 
purity.
The success of the affinity purification was first analysed by evaluating
the anti-NIP ScFv activity o f  the fresh and spent supernatant and the affinity-
purified fraction (Fig. 4.18). Two points are clear from this graph. Firstly, the
column was very efficient in that it removed nearly all the anti-NIP ScFv
activity from the culture supernatant (compare the fresh supernatant with the
spent supernatant). The second point to note is that, the affinity-purified
sample had 50 times the activity o f the fresh supernatant. Now, if  the affinity
purification had been 100% successful (100% recovery o f anti-NIP ScFv with
full retention o f specific activity) one would have expected a 100-fold increase
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fraction number
in activity (200ml fresh supernatant, only 2ml o f  affinity-purified sample). 
Although the recovery o f protein was certainly not 100%, it was probably over 
90% given the sharp peak that eluted off the column. This suggested that the 
affinity purification lead to a 50% decrease in specific activity. The reason for 
this is not readily apparent. Certainly, the elution pH used was quite gentle. 
One possibility is that, some o f the anti-NIP ScFv in the fresh supernatant 
existed in dimerised form (Nissim el ah, 1994) and had a higher specific 
activity than the monomeric form due to the 'bonus effect o f multivalency'. 
Upon exposure to low pH it is reasonable to suggest that these dimers may 
have been converted back to monomers - explaining the reduced specific 
activity o f the affinity-purified fraction compared to the fresh supernatant.
d ilu tion  o f cu ltu re  su pe rn a ta n ts
 1 1 1 1 1 1 1
0.0e+0 2,0e~6 4.0e~6 6.0e-6 8,0e-6 1.0e-5 1.2e-5
d ilu tion o f ’a ffin ity -p u rified  an ti-N IP  S cFv'
Fig. 4.18: The anti-NIP ScFv activity possessed by a  supernatant, both before 
("fresh") and after ("spent") being passed through a BSA-NIP column, along 
with that possessed by the eluted protein ("affinity-purified anti-NIP ScFv") 
was titrated by ELISA (carried out as described in the legend to Fig. 4.16). 
The data suggests that, the affinity-purified sample contained 50-times more 
anti-NIP ScFv activity than the fresh  supernatant.
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Finally, the purity o f the affinity-purified fraction was assessed by 
SDS-PAGE analysis (section 2.8.3.3). The SDS-PAGE gel was stained with 
Coomassie blue and the resulting banding pattern is presented in Fig. 4.19.
Fig. 4.19: The affinity- 
purified anti-NIP
ScFv was run through 
a SDS-PAGE gel and  
stained with
Coomassie Blue, as 
described in section 
2.8.3.3. Although one
major band was Mw afWv ourified anti-wip
evident at 31kDa, and was tentatively identified as the anti-NIP ScFv, many 
other contaminating proteins were present in this preparation. (Fractions 
containing anti-NIP ScFv, affinity-purified from  the periplasmic lysate, were 
run in the unlabelled lanes).
The result was quite disappointing. As expected one major band occurred at 
31kDa, the expected size o f a ScFv. However, many other higher molecular 
weight bands were evident with one or two minor low molecular weight bands. 
A rough assessment suggested that, the affinity-purified fraction was 
composed of only 50% (w/w) ScFv - the remainder being composed of 
contaminating proteins.
Although not ideal for in vivo immunisation, it was felt that, overall, it 
was not worthwhile investing time and effort to further improve the purity; 
accordingly, this fraction was used as the immunogen to generate the anti-NIP 
ScFv antiserum.
4.2.3.2 G eneration of the anti-N IP ScFv antiserum : The protocol used to raise an 
antiserum to the affinity-purified anti-NIP ScFv is described in section 2.9.2.
In Figs. 4.20-4.22, the anti-(anti-NIP ScFv) activity o f  the various bleeds are
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compared. The tertiary bleed showed a similar titration curve to  the secondary 
bleed. As a result, the rabbit was killed at this stage and its antiserum 
collected.
4.2.3.3 Serological identification o f the pp6 gene product using the  anti-N IP ScFv 
antiserum : pp6 was transfected into the BHK cell line as previously described 
(section 4.2.1). 48hrs later, the cell population was analysed for expression o f 
the gene product using the anti-NIP ScFv antiserum, essentially as described in 
section 2.8.2.2. The antiserum, at a dilution o f 1:1000, was used as the 
primary probe, rather than the anti-c-myc. Also, a FITC-anti-rabbit IgG 
secondary antibody was used, at the manufacturer's recommended dilution. A 
typically stained cell is shown in Fig. 4.23. This experiment provided final, 
conclusive proof that, the desired intrabody was, indeed, being expressed, 
apparently in the cytosol. On the other hand, it was equally clear that, the poor 
expression levels indicated by the anti-c-myc probe were genuine and not due 
to selective degradation o f the c-myc tag. Using the anti-NIP ScFv antiserum 
under these conditions, only 5 times as many cells were detected as positive 
for intrabody expression compared with when the anti-c-myc probe was used 
(see appendix B).
The anti-NIP ScFv antiserum was also used to probe four of the panel 
of 19 stably transfected cell lines (N8, N9, N10 and N12) in the belief that this 
probe was more sensitive than the c-myc probe. When these four cell lines 
were analysed, immunocytochemically, no conclusive evidence o f pp6 
expression was found. N9 did appear to be very slightly positive for 
expression but the fluorescence was too faint to document photographically.
As indicated by Fig. 4.14, cell extracts had been prepared, according to 
section 2.8.3.1, from some o f the stable transfectants (N1-N12) during their 
initial propagation. These were probed with the antiserum by blotting as 
described in sections 2.8.3.3-2.8.3.5. All extracts were negative (results not 
shown). In retrospect, and aside from the low expression level o f  the pp6 
intrabody, this is not too surprising. Greenman et al. (1996) have reported that 
NP40 lysates o f cell lines stably transfected with an intrabody contained very 
little detectable ScFv. However, much more ScFv was detected when whole
cell lysates were generated using SDS sample buffer.
193
C
04
05
nm
Fig. 4.20 Fig. 4.21
dlution of bieecfe
dilution of bleeds
Fig. 4.22
Figs. 4.20-4.22: A rabbit was 
immunised with the affinity-purified 
anti-NIP ScFv, as described in 
section 2.9.2. The anti-(anti-NIP 
ScFv) activity o f  the various bleeds 
was titrated by ELISA. The tertiary 
bleed showed a titre o f  at least 
1:500,000 (Fig. 4.22) and was
dilution of bleedsmuch higher in all probability. (The 
titre is defined here as the highest
dilution used which gave an OD 405nm reading significantly greater than the 
background). Also, the tertiary and secondary bleeds gave similar titration 
curves. Therefore, the rabbit was killed at this stage and its antiserum 
harvested (section 2.9.2).
ELISA: The ELISA was carried out as described in section 2.8.1.1. A  
lOpg/ml solution o f  the affinity-purified anti-NIP ScFv was used as the coating 
antigen. An alkaline phosphatase conjugated to goat anti-rabbit IgG was used 
as the secondary antibody a t the manufacturer's recommended dilution.
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Fig. 4.23: A typical BHK cell expressing pp6 gene product is presented in the 
above photograph (lOOOx magnification). The gene product was detected with 
the anti-NIP ScFv antiserum at a 1:1000 dilution and a FTTC-anti-Rabbit IgG 
at the manufacturer’s recommended dilution. A t any higher concentration, the 
anti-NIP ScFv antiserum gave rise to unacceptable levels o f  non-specific 
background. Again, the gene product was in evidence throughout the entire 
cell, as was expected fo r  a small cytosolic protein.
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4.3 Conclusions
The ultimate aim o f all the intrabody studies reported in this thesis (this 
chapter and chapter 5) was to generate an intrabody library, for the purposes 
described in section 1.4.4.1. To this end, the studies recorded in this chapter 
were carried out to validate a generic strategy for targeting Nissim ScFvs to 
eukaryotic cytosols. The results o f this study, while not as good as one might 
have hoped, give cause for guarded optimism with regard to the feasibility o f 
intrabody libraries. In so far as one can tell using light microscopy, an anti- 
NIP intrabody was clearly expressed in the cytoplasm. However, the 
expression levels appear to be very low presumably due to a very short 
intracellular half-life. While, it would be advantageous to be able to argue 
that, the low expression levels observed are atypical and due to the particular 
intrabody under study, this is not the case. The anti-NIP intrabody appears to 
be quite average, neither over- nor under-expressed relative to the majority o f  
potential intrabodies. This statement will be justified in chapter five.
The low expression levels observed have obvious ramifications for any 
application o f cytosolic intrabody libraries - in order to favour phenotypic 
knockout o f any intracellular protein, one ideally requires that the intrabody be 
expressed in as high an intracellular concentration as possible. This ensures 
that the antibody-antigen equilibrium favours formation o f the
antigen: antibody complex. High expression levels are, probably, a prerequisite 
for any application o f intrabodies, but the requirement is more severe in the 
case o f libraries. This is because, while intrabodies to a specific protein can be 
chosen to have a very high affinity, intrabody libraries will only contain 
intrabodies o f mediocre affinity at best. Hence, one would have to conclude, 
based on current ScFv designs, that cytosolic intrabody libraries are not 
feasible.
This being the case, why the optimism? One remains optimistic for a 
number o f reasons. Firstly, these studies have not addressed the feasibility o f 
targeting intrabody libraries to other sub-cellular locations. As discussed in 
section 1.4.1, the cytosol appears to be the most inimical environment for 
intrabody expression. Based on observations reported in the literature, 
targeting o f the nucleus, ER or mitochondria - locations o f equal importance to
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the cytosol- might be expected to lead to far superior expression levels (Biocca 
and Cattaneo, 1995).
Secondly, there is reason for cautious optimism that, in the long term, 
cytosolic intrabody libraries may be feasible. Current problems with the 
expression of ScFvs in the cytosol appear to stem from the fact, that natural 
variable regions have evolved over millions of years for expression in the 
endoplasmic reticulum, an organelle quite different in character from the 
cytoplasm. It may be possible, however, starting from 'natural' ScFvs (i.e. 
those based on naturally occurring variable regions) to engineer artificial 
'variable region molecules' capable o f  high level expression in the eukaryotic 
cytosol.
Before discussing potential strategies to accomplish this, the 
assumption is made that the major reason for the short half-life o f cytosolic 
intrabodies is the inability o f the ScFv to fold in this environment. More 
specifically, the ScFv cannot form the requisite disulfide bonds for variable 
domain stability. This is a reasonable working assumption (Worn and 
Pluckthun, 1998), backed up by some experimental evidence (Biocca et al., 
1995). Such abnormal ScFvs are likely to be quickly degraded in the cytosol 
by the ubiquitin-dependent proteolytic pathway (Dice, 1987). By analogy with 
observations made in the bacterial cytoplasm, these abnormal ScFvs may also 
aggregate to form insoluble inclusion bodies.
Another potential reason for the low expression levels is that, the 
cytoplasm and the associated lysosomes are the major intracellular site o f 
protein degradation. Even correctly folded ScFv may be expected to degrade 
with far greater rapidity in this environment than the endoplasmic reticulum.
These considerations suggest that, it is necessary to  make the ScFv 
folding reaction more thermodynamically and kinetically favourable. It would 
also make sense to increase the solubility o f  the native ScFv and its folding 
intermediates. Studies to increase the resistance o f the intrabody to proteolysis 
would be desirable, also. Such ideas are guiding the molecular evolution o f 
ScFvs, using a combination o f rational design and random mutagenesis.
The intrabody design presented in this chapter has both good and bad
aspects with regard to its susceptibility to proteolysis. The intrabody is
expected to have a Met amino acid at its n-terminus. This is expected to
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protect the protein from cytosolic proteolysis, to some extent (Dice, 1987). 
However, as noted earlier in the chapter, the c-myc tag at the intrabodies C- 
terminus can be expected to decrease the half-life o f  the intrabody. The C- 
terminal extensions possessed by a protein are known to be an important 
determinant o f half-life (Bowie and Sauer, 1989) and it is worth noting that, 
one generally applicable strategy for increasing the stability o f cytosolic 
intrabodies has been the use o f selected C-terminal tags. The addition o f a 
constant domain to the ScFv has been advocated (Mhashilkar et a l, 1995; 
Jannot and Hynes, 1997). Schouten et al., (1996 and 1997) reported that the 
addition o f the ER-retention tetrapeptide KDEL increased the expression o f 
two different ScFvs in the cytosol o f tobacco protoplasts. The reason(s) for the 
increases in intrabody stability were not determined. One suggestion 
(Schouten et al., 1997) was that, these C-terminal tags actually prevent the 
action o f exonucleases acting at this terminus.
Pluckthuns group has provided the most elegant examples o f  ScFv 
evolution. Two relevant examples are discussed below.
Nieba et al. (1997) have pointed out that, the variable/constant domain 
interfaces o f the whole antibody are exposed in the ScFv format. This 
interface is very hydrophobic and these authors have demonstrated most 
elegantly that, replacing selected hydrophobic residues with hydrophilic ones 
increases, dramatically, the solubility o f  the folding intermediates. The result 
was that, the particular ScFv under study, in mutated form, accumulated in the 
cytoplasm o f E. coli at 25 times the level o f  the wild-type.
More recently, two papers (Proba et al., 1998; Worn and Pluckthun, 
1998) have demonstrated that, when the disulfide-forming cysteine residues o f 
two different ScFvs were replaced with valine - alanine, the mutant ScFv 
showed a greater thermodynamic stability than the reduced wild-type. These 
authors have suggested that, this may be a generically applicable strategy to 
increase intrabody stability in the cytoplasm o f eukaryotic cells.
Two major points are evident from these studies. Firstly, the
expression o f individual ScFvs in harsh ectopic environments, such as
bacterial and eukaryotic cytosols, may be improved by molecular evolution
techniques. Secondly, in the long term, these techniques may lead to the
design/selection of 'super-frameworks'. These frameworks would offer
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increased resistance to proteolysis and improved folding characteristics 
(Hudson, 1998; Worn and Pluckthun, 1998). They would form the basis o f 
'CDR-graft' libraries (Worn and Pluckthun, 1998), suitable for use as intrabody 
libraries.
The tools developed and reported in this chapter (the anti-c-myc and 
the anti-NIP ScFv antiserum, the cytochemical assays for intrabody expression 
level), in conjunction with the library technology to be reported in the next 
chapter, may make the anti-NIP intrabody an attractive model with which to 
test out some o f the ideas promulgated above. Derivatives o f the anti-NIP 
intrabody could be created and their expression level relative to the parental 
anti-NIP intrabody assayed by transfection into the BHK cell line followed by 
immunocytochemical analysis with the anti-(anti-NIP ScFv) probe. 
Specifically, in the immediate future it will prove possible to remove the c- 
myc tag from the anti-NIP intrabody described in this chapter and, 
subsequently, determine whether expression levels are improved. Taking this 
approach to its logical conclusion one could equip the anti-NIP moiety with a 
variety o f C-terminal tags and assay their expression levels. In this regard, a 
review of the literature to determine stabilising C-terminal tags may facilitate 
the rational redesign of the anti-NIP intrabody. Alternatively a random 
approach could be pursued, whereby the MIK2 primer is redesigned to contain 
random sequences o f nucleotides at its 5' end. The product o f a PCR with such 
a mixture o f primers would be a gene library encoding the anti-NIP ScFv 
moiety attached to random c-terminus tags. Stabilising tags would then be 
isolated from the library. A similar approach may reveal stabilising n-terminus 
tags.
Equally, one could redesign the anti-NIP intrabody so that it contains 
the amino acid substitutions suggested by the work o f  Nieba (1997) and Proba 
et al. (1998). Indeed, given that the amino acid substitutions suggested by 
these authors were selected in bacteria, it may prove fruitful to repeat their 
experiments and select stabilising substitutions in the eukaryotic cytosol. 
Many other approaches to improve the expression level o f the anti-NIP 
intrabody can be articulated, including rational design based on the structures 
and sequences o f intrabodies reported as successfully knocking out their 
complementary ligands.
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The value o f such studies should not be underestimated. Ideally, the 
design modifications resulting from studies with the anti-NIP intrabody could 
be generally applied to increase the stability o f any cytosolic intrabody. I f  the 
resulting increases in intrabody stability were sufficiently large, cytosolic 
intrabody libraries based on such designs may become feasible. Given the 
poor expression levels observed in this study, this may be a lot to expect. 
However, even modest increases in cytosolic stability might make all the 
difference to the effectiveness o f intrabodies designed from antibodies selected 
to specific proteins, e.g., the HIV protein Rev with consequences for, in this 
instance, therapeutic efficiency. The worst case scenario would be where the 
design modifications proved to be effective only for the anti-NIP intrabody. 
Even if this came to pass, the types o f techniques used to improve the stability 
o f the anti-NIP intrabody could be applied to any other relevant intrabody in 
order to provide 'tailor-made' modifications resulting in higher expression 
levels.
It may be argued that the potential for remodelling cytosolic 
intrabodies (libraries or particular intrabodies) in order to enhance their 
stability has been overstated. Whether or not this is so will only become 
apparent by putting the above ideas into practice. In the case o f intrabodies 
targeted to specific proteins, it may also be argued that attempts to enhance 
their effectiveness by increasing their stability is futile to begin with, as it may 
be accomplished at the expense o f binding site activity. The problem is 
acknowledged. Some o f the proposed modifications such as C-terminal tags 
can reasonably be expected to increase stability without significantly reducing 
the binding activity o f  the intrabody. Problems may be expected to arise when 
one modifies framework residues. As noted in section 1.1.1.3, residues in the 
framework can affect the conformation o f the CDRs. Equally, in some 
antibodies, framework residues may actually participate in binding antigen 
(section 1.1.4). Thus, mutating a framework or, perhaps, replacing a 
framework may or may not affect the binding activity o f  an intrabody. Thus, it 
is true to say, that not all mutations increasing the stability o f  a particular 
intrabody can be expected to result in enhanced phenotypic knockout. 
Notwithstanding, the selection o f mutants, which enhance the stability o f
particular intrabodies is still considered relevant. While not all mutants
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enhancing intrabody stability will increase the potential for phenotypic 
knockout, all mutations enhancing phenotypic knockout can be expected to 
result from an increase in stability. Thus, selecting mutants to increase 
stability may be a useful first step in screening for mutants enhancing 
phenotypic knockout.
Increasing the stability of cytosolic intrabodies is almost certainly a 
long-term aspiration. The strategies proposed to  achieve this are not trivial; 
neither are they guaranteed success. However, there are many potential 
benefits to be gained, which may justify undertaking the relevant studies. The 
tools reported in this chapter may usefully play a role in these studies.
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CHAPTER 5 
GENERATION OF AN INTRABODY LIBRARY
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It was highlighted in the previous chapter that, high expression levels 
of the constituent intrabodies are an essential pre-condition, if  the intrabody 
library concept is ever to become feasible. An equally important pre-requisite 
is that the library be sufficiently diverse and the work to be presented in this 
chapter stemmed from a consideration o f how diverse it should be.
Diversity is hugely important for the simple reason that, the more 
diverse the library, the greater the expected affinities o f its constituents for any 
randomly chosen antigen. For any intrabody, it is the combination o f its 
affinity and intracellular concentration that will determine whether it 
successfully 'knocks-out' its complementary ligand. Looked at from this 
perspective, it may seem that the library could never be too diverse. While this 
may very well be true, in practice there is an upper limit to the number o f 
different specificities, which can be transfected into a population o f eukaryotic 
cells (one can only work with a limited number o f cells). This upper limit is 
lxlO7 specificities, approximately, so as an initial goal, the potential for 
generating a cytosolic intrabody library, containing lx l  07 different 
specificities, was investigated.
Viewed retrospectively, in light o f the results presented in chapter four, 
this work might seem premature. However, while there is no hope o f applying 
the cytosolic library to be described in this chapter, as originally envisaged, it 
may yet prove useful for molecular evolution studies. Furthermore, the 
technologies and ideas developed during these studies should aid the design o f 
intrabody libraries targeted to locations other than the cytosol.
Exonuclease-based PCR-cloning: An initial consideration o f  the problem of 
constructing a cytosolic intrabody library suggested that, two modifications to 
the strategy used to generate the anti-NIP intrabody were required. The first 
modification was trivial. Plasmid prepared from the entire Nissim library 
rather than one isolate was required for the PCR (see Fig. 4.2).
The second modification involved finding a more efficient alternative 
to TA-cloning o f PCR product. The reason for this was as follows. If  the 
intrabody library was to contain lxlO 7 specificities, a library consisting o f at 
least lxlO7 independent transformants, containing insert in the correct 
orientation, was required. Referring to section 4.1.2, TA-cloning resulted in
only 350 transformants from 36ng o f ligation reaction product. Furthermore, 
as only two o f seven colonies tested contained the insert in the correct 
orientation, only 100 o f the 350 colonies were relevant. This experiment used 
chemically competent cells. Even using the most efficient electroporation 
competent cells, one could only expect a 50-fold increase in the number of 
transformants obtained (5000 transformants per 36ng o f ligation product). 
Thus, to create a library o f the desired size using TA-cloning, the 'brute-force' 
cloning of *  72(xg o f ligation product would be required. This was not 
practical and necessitated a TCR-cloning' strategy o f greater efficiency than 
'TA-cloning'.
The inefficiency o f  TA-cloning has as its root cause, a dependency 
upon very short (one base) complementary 'sticky-ends'. A review o f  the 
literature revealed that by careful choice o f the sequences at the 5' end o f PCR 
primers, much longer 'sticky-ends' could be generated by post-reaction 
modification o f the PCR product. These strategies include 'ligase-free' 
subcloning (Schuldiner et al., 1991), exonuclease-based strategies (Stoker, 
1990; Kuijper et al., 1992; Hsiao, 1993), restriction cut-back (Kaufman and 
Evans, 1990) and heterostagger cloning (Liu, 1996).
The strategy o f Kuijper et al. (1992) was o f particular interest as it was 
highly efficient, involved directed-cloning and produced very low non­
recombinant backgrounds. This strategy as applied to create an intrabody 
library is depicted in Fig. 5.1. Two new primers designated MIKL1 and 
MIKL2 were designed. These differed from MIK1 and MIK2 in that they 
contained additional 5' sequences. Thus, they were expected to amplify the 
same sequence as the parental primers. It was important that these additional 
sequences were composed, primarily, o f only three o f the four possible 
nucleotides. The missing nucleotide was dTTP. As Fig. 5.1 makes clear, 
when the purified PCR product is incubated with T4 DNA polymerase, with 
dATP as the sole nucleotide present in the buffer, the 3'-5' exonucleolytic 
activity o f  the enzyme generates 13bp 'sticky-ends' on the PCR product. This 
is referred to as 'cut-back' o f the product. The large size o f these sticky-ends, 
combined with the fact that, their sequences differ on the sense and antisense 
strands, underlies the highly efficient, directed-cloning o f the product.
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A G G G A G A C C G G A A T----- ►  ------------------------------------------- A A TTC TG TG C TC TG TC  PCR product
TC C C  TC  TG G CCT T A --------------------------------------- <4------  TTA A G A C A C G A G A C A G
MDC2
T4 DNA polymerase and dATP
▼
A G G G A G A C C G G A A T----- ►  ------------------------------------------ A A
A --------------------------------------- M------  TTA A G A C A C G A G A C A G  Cut-back PCR product
A G C TA T A A TTC TG TG C TC TG TC A A TT Cut-back pM IK
TC G A T A TC C C TC TG G C C TT A A  TT A A
▲
T4 DNA polymerase and dTTP,
EcoBl restriction
MTK1
-----------------A GCTA TA GGGA GA CCGGAA TTCTGTG CTCT GTCAATl---------------------------------- p M  IK
---------------------TCG ATATCCC TC TGGCCTTAAGACACGAGACAGTTAA----------------------------------
Fig. 5.1 : The exonucleolytic cloning strategy used to generate an intrabody library is depicted in the above diagram. pM IK is 
described in appendix A and section 5.1.1. The synthetic duplex DNA used to create pM IK is shown in italics with the EcoRl 
restriction site underlined. Sequences removed by the 3 -5 ' exonucleolytic activity o fT 4  DNA polymerase are shown in blue.
No mammalian expression vector was available that could be modified 
to produce complementary sticky-ends. Therefore, the eukaryotic expression 
vector pcDNA3.1+ (see appendix D for plasmid map and sequence) was 
modified by inserting duplex DNA into its multiple-cloning-site, and the 
resulting vector was termed pMIK (see appendix A). The sequence o f the 
duplex DNA was chosen so that, restriction by EcoRI followed by cut-back, 
would reveal sticky ends complementary to those on the cut-back PCR product 
(Fig. 5.1).
5.1.1 Creation of pM IK : pcDNA3.1+ was transformed into E. coli ToplOF' 
according to the manufacturer's instructions; one transformant was picked as a 
source o f this plasmid. Ultrapure plasmid was purified from this clone 
according to section 2.7.2.2. pMIK was generated, by inserting a synthetic 
duplex DNA oligonucleotide into doubly-digested {HindlTL and £coRI) 
pcDNA3.1+, as described in section 2.7.5.1, and depicted in appendix A.
The synthetic duplex DNA inserted, was designed to contain two 
sticky-ends, one complementary to HindUl and one complementary to EcoRI 
sticky-ends. Although complementary, they did not have the ability to recreate 
these restriction sites. The synthetic DNA did, however, contain an internal 
EcoRI site. Thus, the recombinant plasmid was expected to have lost the 
unique HindlTL site and retain a unique EcoRI site.
As noted in section 2.7.5.1, transformants had to be analysed by 
restriction digest in order to identify a transformant containing a recombinant 
plasmid. Screening for recombinants was carried out, by digesting plasmids in 
two separate reactions with HindUl and EcoRI. 8 transformants were screened 
in this fashion and the results are depicted in Fig. 5.2. In total, half of the 
colonies contained recombinant plasmids; one colony was maintained and its 
plasmid referred to as pM IK
5.1.2 PCR: Initially, in order to test the two new primers, MIKL1 and MIKL2 were 
substituted for MIK1 and MIK2, respectively, in the PCR described in section
4.1.1. Fig. 5.3 demonstrates that these primers worked just as efficiently as 
their parental primers.
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Figs. 5.2: Plasmid preparations from  8 different transformants (numbered 1-8) 
were restricted with EcoRI or H indlll (lanes labelled a) in two separate 
reactions. I t was evident that the plasmids 1-4 were non-recombinant as they 
were restrictable by both restriction enzymes. However, plasmids 5-8 were 
only restricted by EcoRI and were considered recombinant. That colony from  
which plasmid 5 was isolated was maintained and the plasm id was named 
pMIK. (The M w markers are as described in Fig. 4.3).
Fig. 5.3 : Two PCRs were set up, 
essentially as described in section
2.7.3.1. Both PCRs contained ultrapure 
p H en-V l + anti-NIP as template DNA.
One PCR (lane 2) contained MIK1 and  
MIK2 as primers, while the other (lane 
3) contained MIKL1 and MIKL2 as 
primers. The products o f  the PCRs were 
size-fractionated by gel electrophoresis.
Both sets o f  primers gave a very similar product as expected. However, the 
product produced by amplification with MIKL1 and A4IKL2 was slightly 
larger. This was as expected as the MIKL1 and MTKL2 primers are each & 
14bp longer thanM IK l andMIK2.
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In order to generate a 'PCR-library' o f  intrabody genes, suitable for 
exonucleolytic cloning, DNA was purified from the Nissim library, rather than 
one isolate. 50|_il o f Nissim library glycerol stock (108 bacteria) were grown 
overnight in 10ml of 2xTY medium supplemented with glucose and 
carbenicillin to final concentrations o f 1% (w/v) and 100p.g/ml, respectively. 
Plasmid was purified from this culture according to section 2.7.2.1. The 
plasmid was restricted, subsequently, with EcoRI, and gel purified according 
to section 2.7.2.1.
15 PCRs were set up, according to section 2.7.3.2, using this source of 
template DNA and MIKL1 and MIKL2 as primers. The reason for using Pwo 
polymerase was that, the 5' overhangs generated by Tag polymerase could 
have inhibited cut-back of the PCR product. A random sample (6) of the 
PCRs were analysed by gel electrophoresis (Fig. 5.4). They worked perfectly 
and all PCRs were combined. The reaction product was purified using a PCR 
cleanup kit, according to the manufacturer's instructions, and eluted in 60j_il o f 
TE buffer, pH 8.0. The concentration o f purified PCR product was estimated 
by gel electrophoresis at 0.125mg/ml.
5.1.3 pM IK  cut-back: pMIK was restricted with EcoBl and cut-back as described 
in sections 2.1 .52  and 2.7.5.3, respectively. No analytical technique was 
available to assess the success or otherwise o f  this reaction. It was simply 
assumed to have occurred.
5.1.4 PCR  cut-back: This was carried out according to section 2.7,5.4. Again the 
reaction was assumed to have occurred.
5.1.5 Ligation of cut-back p M IK  with cut-back PCR: This reaction was carried 
out as described in section 2.7.5.5. This reaction was analysed by gel 
electrophoresis (Fig. 5.5) and appeared to be quite successful.
5.1.6 Transformation: Transformation o f the product o f  the ligation reaction into 
E. coli XLl-Blue MRF' took place according to section 2.7.5.6. The size of 
the library was estimated, by plating, as 1.3xl07 independent clones.
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Fig. 5.4 : 15 PCRs were set up as described in section 2.7.3.2. Ultrapure 
plasmid DNA isolated from  a sample o f  the Nissim library was used as the 
template DNA. MIKL1 and MIKL2 were used as forward and reverse primers, 
respectively. 6 o f the PCRs were chosen at random, and their product was 
size-fractionated by gel electrophoresis (lanes 1-6). The PCRs worked very 
well. Only one major band was evident and it occurred where one would 
expect an 810bp product to occur.
Fig. 5.5 : Cut-back PCR product was ligated to cut-back pM IK as described in 
section 2.7.5.5. The product was restricted with EcoRV and, subsequently, 
size-fractionated by gel electrophoresis (lane 3). Cut-back pM IK was also run 
through the gel (lanes 1 and 2) as were molecular weight markers. This vector 
was expected to be ~5432bp in size (this is the stated size ofpcDNA3.1+), an 
expectation confirmed by the gel. The ligation product, as expected, appeared 
to be o f higher molecular weight than the cut-back vector. The ligation 
reaction appeared to have gone to completion as indicated by the fact that 
only one major band was evident.
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Figs. 5.6 : Plasmids were purified from  10 different transformants and  
restricted with EcoRV (lanes numbered 1-10). M w markers were also run on 
the gel, as indicated in the margins o f  the pictures. The plasmids were 
expected to be & 6,250bp in size i f  they were recombinant. I f  non­
recombinant, they were expected to be & 5432bp in size. A ll the above 
plasmids appear to be recombinant by this criterion. Note that, in one case 
(plasmid run in lane 9) the plasm id appeared to contain an EcoRV site in its 
insert, as two bands are evident in this lane.
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In order to determine the percentage o f these colonies that contained 
recombinant plasmids, plasmids from 10 colonies were purified, restricted 
with EcoKV  (unique site in both pcDNA3.1+ and pM K ), and their size was 
estimated by gel electrophoresis (Fig. 5.6). All 10 colonies appeared 
recombinant according to this criterion. Subsequently, a mock ligation was set 
up (no cut-back PCR product) exactly as per section 2.7.5.5. The product o f 
this ligation reaction was transformed into E  coli XL 1-Blue MRF' exactly as 
described in section 2.7.5.6. The number o f clones which resulted was only
0.2% o f the number o f clones in the library. This suggested that the library 
consisted o f 99.8% recombinant transformants.
Overall, it was evident that the strategy used to generate the library had 
been extremely successful from the points o f view o f library size and 
percentage recombinants. This success can be attributed to three factors. 
Firstly the use o f the highly efficient exonucleolytic cloning strategy, secondly, 
the use o f a large scale ligation reaction, and thirdly, the use o f high efficiency 
(>5xl 09 transformants per pig o f DNA) electrocompetent cells. The problem 
of describing the diversity o f  this library is discussed in the next section.
5.2 L ibrary  diversity: Having produced the library, an attempt was made to 
estimate how diverse it was. The diversity o f any library is bound at its upper 
end by the diversity o f  its starting material. The starting material for the 
intrabody library was the Nissim library which, probably, contains 1x10s 
specificities. For the sake o f argument, this discussion proceeds under the 
assumption that, it was composed of this number o f different specificities.
Having established an upper limit, it should be noted that, at each step 
o f library construction you lose diversity. In this section, in as far as is 
possible, this loss o f diversity is modelled.
5.2.1 Bacterial growth: 50(il o f  the Nissim library glycerol stock (lx lO 8 bacteria) 
was used as the starting material for the intrabody library. Probablity theory 
indicates that this sample o f the Nissim library did not contain lxlO 8 different 
specificities. The number o f specificities can be calculated as a function o f 
sample size, for any degree o f  certainty (Fig. 5.7). The relevant model is:
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5.2.2
1-P= (z /lx l0 8)n
where P is the probability o f  picking, in n attempts, a new specificity from 
lx l  08 specificities, and z is the number o f different specificities already 
picked.
Fig. 5.7: This graph 
depicts, a t the 95% 
confidence level, the 
number o f
specificities (z), as a 
function o f  sample 
size (s) when one is 
sampling the Nissim  
library. Values o f  z 
fa , z2, z3....) were 
calculated fo r  each 
value o f  n (nj, » 2, 113. . . . ) .  The corresponding values o f  s  fa , S2, S3 . . . . )  were 
calculated using the following formula: sr = zi + 27 ((nr-i+nr)/2)zr.
Using this graph, it is evident that, the sample o f  the Nissim library chosen, 
contained 3x107 different specificities. Bacterial growth occurred in the 
presence o f glucose to inhibit expression o f ScFv. As a result, it is assumed 
that no selective pressure reduced library diversity during the growth of the 
sample. The final plasmid preparation was expected, therefore, to contain 
3xl07 different specificities at an average frequency o f l/3 x l0 7.
PCR: The next step involved selecting a sample o f plasmids for use as 
templates during the PCR. Fig. 5.8 similar to Fig. 5.7 depicts diversity as a 
function o f sample size. It was calculated exactly as for Fig. 5.7, from the 
formula:
1-P = (z/3xl07)n.
sample size
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Fig. 5.8 : This graph depicts the number o f  specificities (z) as a  function o f  
sample size (s), when one is sampling from  a population o f plasmids encoding 
3x1O7 different specificities. See the legend to Fig. 5.7 fo r  further details.
The sample size for the PCR reaction was 1.5xl07 template molecules (15 
PCR reactions each containing lx l0 6 template molecules). The above graph 
indicated that this sample only contained 9x106 different specificities.
Unfortunately, no data is available with regards to the efficiency o f the 
PCR reactions. Therefore any loss o f diversity during amplification cannot be 
modelled. This discussion proceeds on the assumption that, the PCR reactions 
were 100% efficient, and that no loss o f diversity occurred. Although this may 
seem to be a major assumption, this is balanced, to some extent, by the use of a 
very cautious 95% confidence limit while modelling the loss o f diversity due 
to sampling effects.
.3 Ligation: It is assumed that no significant loss of diversity occurred during the 
ligation step. This is a reasonable assumption, given the number o f molecules 
ligated in comparison with the number o f specificities, and the efficiency of 
ligation.
.4 Transform ation: The loss o f diversity upon transformation is again due to 
sampling effects. The relevant equation is:
1-P = (z/9xl06)n
and the relevant graph o f number o f specificities (z) versus the sample size (s) 
is depicted in Fig. 5.9.
sample size
Fig. 5.9 : The graph o f number o f  specificities (z) versus sample size (s), 
calculated from  1-P = (z/9xl06) n is depicted. See the legend to Fig. 5.7 fo r  
further details.
This graph allowed one to estimate the final diversity o f the intrabody library. 
The number o f transformants (equivalent to sample size) was 1.3xl07. Thus, 
the library was expected to contain 3x l06 different specificities.
Im m unocytochem ical analyses
The gene products expressed by the library were identified serologically, by 
immunocytochemistry, for two reasons. Firstly, to ensure that the gene 
products were expressed as and where expected. Secondly, it was considered 
that such studies would allow one to infer whether the expression levels 
attained by the anti-NIP intrabody were average or otherwise. If  this intrabody 
was atypically stable or unstable, one would expect a decrease or an increase, 
respectively, in the percentage o f BHK cells expressing detectable levels o f 
library gene products.
These studies were carried out as described in section 4.2. A  maxiprep 
o f library DNA was prepared as described in section 2.7.2.2. The DNA was 
transfected into the BHK cell line as described in section 2.5.8.1, using
previously optimised conditions (section 4.2.1). After 48 hrs the resulting cell 
population was probed with either anti-c-myc or the anti-NIP antiserum, as 
previously described in section 4.2.2 and 4.3.2.3, respectively.
Figs. 5.10 and 5.11 show typical cells expressing library gene product 
as detected with anti-c-myc (Fig. 5.10) and anti-NIP antiserum (Fig. 5.11). 
These studies led to three conclusions. Firstly, they indicated that the gene 
products were, apparently, ScFvs expressed in the cytosol. They allowed the 
positive identification o f the gene products as cytosolic intrabodies. Secondly, 
it was evident that, the anti-NIP antiserum appeared to have a general ability to 
detect ScFvs from the Nissim library. This was quite a surprising observation 
at first. However, the Nissim library contains only the one light chain variable 
domain. It is this feature, shared by all Nissim ScFvs, which, presumably, 
facilitates the detection of Nissim ScFvs by the antiserum. Thirdly, and 
without carrying out a detailed experimental comparison, the number o f BHK 
cells expressing library gene product was strongly reminiscent o f the numbers 
expressing pp6 gene product. This was taken as evidence in favour o f the anti- 
NIP intrabody being relatively average, in terms of expression level.
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Fig. 5.10: This photograph was obtained by probing a BHK cell population, 
which had been transfected with intrabody library DNA, with anti-c-myc as 
previously described (see section 4.22 and Fig. 4.10). The entire cell was 
diffusely stained, the nucleus to a lesser extent than the cytoplasm.
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Fig. 5.11: This photograph was obtained under similar conditions to that 
presented in Fig, 5.10. However, the anti-NIP antiserum was used as a probe 
(see section 4.3.2.3 and Fig. 4.23) rather than the anti-c-myc. The staining 
pattern here is quite similar to that o f  Fig. 5.10. In contrast to that 
photograph, two distinct areas o f  the nucleus are stained to a lesser extent 
than the remaining portion. These two areas were not identified but may 
represent the nucleoli.
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5.4 Conclusions
The first conclusion reached from the series of experiments reported in this 
chapter, is more pertinent to chapter four and the topic o f intrabody expression 
levels, than it is to this chapter and the topic of diversity. This was that the 
expression levels achieved by the anti-NIP intrabody were representative of 
those achievable by Nissim ScFvs, in general. Quite clearly, based upon 
expression levels alone, it is not feasible to use this cytosolic library as 
envisaged initially.
Equally, a number o f useful points emerged, with respect to the 
creation o f highly diverse intrabody libraries. Firstly, the library construction 
strategy presented in this chapter is, probably, sufficiently efficient to allow 
the construction o f highly diverse intrabody libraries. While, the model 
presented to evaluate loss o f diversity during library construction suggests a 
severe decrease in diversity (from lxlO 8 —> 3x l06 specificities), the final 
diversity is not too far removed from the initial target o f lxlO7 specificities. 
This suggests that the target diversity can be achieved relatively easily using 
the proposed strategy. One could, for example, combine the above library 
with other libraries generated from differing sources o f variable regions such 
as splenic mRNA or the Griffiths library (Griffiths et al., 1994). Indeed, the 
model suggests that these would be a far superior source o f variable regions 
than the Nissim library, due to their greater inherent diversity (lx lO 10). In fact, 
using a primary source of such diversity, it should be possible to generate an 
intrabody library containing lx l0 7 specificities in one go.
Having made this point, it must be said that the target diversity 
proposed for intrabody libraries at the start o f this chapter was underestimated 
considerably. This became evident while modelling the loss o f diversity due 
to sampling effects during library construction. If, as originally proposed, one 
should aim to  transfect lx l  07 specificities into a population o f eukaryotic cells, 
sampling effects will require that the intrabody library contains not lx l0 7 
specificities, but 4x107 specificities.
A final point, which emerged during the modelling o f diversity, was 
that, the generation o f diversity during the PCR process would greatly aid in 
the creation o f highly diverse intrabody libraries. The Nissim ScFv library
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was constructed in such a fashion. The heavy chain CDR3 was added, 
randomly, during amplification o f the 50 germline Vh segments (Nissim et al., 
1994).
Based on the experimental evidence presented, and assumptions made, 
in this chapter and chapter four, the following conclusion can be drawn. The
7  • • • •«
generation o f intrabody libraries o f > 4x10 specificities is very possible. In 
order to accomplish this diversity, one o f two different approaches would 
ideally be used. Firstly, one could sub-clone from a phage-display library 
containing a greater diversity o f  variable regions than the Nissim library. The 
Griffith library may be suitable. Preferably, one would create a semi-synthetic 
intrabody library using, e.g., the technology used to create the Nissim library 
rather than sub-cloning from this library. While, intrabody expression in the 
cytosol is not presently feasible, these techniques, in the short-term, should 
allow the creation o f intrabody libraries targeted to a more suitable sub-cellular 
location, such as the endoplasmic reticulum. This may allow a clearer 
evaluation o f the potential o f the strategy.
Finally, it may be speculated that, the cytosolic library, and the 
technology used to generate it, may prove useful for the molecular evolution of 
stable cytosolic intrabodies, a topic previously discussed in section 4.3. The 
actual technology for generating a library is essential to some o f the strategies 
mentioned in section 4.3 aimed at redesigning the anti-NIP intrabody so that it 
accumulates in the cytoplasm at high levels. The library technology outlined 
in this chapter is eminently suited to this purpose. A final idea, which might 
be worth pursuing, is as follows. It was proposed in section 4.3, that certain 
frameworks may be inherently more stable than others in the cytosol. Such 
'super-frameworks' might form the basis for a second-generation intrabody 
library. It was suggested that one strategy for generating such frameworks was 
to mutate the anti-NIP intrabody and assay for enhanced accumulation in the 
cytosol. Perhaps certain frameworks are more stable than others, and the 
possibility that the anti-NIP framework may not be an ideal template from 
which to mould 'super-frameworks' must be entertained. One way to choose 
an improved template might be to select from the intrabody library created 
during the course o f these studies, those intrabodies that are most stably
expressed. It is entirely feasible that this could be accomplished by
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transfecting the library into BHK cells, probing the population o f cells with 
anti-c-myc, and selecting those cells most intensely stained, with a FACS 
(fluorescence-activated cell sorter). Selected ScFvs might be further improved 
(in terms o f expression levels achieved) by expressing their heavy chain 
variable domain with a library o f light chain variable domains and repeating 
the procedure. The selected ScFv would then be used in place o f  the anti-NEP 
intrabody in the mutagenesis studies suggested in section 4.3.
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CHAPTER 6 
OVERALL CONCLUSIONS
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At the start o f this thesis two major aims were outlined. The first aim 
was to initiate a study on antibody polyreactivity with particular reference to 
antibodies raised by in vitro immunisation. The second aim was to investigate 
the feasibility o f generating intrabody libraries as a source o f therapeutic 
proteins or, perhaps, a tool for functional genomic analysis.
It is felt that both o f these studies provided much useful information, 
which can be summarised as follows. The polyreactivity studies (chapter 3) 
provided clear proof, that IVI may generate polyreactive Mabs. On a more 
basic level, potential problems which may prevent the unbiased screening of 
antibody repertoires, that is to say screening without under- or over-estimating 
the extent o f polyreactive antibodies, were highlighted. An under-estimation 
may be expected if  the antibody repertoire was screened while part o f a 
complex biological matrix. Unless one is careful, however, the process o f 
purifying the antibody repertoire may create polyreactive antibodies from 
monoreactive ones, therefore over-estimating the extent o f polyreactivity. 
This may lead, in turn, to a distorted perception o f the role o f polyreactive 
antibodies in immune and, perhaps, non-immune phenomena.
The intrabody studies (chapters 4 and 5) were equally informative. 
Three main conclusions were reached. Firstly, the results suggest that the 
possibility o f creating and utilising cytosolic intrabody libraries, or, certainly, 
those based on the Nissim ScFv design, can be disregarded. Creating a 
sufficiently diverse library (chapter 5) is not a problem, but intrabody 
expression in the cytosol or, more precisely, the lack o f it (chapter 4) is a 
serious problem. Secondly, it was also pointed out, that intrabody expression 
levels could be expected to be higher in many other sub-cellular locations, 
such as the endoplasmic reticulum. It was proposed that the intrabody library 
concept could possibly be more fully evaluated by generating an intrabody 
library targeted to this organelle. Thirdly, a plethora o f strategies aimed at 
improving the expression levels o f cytosolic intrabodies were articulated. The 
tools developed during the course o f this work (anti-NIP intrabody, anti-NIP 
antiserum, the assay for intrabody expression levels and the library strategy 
developed) can now be used to investigate these strategies.
Finally, it is worth noting, that the concept o f antibody polyreactivity
impinges upon the practical use o f antibodies. In particular, the feasibility o f
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the intrabody library concept is dependent not just upon the expression levels 
and diversity o f its constituent intrabodies. It is also dependent upon their 
monospecificity. The techniques used in chapter 3 for investigating 
polyreactivity can now be applied to evaluate the quality o f  naive ScFv 
libraries, such as the Nissim library, in terms o f the extent to which they are 
composed of polyreactive antibodies. This in turn may affect the feasibility o f  
intrabody libraries.
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pcDNA 3.1+
GCGTTTAAAC TTAAGCTTGG TACCGAGCTC GGATCCACTA GTCCAGTGTG GTGGAATTCT ' 
• CGCAAATTTG AATTCGAACC ATGGCTCGAG CGTAGGTGAT CAGGTCACAC CACCTTAAGA
I
Double-digestion with £coRI and HindHI
. GCGTTTAAAC TTA 
CGCAAATTTG AATTCGA
AATTCT . 
GA
heteroduplex DNA
toL/l
AGCTATA GGGAGACCGG AATTCTGTGC TCTGTC
TAT CCCTCTGGCC TTAAGACACC AGACAGTTAA
pMIK i Ligate the synthetic duplex DNA to the restricted pcDNA 3.1+ to generate pMIK
GCGTTTAAAC TTAAGCTATA GGGAGACCGG AATTCTGTGC TCTGTCAATT CT 
CGCAAATTTG AATTCGATAT CCCTCTGGCC TTAAGACACC AGACAGTTAA GA
A
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Appendix B: Percentages of transiently transfected cells
expressing gene products.
Throughout chapter four, the percentage o f  transiently transfected cells (NIH3T3, C H O  
or B H K )  expressing detectable levels o f  either P-galactosidase from the p C H llO  
reporter plasmid, or anti-NIP intrabody from the pp6 plasmid were reported. (The 
structures and sequences o f  all plasmids are depicted in appendix D). These 
percentages are collated in Table A2.
P-galactosidase, which is stably expressed in mammalian cells, is expressed 
from the sv40 early promoter. This promoter allows efficient transcription in all three 
cell lines used (Pharmacia Biotech Technical Services, personal communication). Thus, 
the percentage o f  cells expressing detectable levels o f  P-galactosidase (as determined by 
enzyme cytochemistry - section 2.8.2.1) was taken as the transfection efficiency for that 
cell line.
Cells expressing detectable levels o f  the anti-NIP intrabody were enumerated by 
immunocytochemistry (section 2.8.2.2) and this value used to calculate the percentage 
o f  cells expressing detectable levels o f  anti-NIP intrabody as described in the footnote 
to page 181. For any given ce ll line, the ratio o f  the percentage o f cells expressing 
detectable levels o f  anti-NIP intrabody to the percentage o f  cells expressing detectable 
levels o f  P-galactosidase was taken as a measure o f  the efficiency o f  expression o f 
intrabody.
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p-galactosidase anti-NIP intrabod} anti-NIP intrabody (anti-
(anti-c-myc probe) N IP ScFv antiserum)
N IH 3T3 0.1% 0.02% N D
C H O  1% 0% N D
B H K  10-30% 0.05% 0.25%
Table A2: The percentages o f cells (NIH3T3, CHO or BHK) expressing detectable 
levels o f fi-galactosidase, from pCHHO, were determined by enzyme cytochemistry 
(section 2.8.2.1). The percentages o f cells (NIH3T3, CHO or BHK) expressing 
detectable levels of anti-NIP intrabody, from pp6, were determined by 
immunocytochemistry (section 2.8.2.2) using either an anti-c-myc probe (section 4.2.2) 
or an anti-NIP ScFv probe (section 4.2.3.3).
The poor expression level o f  the anti-NIP intrabody in  the CH O  and B H K  cell 
lines was attributed to rapid degradation o f  the protein. It could not be attributed to 
poor transcription as pp6 expresses the anti-NIP intrabody from the C M V  immediate- 
early promoter, which is very active in the three cell lines used in this study (Invitrogen 
Technical Services, personal communication).
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Appendix C: Biological Solutions.
2-Amino-2-Methyl-l-Propanol buffer: 740(iM  M gC^, 0.01% (v/v) Triton X-405, 
0.1% (w/v) NaN3, 9.85% (v/v) 2-amino-2-methyl-1-propanol.
Alkaline lysis solution 1: 25mM Tris.C l (pH 8.0), 50mM glucose, lOm M  ED T A .
Alkaline lysis solution 2: 0.2M NaOH, 1% (w/v) sodium dodecyl sulphate.
Alkaline lysis solution 3: 3M  K C 2H 3O 2, 11.5% (v/v) glacial acetic acid.
Coating buffer: lO m M  K2HPO4 , 5m M KH2PO4 , Im M  EDTA, 0.14M  NaC l, 0.05% 
(w/v) N aN 3 .
Coomassie Blue stain solution: 0.1% (w/v) Coomassie B lue R-250, 45% (v/v) 
methanol, 10% (v/v) acetic acid.
Cut-back buffer: 66m M Tris.C l (pH 7.9), 134mM K C 2H 30 2, 20mM M g C 2H 302, 
lOm M  dTT, 0.1% (w/v) gelatin, 400pM  dTTP or dATP.
Destain solution: 10% (v/v) methanol, 10% (v/v) acetic acid.
Dissection Hank's Balanced Salt Solution: 1.5mM CaCI2, 5.4mM KC1, 344pM  
K 2H PO 4, 483( iM  M g C l2, 410nM  M g S 0 4, 0.137M NaC l, 5.5mM glucose, 0.01% 
(w/v) Phenol Red, 50ng/ml gentamicin, 2.5|j,g/ml amphotericin.
Electrophoresis buffer: 25m M Tris, 0 .2M  glycine, 0.1% (w/v) sodium dodecyl 
sulphate.
Fix solution: 0.1M  phosphate buffer (pH 7.3), 0.2% (v/v) glutaraldehyde, 0.05M  
E G T A ,2 m M M g C l2.
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Gey ’s A: 0.654M N H 4CI, 0.025M KC1, 637 jiM  K 2H PO 4, 27.7mM glucose, 0.02% 
(w/v) Phenol Red, 2.5% (w/v) gelatin.
Gey's B: 20.7mM M g C l2, 6m M  M g S 0 4, 3 lm M  C aC l2.
Homogenising buffer: 60m M Tris.C l (pH 6.8), 0 .1M  dTT, 800|jM  E D T A , 2% 
(w/v) sodium dodecyl sulphate, ljxg/ml aprotinin, ljig /m l pepstatin, 50(ig/ml T LC K .
Ligation buffer: 0.1M  Tris.C l (pH 7.8), lO m M  M g C l2, 20m M dTT, 20(iM  dATP.
Lysis buffer: 0.1M  Tris.C l (pH 8.0), lm M  KC1, 525( iM  M g C l2, 0.5% (v/v) NP-40, 
l|ig/m l aprotinin, l^g/ml pepstatin, 50|ig/ml T LC K .
Rinse solution: 0.1M  phosphate buffer (pH 7.3), 2m M  MgC12, 0.01% (w/v) sodium 
deoxycholate, 0.02% (v/v) NP-40.
Sample buffer: 0.06M Tris.C l (pH 6.8), 25% (v/v) glycerol, 2% (w/v) sodium 
dodecyl sulphate, 5% (v/v) 2-mercaptoethanol, 0.1% (w/v) bromophenol blue.
Solution A: 30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide.
Solution B: 1.5M Tris.C l (pH 8.8), 0.4% (w/v) sodium dodecyl sulphate.
Solution C: 0.5M  Tris.C l (pH 6.8), 0.4% (w/v) sodium dodecyl sulphate.
Stain solution: See Rinse solution w ith 1 mg/ml 5-bromo-4-chloro-3-indolyl
phosphate, p-toluidene salt, 0.165% (w/v) sodium ferricyanide, 0.165% (w/v) sodium 
ferrocyanide.
Transfer buffer: 25m M Tris, 0 .2M  glycine, 20% (v/v) methanol.
Tris/EDTA buffer: lOm M  Tris.C l (pH 8.0), lm M  ED TA .
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Wash buffer: lOm M  Tris.C l (pH 7.4), 0.14M NaC l, 0.005% (w/v) Thimerosal,
0.1% (v/v) Tween 20.
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Appendix D: Commercial vectors used during the course of 
this study.
The follow ing pages include plasmid maps and sequences for the three commercial 
vectors used during the course o f this study. These are pCR3-Uni, pcDNA3.1+ and 
p C H llO . The maps and sequences o f  pCR3-Uni and pcDNA3.1+ are available on the 
world-wide-web at www.invitrogen.com (both vectors are supplied by Invitrogen, 
DeSchlep, Netherlands). The sequence o f  p C H llO  was obtained from the GenBank 
database, available on the world-wide-web at www2.ncbi.nlm.nih.gov. The 
corresponding map was obtained from Clontech Laboratories, Palo A lto, California, 
U.S.A., who provide this plasmid.
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pCR3-Uni: This vector was generated by removing a total o f  32bp between the 
HinAlW and EcoBI sites o f the polylinker o f  pCR3 (plasmid map and sequence are 
provided below:
Comments far ¡[>CFf”’3 
tV0fi.fi r>nck>otrctes
OMV pfomoic#: basa* i
P itm S v* T rftra a J p io n e l S w rC  ite f> -$£5
T7 pionK'hjl: *jbs«s
Multiple Ooni)>0 Si»* bas*s
8P5 pfomoMf t>»$«s 774-79‘1
BGHpeiyA: bus#* 7-W-1024
Ct>l£ 1 fcW5*s 1165-5738
TK jroly A signal bits ft* 1J23-2154
Ktinwvydn'wonmin»sistam»: b«s*s2iS5-'S1^ i
5V40 piomc'ttM.'c*)ciit«; bw»siii$£-t&4£
Aropwi^ fissistein«» tw asssSSiii^iS 
F1 origin (>©$1» 4500-505«
(Eagl>
7 7 P t» m * te t Hind Bl K.pn I Sac I* BamMl Spol* Xme Mf
TAATAa:ACTCACm AGG<^ CW VCCY;j^ W 'm ;rn7\C,CGAr<nti>GATCCftKTAG"JAAci>CK;
ATmCiC'TGAGTCJlTATCCCl’CTO^TTCtAACCATCiGCTCliAMCiAOGTOilTCA'riWCO
esixi EuoHI 
CGCCAG'Tf/hitTfidkAT TCXGCTtI 
«T><rj-cAC7 ;^«AccrrAAWxr J^ PC 3 Prcdu©
H3& < . 
■  n
E<MFfl PistJ ECORV 
JCCckftTTCTGCili^ATCC 
rrojGcrrARGACcrnrjATAGG
BstX) Kb) I X)» 1 3ph f  Msl t* ««a I Ap* I S P S  Fifjiwtlei
MTCM^WlGcbMCoAcCAdblWrATCTAC^GGCCCTA'ltjrrtX^llfi'KlTCACCmAi 
rACTCTCiWiCGCniGCGAGCTCGTfcCCrrAGATCTCCCGCGAT.WiA'IAlCACAGTGGA'ri'rft
* Sites-are na  unque (o 
I he mullfrie clcratg hIb
VI lM *107115?
U.S. Headquarters
Ts); Il-*0i>-«i5-*®» 
F*x: «H'e-5®?-62CH
European PeacDquuarters 
Tel: +3FJ iOi S&45-15175 
Fait: +31 '{0)5646-15312
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□□
10 20 30 40 50 60
□
GCGCGCGTTG ACATTGATTA TTGACTAGTT ATTAATAGTA ATCAATTACG GGGTCATTAG
70 80 90 100 110 120
TTCATAGCCC ATATATGGAG TTCCGCGTTA CATAACTTAC GGTAAATGGC CCGCCTGGCT
130 140 150 160 170 180
GACCGCCCAA CGACCCCCGC CCATTGACGT CAATAATGAC GTATGTTCCC ATAGTAACGC
190 200 210 220 230 240
CAATAGGGAC TTTCCATTGA CGTCAATGGG TGGACTATTT ACGGTAAACT GCCCACTTGG
250 260 270 280 290 300
CAGTACATCA AGTGTATCAT ATGCCAAGTA CGCCCCCTAT TGACGTCAAT GACGGTAAAT
310 320 330 340 350 360
GGCCCGCCTG GCATTATGCC CAGTACATGA CCTTATGGGA CTTTCCTACT TGGCAGTACA
370 380 390 400 410 420
TCTACGTATT AGTCATCGCT ATTACCATGG TGATGCGGTT TTGGCAGTAC ATCAATGGGC
430 440 450 460 470 480
GTGGATAGCG GTTTGACTCA CGGGGATTTC CAAGTCTCCA CCCCATTGAC GTCAATGGGA
490 500 510 520 530 540
GTTTGTTTTG GCACCAAAAT CAACGGGACT TTCCAAAATG TCGTAACAAC TCCGCCCCAT
550 560 570 580 590 600
TGACGCAAAT GGGCGGTAGG CGTGTACGGT GGGAGGTCTA TATAAGCAGA GCTCTCTGGC
610 620 630 640 650 660
TAACTAGAGA ACCCACTGCT TACTGGCTTA TCGAAATTAA TACGACTCAC TATAGGGAGA
670 680 690 700 710 720
CCCAAGCTTG GTACCGAGCT CGGATCCACT AGTAACGGCC GCCAGTGTGC TGGAATTCTG
730 740 750 760 770 780
CAGATATCCA TCACACTGGC GGCCGCTCGA GCATGCATCT AGAGGGCCCT ATTCTATAGT
790 800 810 820 830 840
GTCACCTAAA TGCTAGAGCT CGCTGATCAG CCTCGACTGT GCCTTCTAGT TGCCAGCCAT
850 860 870 880 890 900
CTGTTGTTTG CCCCTCCCCC GTGCCTTCCT TGACCCTGGA AGGTGCCACT CCCACTGTCC
910 920 930 940 950 960
TTTCCTAATA AAATGAGGAA ATTGCATCGC ATTGTCTGAG TAGGTGTCAT TCTATTCTGG
970 980 990 1000 1010 1020
GGGGTGGGGT GGGGCAGGAC AGCAAGGGGG AGGATTGGGA AGACAATAGC AGGCATGCTG
1030 1040 1050 1060 1070 1080
GGGATGCGGT GGGCTCTATG GCTTCTGAGG CGGAAAGAAC CAGTGGCGGT AATACGGTTA
1090 1100 1110 1120 1130 1140
T CCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGT GAG CAAAAGGCCA GCAAAAGGCC
261
1150 1160 1170
AGGAACCGTA AAAAGGCCGC GTTGCTGGCG
1210 1220 1230
CATCACAAAA ATCGACGCTC AAGTCAGAGG
1270 1280 1290
CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG
1330 1340 1350
GGATACCTGT CCGCCTTTCT CCCTTCGGGA
1390 1400 1410
AGGTATCTCA GTTCGGTGTA GGTCGTTCGC
1450 1460 1470
GTTCAGCCCG ACCGCTGCGC CTTATCCGGT
1510 1520 1530
CACGACTTAT CGCCACTGGC AGCAGCCACT
1570 1580 1590
GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG
1630 1640 1650
TTTGGTATCT GCGCTCTGCT GAAGCCAGTT
1690 1700 1710
TCCGGCAAAC AAACCACCGC TGGTAGCGGT
1750 1760 1770
CGCAGAAAAA AAGGATCTCA AGAAGAT CCT
1810 1820 1830
TGGAACGAAA ACTCACGTTA AGGGATTTTG
1870 1880 1890
TAGATCCTTT TAAATTAAAA ATGAAGTTTT
1930 1940 1950
GAGGCTATGG CAGGGCCTGC CGCCCCGACG
1990 2000 2010
CTTGGGGGGT GGGGTGGGGA AAAGGAAGAA
2050 2060 2070
GGTGGGGTAT CGACAGAGTG CCAGCCCTGG
2110 2120 2130
CCAACACCGT GCGTTTTATT CTGTCTTTTT
2170 2180 2190
ATTGTCTCCT TCCGTGTTTC AGTTAGCCTC
2230 2240 2250
AGATCCCCGC GCTGGAGGAT CATCCAGCCG
2290 2300 2310
CTTTCATAGA AGGCGGCGGT GGAATCGAAA
1180 1190 1200
TTTTTCCATA GGCTCCGCCC CCCTGACGAG
1240 1250 1260
TGGCGAAACC CGACAGGACT ATAAAGATAC
1300 1310 1320
CGCTCTCCTG TTCCGACCCT GCCGCTTACC
1360 1370 1380
AGCGTGGCGC TTTCTCATAG CTCACGCTGT
1420 1430 1440
TCCAAGCTGG GCTGTGTGCA CGAACCCCCC
1480 1490 1500
AACTATCGTC TTGAGTCCAA CCCGGTAAGA
1540 1550 1560
GGTAACAGGA TTAGCAGAGC GAGGTAT GTA
1600 1610 1620
CCTAACTACG GCTACACTAG AAGGACAGTA
1660 1670 1680
ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA
1720 1730 1740
GGTTTTTTTG TTTGCAAGCA GCAGATTACG
1780 1790 1800
TTGATCTTTT CTACGGGGTC TGACGCTCAG
1840 1850 1860
GTCATGAGAT TATCAAAAAG GATCTTCACC
1900 1910 1920
AAATCAATCT AAAGTATATA TGAGTAACCT
1960 1970 1980
TTGGCTGCGA GCCCTGGGCC TTCACCCGAA
2020 2030 2040
ACGCGGGCGT ATTGGCCCCA ATGGGGTCTC
2080 2090 2100
GACCGAACCC CGCGTTTATG AACAAAC GAC
2140 2150 2160
ATTGCCGTCA TAGCGCGGGT TCCTTCCGGT
2200 2210 2220
CCCCTAGGGT GGGCGAAGAA CTCCAGCATG
2260 2270 2280
GCGTCCCGGA AAACGATTCC GAAGCCCAAC
2320 2330 2340
TCTCGTGATG GCAGGTTGGG CGTCGCTTGG
262
2350 2360 2370 2380 2390 2400
TCGGTCATTT CGAACCCCAG AGTCCCGCTC AGAAGAACT C GTCAAGAAGG C GAT AGAAGG
2410 2420 2430 2440 2450 2460
CGATGCGCTG CGAATCGGGA GCGGCGATAC CGTAAAGCAC GAGGAAGCGG TCAGCCCATT
2470 2480 2490 2500 2510 2520
CGCCGCCAAG CTCTTCAGCA ATAT CACGGG TAGCCAACGC TATGTCCTGA TAGCGGTCCG
2530 2540 2550 2560 2570 2580
CCACACCCAG CCGGCCACAG TCGATGAATC CAGAAAAGCG GCCATTTTCC ACCATGATAT
2590 2600 2610 2620 2630 2640
TCGGCAAGCA GGCATCGCCA T GGGT CACGA C GAGAT C CT C GCCGTCGGGC ATGCTCGCCT
2650 2660 2670 2680 2690 2700
TGAGCCTGGC GAACAGT T C G GCTGGCGCGA GCCCCTGATG CTCTTGATCA TCCTGATCGA
2710 2720 2730 2740 2750 2760
CAAGACCGGC TTCCATCCGA GTACGTGCTC GCTCGATGCG ATGTTTCGCT TGGTGGTCGA
2770 2780 2790 2800 2810 2820
ATGGGCAGGT AGCCGGATCA AGCGTATGCA GCCGCCGCAT TGCATCAGCC ATGATGGATA
2830 2840 2850 2860 2870 2880
CTTTCTCGGC AGGAGCAAGG T GAGAT GACA GGAGAT CCT G CCCCGGCACT TCGCCCAATA
2890 2900 2910 2920 2930 2940
GCAGCCAGTC CCTTCCCGCT TCAGTGACAA CGTCGAGCAC AGCTGCGCAA GGAACGCCCG
2950 2960 2970 2980 2990 3000
TCGTGGCCAG CCACGATAGC CGCGCTGCCT CGTCTTGCAG TTCATTCAGG GCACCGGACA
3010 3020 3030 3040 3050 3060
GGTCGGTCTT GACAAAAAGA ACCGGGCGCC CCTGCGCTGA CAGCCGGAAC ACGGCGGCAT
3070 3080 3090 3100 3110 3120
CAGAGCAGCC GATTGTCTGT TGTGCCCAGT CATAGCCGAA TAGCCTCTCC ACCCAAGCGG
3130 3140 3150 3160 3170 3180
CCGGAGAACC TGCGTGCAAT CCATCTTGTT CAATCATGCG AAACGATCCT CATCCTGTCT
3190 3200 3210 3220 3230 3240
CTTGATCGAT CTTTGCAAAA GCCTAGGCCT CCAAAAAAGC CTCCTCACTA CTTCTGGAAT
3250 3260 3270 3280 3290 3300
AGCT CAGAGG CCGAGGCGGC CTCGGCCTCT GCATAAATAA AAAAAATTAG TCAGCCATGG
3310 3320 3330 3340 3350 3360
GGCGGAGAAT GGGCGGAACT GGGCGGAGTT AGGGGCGGGA TGGGCGGAGT TAGGGGCGGG
3370 3380 3390 3400 3410 3420
ACTATGGTTG CTGACTAATT GAGATGCATG CTTTGCATAC TTCTGCCTGC TGGGGAGCCT
3430 3440 3450 3460 3470 3480
GGGGACTTTC CACACCTGGT TGCTGACTAA TTGAGATGCA TGCTTTGCAT ACTTCTGCCT
3490 3500 3510 3520 3530 3540
GCTGGGGAGC CTGGGGACTT TCCACACCCT AACT GACACA CATTCCACAG CTGGTTCTTT
3550 3560 3570 3580 3590 3600
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CCGCCTCAGG ACTCTTCCTT TTTCAATAAA TCAATCTAAA GTATATATGA GTAAACTTGG
3610 3620 3630
TCTGACAGTT ACCAATGCTT AATCAGTGAG
3670 3680 3690
TCATCCATAG TTGCCTGACT CCCCGTCGTG
3730 3740 3750
TCTGGCCCCA GTGCTGCAAT GATACCGCGA
3790 3800 3810
GCAATAAACC AGCCAGCCGG AAGGGCCGAG
3850 3860 3870
TCCATCCAGT CTATTAATTG TTGCCGGGAA
3910 3920 3930
TTGCGCAACG TTGTTGCCAT TGCTACAGGC
3970 3980 3990
GCTTCATTCA GCTCCGGTTC CCAACGATCA
4030 4040 4050
AAAAAAGCGG TTAGCTCCTT CGGTCCTCCG
4090 4100 4110
TTATCACTCA TGGTTATGGC AGCACTGCAT
4150 4160 4170
TGCTTTTCTG TGACTGGTGA GTACTCAACC
4210 4220 4230
CCGAGTTGCT CTTGCCCGGC GTCAATACGG
4270 4280 4290
AAAGTGCTCA TCATTGGAAA ACGTTCTTCG
4330 4340 4350
TTGAGATCCA GTTCGATGTA ACCCACTCGT
4390 4400 4410
TTCACCAGCG TTTCTGGGTG AGCAAAAACA
4450 4460 4470
AGGGCGACAC GGAAATGTTG AATACT CATA
4510 4520 4530
TATCAGGGTT ATTGTCTCAT GAGCGGATAC
4570 4580 4590
ATAGGGGTTC CGCGCACATT TCCCCGAAAA
4630 4640 4650
TTAAGCGCGG CGGGTGTGGT GGTTACGCGC
4690 4700 4710
GCGCCCGCTC CTTTCGCTTT CTTCCCTTCC
4750 4760 4770
CAAGCTCTAA ATCGGGGGCT CCCTTTAGGG
3640 3650 3660
GCACCTATCT CAGCGATCTG TCTATTTCGT
3700 3710 3720
TAGATAACTA CGATACGGGA GGGCTTACCA
3760 3770 3780
GACCCACGCT CACCGGCTCC AGATTTATCA
3820 3830 3840
CGCAGAAGTG GTCCTGCAAC TTTATCCGCC
3880 3890 3900
GCTAGAGTAA GTAGTTCGCC AGT TAATAGT
3940 3950 3960
ATCGTGGTGT CACGCTCGTC GTTTGGTATG
4000 4010 4020
AGGCGAGTTA CATGATCCCC CATGTTGTGC
4060 4070 4080
ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG
4120 4130 4140
AATTCTCTTA CTGTCATGCC ATCCGTAAGA
4180 4190 4200
AAGTCATTCT GAGAATAGT G TATGCGGCGA
4240 4250 4260
GATAATACCG CGCCACATAG CAGAACTTTA
4300 4310 4320
GGGCGAAAAC TCTCAAGGAT CTTACCGCTG
4360 4370 4380
GCACCCAACT GATCTTCAGC ATCTTTTACT
4420 4430 4440
GGAAGGCAAA ATGCCGCAAA AAAGGGAATA
4480 4490 4500
CTCTTCCTTT TTCAATATTA TTGAAGCATT
4540 4550 4560
ATATTTGAAT GTATTTAGAA AAATAAACAA
4600 4610 4620
GTGCCACCTG ACGCGCCCTG TAGCGGCGCA
4660 4670 4680
AGCGTGACCG CTACACTTGC CAGCGCCCTA
4720 4730 4740
TTTCTCGCCA CGTTCGCCGG CTTTCCCCGT
4780 4790 4800
TTCCGATTTA GTGCTTTACG GCACCTCGAC
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4810 4820 4830 4840 4850 4860
CCCAAAAAAC TTGATTAGGG TGATGGTTCA C GTAGT GGGC CATCGCCCTG ATAGACGGTT
4870 4880 4890 4900 4910 4920
TTTCGCCCTT TGACGTTGGA GTCCACGTTC TTTAATAGTG GACTCTTGTT CCAAACTGGA
4930 4940 4950 4960 4970 4980
ACAACACTCA ACCCTATCTC GGTCTATTCT TTTGATTTAT AAGGGATTTT GCCGATTTCG
4990 5000 5010 5020 5030 5040
GCCTATTGGT TAAAAAATGA GCTGATTTAA CAAAAATTTA ACGCGAATTT TAACAAAATA
5050 5060 5070 5080 5090 5100
TTAACGCTTA CAATTTAC
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pcOMA3.i reverse prtmlrig site: liases 1022-1039 
BdHpofyA: bases 1021-1235 
11 origin of replication: bases 1298-1711 
SV40 ptomolef arid origin: bases 1776-2101 
Neomyan resistance gene: bases 2137-2931 
SV40 polyaderr>1atton. signal: base« 2986-3358 
CotE1 origin. DaseS 36TB-42S1 
A'itpicillin resistance gene: bases 4436-5297
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GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTT
AA
GCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAAC
AA
GGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGT
AC
GGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGT
TC
ATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGA
CC
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
AT
GGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTAGATCAAGTGTATCATATGCCAAGTACGCCCCC
TA
TTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC
TT
GGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TG
GATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCA
CC
AAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGT
AC
GGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAAT
TA
ATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCC
AC
TAGTCCAGTGTGGTGGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGTTT
AA
ACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTT
CC
TTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGA
GT
AGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCA 
GG
CATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATC
CC
CACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTG
CC
AGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTC
AA
GCTCTAAATCGGGGCATCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTG
AT
TAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCA
CG
TTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATT
TA
TAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATT
AA
TTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAA
GC
ATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAA
GC
ATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCA
GT
TCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCT
CT
GAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTT
GT
ATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGC
AC
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GCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCT
CT
GATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTG
CC
CTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCGACGACGGGCGTTCCTTGCGCAGCTG
TG
CTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGT
CA
TCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATC
CG
GCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTC
TT
GTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGG
CG
CGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAA
AT
GGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGG
CT
ACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCG
CT
CCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGA
AA
TGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTT
GG
GCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTT
CG
CCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAA
TA
AAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTAT
AC
CGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCT
CA
CAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACT
CA
CATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAAT
CG
GCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCG
CT
CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGG
GG
ATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCT
GG
CGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAA
CC
CGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCT
GC
CGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAG
GT
ATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCG
CT
GCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC
CA
CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTA
CG
GCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG
TA
GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCG
CA
GAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTC
AC
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GTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAG
TT
TTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC
TA
TCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACG
GG
AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATC
AG
CAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTC
TA
TTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGC
TA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCG
AG
TTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAA
GT
TGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAG
AT
GCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTC
TT
GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACG
TT
CTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACC
CA
ACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGC
AA
AAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT
TT
ATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCC
GC
GCACATTTCCCCGAAAAGTGCCACCTGACGTC
269
pCHllO:
Hina I¡i ( li ATÍJ Kpr. i.
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Sequence 7128 BP; 1710 A; 1849 C; 1817 G; 1752 T; 0 other; 
aagcttgatc tctataatct cgcgcaacct attttcccct cgaacacttt ttaagccgta 
gataaacagg ctgggacact tcacatgagc gaaaaataca tcgtcacctg ggacatgttg 
cagatccatg cacgtaaact cgcaagccga ctgatgcctt ctgaacaatg gaaaggcatt 
attgccgtaa gccgtggcgg tctggtaccg gtgggtgaag accagaaaca gcacctcgaa 
ctgagccgcg atattgccca gcgtttcaac gcgctgtatg gcgagatcga tcccgtcgtt 
ttacaacgtc gtgactggga aaaccctggc gttacccaac ttaatcgcct tgcagcacat 
ccccctttcg ccagctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 
ttgcgcagcc tgaatggcga atggcgcttt gcctggtttc cggcaccaga agcggtgccg 
gaaagctggc tggagtgcga tcttcctgag gccgatactg tcgtcgtccc ctcaaactgg 
cagatgcacg gttacgatgc gcccatctac accaacgtaa cctatcccat tacggtcaat 
ccgccgtttg ttcccacgga gaatccgacg ggttgttact cgctcacatt taatgttgat 
gaaagctggc tacaggaagg ccagacgcga attatttttg atggcgttaa ctcggcgttt 
catctgtggt gcaacgggcg ctgggtcggt tacggccagg acagtcgttt gccgtctgaa 
tttgacctga gcgcattttt acgcgccgga gaaaaccgcc tcgcggtgat ggtgctgcgt 
tggagtgacg gcagttatct ggaagatcag gatatgtggc ggatgagcgg cattttccgt 
gacgtctcgt tgctgcataa accgactaca caaatcagcg atttccatgt tgccactcgc 
tttaatgatg atttcagccg cgctgtactg gaggctgaag ttcagatgtg cggcgagttg 
cgtgactacc tacgggtaac agtttcttta tggcagggtg aaacgcaggt cgccagcggc 
accgcgcctt tcggcggtga aattatcgat gagcgtggtg gttatgccga tcgcgtcaca 
ctacgtctga acgtcgaaaa cccgaaactg tggagcgccg aaatcccgaa tctctatcgt 
gcggtggttg aactgcacac cgccgacggc acgctgattg aagcagaagc ctgcgatgtc 
ggtttccgcg aggtgcggat tgaaaatggt ctgctgctgc tgaacggcaa gccgttgctg 
attcgaggcg ttaaccgtca cgagcatcat cctctgcatg gtcaggtcat ggatgagcag 
acgatggtgc aggatatcct gctgatgaag cagaacaact ttaacgccgt gcgctgttcg 
cattatccga accatccgct gtggtacacg ctgtgcgacc gctacggcct gtatgtggtg 
gatgaagcca atattgaaac ccacggcatg gtgccaatga atcgtctgac cgatgatccg 
cgctggctac cggcgatgag cgaacgcgta acgcgaatgg tgcagcgcga tcgtaatcac 
ccgagtgtga tcatctggtc gctggggaat gaatcaggcc acggcgctaa tcacgacgcg 
ctgtatcgct ggatcaaatc tgtcgatcct tcccgcccgg tgcagtatga aggcggcgga 
gccgacacca cggccaccga tattatttgc ccgatgtacg cgcgcgtgga tgaagaccag 
cccttcccgg ctgtgccgaa atggtccatc aaaaaatggc tttcgctacc tggagagacg 
cgcccgctga tcctttgcga atacgcccac gcgatgggta acagtcttgg cggtttcgct
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aaatactggc aggcgtttcg tcagtatccc cgtttacagg gcggcttcgt ctgggactgg 
gtggatcagt cgctgattaa atatgatgaa aacggcaacc cgtggtcggc ttacggcggt 
gattttggcg atacgccgaa cgatcgccag ttctgtatga acggtctggt ctttgccgac 
cgcacgccgc atccagcgct gacggaagca aaacaccagc agcagttttt ccagttccgt 
ttatccgggc aaaccatcga agtgaccagc gaatacctgt tccgtcatag cgataacgag 
ctcctgcact ggatggtggc gctggatggt aagccgctgg caagcggtga agtgcctctg 
gatgtcgctc cacaaggtaa acagttgatt gaactgcctg aactaccgca gccggagagc 
gccgggcaac tctggctcac agtacgcgta gtgcaaccga acgcgaccgc atggtcagaa 
gccgggcaca tcagcgcctg gcagcagtgg cgtctggcgg aaaacctcag tgtgacgctc 
cccgccgcgt cccacgccat cccgcatctg accaccagcg aaatggattt ttgcatcgag 
ctgggtaata agcgttggca atttaaccgc cagtcaggct ttctttcaca gatgtggatt 
ggcgataaaa aacaactgct gacgccgctg cgcgatcagt tcacccgtgc accgctggat 
aacgacattg gcgtaagtga agcgacccgc attgacccta acgcctgggt cgaacgctgg 
aaggcggcgg gccattacca ggccgaagca gcgttgttgc agtgcacggc agatacactt 
gctgatgcgg tgctgattac gaccgctcac gcgtggcagc atcaggggaa aaccttattt 
atcagccgga aaacctaccg gattgatggt agtggtcaaa tggcgattac cgttgatgtt 
gaagtggcga gcgatacacc gcatccggcg cggattggcc tgaactgcca gctggcgcag 
gtagcagagc gggtaaactg gctcggatta gggccgcaag aaaactatcc cgaccgcctt 
actgccgcct gttttgaccg ctgggatctg ccattgtcag acatgtatac cccgtacgtc 
ttcccgagcg aaaacggtct gcgctgcggg acgcgcgaat tgaattatgg cccacaccag 
tggcgcggcg acttccagtt caacatcagc cgctacagtc aacagcaact gatggaaacc 
agccatcgcc atctgctgca cgcggaagaa ggcacatggc tgaatatcga cggtttccat 
atggggattg gtggcgacga ctcctggagc ccgtcagtat cggcggaatt ccagctgagc 
gccggtcgct accattacca gttggtctgg tgtcaaaaat aataataacc gggcaggcca 
tgtctgcccg tatttcgcgt aaggaaatcc attatgtact atttaaaaaa cacaaacttt 
tggatgttcg gtttattctt tttcttttac ttttttatca tgggagccta cttcccgttt 
ttcccgattt ggctacatga catcaaccat atcagcaaaa gtgatacggg tattattttt 
gccgctattt ctctgttctc gctattattc caaccgctgt ttggtctgct ttctgacaaa 
ctcggaactt gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt 
tcacaaataa agcatttttt tcactgcatt ctagttgtgg tttgtccaaa ctcatcaatg 
tatcttatca tgtctggatc cccaggaagc tcctctgtgt cctcataaac cctaacctcc 
tctacttgag aggacattcc aatcataggc tgcccatcca ccctctgtgt cctcctgtta 
attaggtcac ttaacaaaaa ggaaattggg taggggtttt tcacagaccg ctttctaagg 
gtaattttaa aatatctggg aagtcccttc cactgctgtg ttccagaagt gttggtaaac
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agcccacaaa tgtcaacagc agaaacatac aagctgtcag ctttgcacaa gggcccaaca 
ccctgctcat caagaagcac tgtggttgct gtgttagtaa tgtgcaaaac aggaggcaca 
ttttccccac ctgtgtaggt tccaaaatat ctagtgtttt catttttact tggatcagga 
acccagcact ccactggata agcattatcc ttatccaaaa cagccttgtg gtcagtgttc 
atctgctgac tgtcaactgt agcatttttt ggggttacag tttgagcagg atatttggtc 
ctgtagtttg ctaacacacc ctgcagctcc aaaggttccc caccaacagc aaaaaaatga 
aaatttgacc cttgaatggg ttttccagca ccattttcat gagttttttg tgtccctgaa 
tgcaagttta acatagcagt taccccaata acctcagttt taacagtaac agcttcccac 
atcaaaatat ttccacaggt taagtcctca tttaaattag gcaaaggaat tcttgaagac 
gaaagggcct cgtgatacgc ctatttttat aggttaatgt catgataata atggtttctt 
agacgtcagg tggcactttt cggggaaatg tgcgcggaac ccctatttgt ttatttttct 
aaatacattc aaatatgtat ccgctcatga gacaataacc ctgataaatg cttcaataat 
attgaaaaag gaagagtatg agtattcaac atttccgtgt cgcccttatt cccttttttg 
cggcattttg ccttcctgtt tttgctcacc cagaaacgct ggtgaaagta aaagatgctg 
aagatcagtt gggtgcacga gtgggttaca tcgaactgga tctcaacagc ggtaagatcc 
ttgagagttt tcgccccgaa gaacgttttc caatgatgag cacttttaaa gttctgctat 
gtggcgcggt attatcccgt gttgacgccg ggcaagagca actcggtcgc cgcatacact 
attctcagaa tgacttggtt gagtactcac cagtcacaga aaagcatctt acggatggca 
tgacagtaag agaattatgc agtgctgcca taaccatgag tgataacact gcggccaact 
tacttctgac aacgatcgga ggaccgaagg agctaaccgc ttttttgcac aacatggggg 
atcatgtaac tcgccttgat cgttgggaac cggagctgaa tgaagccata ccaaacgacg 
agcgtgacac cacgatgcct gcagcaatgg caacaacgtt gcgcaaacta ttaactggcg 
aactacttac tctagcttcc cggcaacaat taatagactg gatggaggcg gataaagttg 
caggaccact tctgcgctcg gcccttccgg ctggctggtt tattgctgat aaatctggag 
ccggtgagcg tgggtctcgc ggtatcattg cagcactggg gccagatggt aagccctccc 
gtatcgtagt tatctacacg acggggagtc aggcaactat ggatgaacga aatagacaga 
tcgctgagat aggtgcctca ctgattaagc attggtaact gtcagaccaa gtttactcat 
atatacttta gattgattta aaacttcatt tttaatttaa aaggatctag gtgaagatcc 
tttttgataa tctcatgacc aaaatccctt aacgtgagtt ttcgttccac tgagcgtcag 
accccgtaga aaagatcaaa ggatcttctt gagatccttt ttttctgcgc gtaatctgct 
gcttgcaaac aaaaaaacca ccgctaccag cggtggtttg tttgccggat caagagctac 
caactctttt tccgaaggta actggcttca gcagagcgca gataccaaat actgtccttc 
tagtgtagcc gtagttaggc caccacttca agaactctgt agcaccgcct acatacctcg 
ctctgctaat cctgttacca gtggctgctg ccagtggcga taagtcgtgt cttaccgggt
tggactcaag acgatagtta ccggataagg cgcagcggtc gggctgaacg gggggttcgt 
gcacacagcc cagcttggag cgaacgacct acaccgaact gagataccta cagcgtgagc 
attgagaaag cgccacgctt cccgaaggga gaaaggcgga caggtatccg gtaagcggca 
gggtcggaac aggagagcgc acgagggagc ttccaggggg aaacgcctgg tatctttata 
gtcctgtcgg gtttcgccac ctctgacttg agcgtcgatt tttgtgatgc tcgtcagggg 
ggcggagcct atggaaaaac gccagcaacg cggccttttt acggttcctg gccttttgct 
ggccttttgc tcacatgttc tttcctgcgt tatcccctga ttctgtggat aaccgtatta 
ccgcctttga gtgagctgat accgctcgcc gcagccgaac gaccgagcgc agcgagtcag 
tgagcgagga agcggaagag cgcctgatgc ggtattttct ccttacgcat ctgtgcggta 
tttcacaccg catatggtgc actctcagta caatctgctc tgatgccgca tagttaagcc 
agtatacact ccgctatcgc tacgtgactg ggtcatggct gcgccccgac acccgccaac 
acccgctgac gcgccctgac gggcttgtct gctcccggca tccgcttaca gacaagctgt 
gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag 
gcagctgtgg aatgtgtgtc agttagggtg tggaaagtcc ccaggctccc cagcaggcag 
aagtatgcaa agcatgcatc tcaattagtc agcaaccagg tgtggaaagt ccccaggctc 
cccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca tagtcccgcc 
cctaactccg cccatcccgc ccctaactcc gcccagttcc gcccattctc cgccccatgg 
ctgactaatt ttttttattt atgcagaggc cgaggccgcc tcggcctctg agctattcca 
gaagtagtga ggaggctttt ttggaggcct aggcttttgc aaaaagct
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